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percentage  of  serious  adverse  advents  is  a  burden  to  society  and  stresses  the  need  for  adequate 
preoperative  assessment  in  order  to  select  and  optimize  surgical  patients.  The  clinical  course  of 
surgical  patients  have  been  the  subject  of  research  focusing  on  perioperative  outcome.  1‐6  The 
influenced time frame expanded from merely improving the direct postoperative surgical outcome to 
influencing  the  long  term  outcome  of  the  surgical  patient.  7‐14  Consequently,  advances  in 
perioperative  care  emphasize  a  more  important  role  of  the  preoperative  evaluation  and  a  more 
comprehensive  risk  stratification  by  the  anesthesiologist.  Recognition  and  optimization  of  chronic 
disease processes prior  to surgery could prove beneficial by reducing  the risk of complications, not 
only  in  the  perioperative  stage,  but  also  on  longer‐term  follow  up. With  the  growing  number  of 
surgical  procedures  performed  yearly  in  modern  societies    we  believe  anesthesiologists  have  a 





adverse  events  consequently  lead  to  significant  morbidity  and  mortality.  17 The  pathophysiologic 
cascade  leading to perioperative myocardial  ischemia  is  in about 50% of cases due to acute plaque 
rupture in coronary arteries and in over 50% due to an oxygen supply and demand imbalance. 18, 19 





adverse  cardiac  events  in  the  vascular  surgical  patient,  particular  attention  was  directed  towards 
cardiac  ischemic  testing  and  monitoring.  Dobutamine  echocardiography  has  been  an  established 
method  to predict  the need  for preoperative  revascularization prior  to elective  vascular  surgery  in 
high‐risk vascular surgical patients according to the recommendations of both the European Society 
of  Cardiology  and  the  the  European  Society  of  Anesthesia  (ESC/ESA)  guidelines  on  non‐cardiac 




not  proven  to  be  beneficial.  22  Because  myocardial  ischemia  can  occur  during  surgery  as  well, 




Despite  pre‐  and  intra‐operative  optimization,  the  incidence  of  perioperative  myocardial 
infarction  in  this  population  remains  high.  Clinical  signs,  ECG  changes,  echocardiographic  new wall 
abnormalities  and  biochemical markers  are  required  for  the  diagnosis  of myocardial  infarction  but 
these  findings  are  less  useful  occurring  in  the  postoperative  phase.  Moreover,  the  occurrence  of 





the  20th  century,  obesity  has  become  a  growing  problem  in  many  parts  of  the  world.  A  Belgian 
scientist and mathematician; Adolphe Quetelet;  first  introduced the body mass (formerly known as 
Quetelet’s  index)  index (BMI) to public health science  in the 19th century as gross  index of body fat 
content. This  index was used as a nutritional estimate for a  long‐time until the epidemic of obesity 
raised  much  attention  to  obesity  and  its  associated  health  risks.  Definition  of  obesity  was  hence 
primarily based on determination of an individual’s BMI by virtues of its simplicity before other more 
specific  measures  of  total  or  particular  body‐fat  content  were  introduced.  The  World  Health 
Organisation  and  the  National  Institute  of  Health  (NIH)  distinguished  4  main  quartiles  of  BMI. 





Consequently,  ageing,  co‐morbidity,  and  obesity  became  more  common  among  vascular 
surgical  patients.  Aging  and obesity  are  strongly  associated with overt  or  occult  cardiac  disease.  A 
preponderance  of  cardiovascular  metabolic  risk  factors  were  found  in  the  overweight  and  obese 



















surgical  patients  particularly  those  with  peripheral  arterial  disease,  coronary  artery  disease,  and 





hallmarked  by  chronicity,  and  our  particular  interest  in  perioperative  cardiovascular medicine,  we 
studied  patients  undergoing  peripheral  arterial  surgery. We  conducted  this  retrospective  study  to 




Chapter  2.  The  Erasmus  University  Medical  Centre  adopted  an  elaborative  preoperative 
screening  strategy  to  identify  patients  with  chronic  obstructive  pulmonary  diseases  (COPD)  by 
performing  preoperative  pulmonary  function  testing  (PFT).  This  study  was  conducted  in  order  to 





analyzed  a  large  population  of  10,427  surgical  patients  who  underwent  a  variety  of  surgical 
procedures.  In  this  study we  investigated  the  association between BMI  categories  and both  short‐ 
and long‐term mortality and length of hospital stay. 
 
Chapter  4.  Because  the  populations  we  examined  represented  mainly  vascular  surgical 
patients with peripheral arterial disease, we investigated another risk factor dictated directly by this 









As  major  perioperative  complications  related  to  vascular  surgery  are  cardiovascular  in  nature  and 
echocardiography  is  the  most  used  functional  cardiovascular  evaluation  tool  in  today’s  practice,  we 
investigated  the  use  of  perioperative  echocardiography  targeting  the  management  of  two  of  the  most 
functionally  impairing  complications  in  non‐cardiac  surgery;  i.e.  myocardial  ischemia/infarction  and  heart 
failure. 
 
Chapter  6.  Preoperative  revascularization  had  not  proven  to  decrease mortality  in  vascular  surgery 
patients with evidence of coronary artery disease prior  to non‐cardiac surgery. We  investigated whether  the 
site of new wall motion abnormalities detected by dobutamine stress echography  in 54 patients undergoing 
major  vascular  surgery  corresponded  with  intraoperatively  new  wall  motion  abnormalities  revealed  by 




Chapter  7.  This  study  was  conducted  to  evaluate  the  prevalence  of  left  ventricular  dysfunction  in 
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Increased body mass index (BMI), a parameter of total body fat content, is associated with an increased 
mortality in the general population. However, recent studies have shown a paradoxic relation between 
BMI and mortality in specific patient populations. This study investigated the association of BMI with long-
term mortality in patients with known or suspected coronary artery disease. In a retrospective cohort study 
of 5,950 patients (mean age 61 ± 13 years; 67% men), BMI, cardiovascular risk markers (age, gender, 
hypertension, diabetes, current smoking, angina pectoris, old myocardial infarction, heart failure, hyper-
cholesterolemia, and previous coronary revascularization), and outcome were noted. The patient 
population was categorized as underweight, normal, overweight, and obese based on BMI according to 
the World Health Organization classification. Mean follow-up time was 6 ± 2.6 years. Incidences of long-
term mortality in underweight, normal, overweight, and obese were 39%, 35%, 24%, and 20%, 
respectively. In a multivariate analysis model, the hazard ratio (HR) for mortality in underweight patients 
was 2.4 (95% confidence interval [CI] 1.7 to 3.7). Overweight and obese patients had a significantly lower 
mortality than patients with a normal BMI (HR 0.65, 95% CI 0.6 to 0.7, for overweight; HR 0.61, 95% CI 
0.5 to 0.7, for obese patients). In conclusion, BMI is inversely related to long-term mortality in patients 
with known or suspected coronary artery disease. A lower BMI was an independent predictor of long-term 
mortality, whereas an improved outcome was observed in overweight and obese patients. 
********************************************************************************************************************** 
This manuscript was published in Am J Cardiol. 2007 Jun 1;99(11):1485-90. Epub 2007 Apr 12. 
PMID: 17531566 
Key words: Body Mass Index; Coronary artery disease; Prognosis. 
Condensed abstract 
Clinical interest is currently focusing on the prognostic importance of body mass index in different patient 
categories rather than the general population. We retrospectively assessed the relation between body 
mass index (BMI) and long-term mortality in 5950 patients with known or suspected coronary artery 
disease. The mean follow-up time was 6 ± 2.6 years. BMI was inversely related to long-term mortality. A 
lower BMI was an independent predictor of long-term mortality, while in overweight and obese patients 






















BMI: Body mass index 
CAD: Coronary artery disease 
HR: Hazard ratio 
95% CI: 95% confidence interval 
MI: Myocardial infarction 
CABG: Coronary artery bypass grafting 




















 In this study, we evaluated the effect of body mass index (BMI) on long-term mortality of patients 
with known or suspected coronary artery disease (CAD) after controlling for coronary risk factors. 
Patients and Methods 
We retrospectively studied 5,950 adult patients with known or suspected CAD who were referred to the 
outpatient clinics of the Erasmus University Medical Center (Rotterdam, The Netherlands) between 
January 1993 and January 2005. Our study population consisted of high-risk patients referred to the 
vascular clinic for evaluation of systemic atherosclerosis, CAD or peripheral arterial disease, and for 
management of underlying risk factors. In these patients, BMI was measured at the time of the first visit 
and cardiac risk factors were noted. We categorized patients as having known (n = 2,486; 42%) or 
suspected (n = 3,464; 58%) CAD. Known CAD was indicated by the presence of angina pectoris, previous 
myocardial infarction (MI), or previous coronary revascularization (i.e., previous percutaneous coronary 
intervention and/or coronary artery bypass grafting). Patients with atypical chest pain, dyspnea, atypical 
electrocardiographic abnormalities (i.e., ST-segment changes without Q waves), or ≥2 cardiac risk factors 
(male gender, current smoker, hypertension, renal dysfunction, hypercholesterolemia, and diabetes) were 
considered to have suspected CAD.1  
The hospital medical ethical committee approved the study protocol. Clinical data were obtained by 
thorough review of medical records and electronic databases and included age, height, weight, previous 
MI, angina pectoris, coronary artery revascularization, heart failure (HF), diabetes mellitus (fasting glucose 
level ≥7.0 mmol/L or requirement of hypoglycemic agents), hypertension (blood pressure ≥140/90 mm Hg 
or intake of antihypertensive medications), current smoker, hypercholesterolemia (plasma cholesterol 
level ≥5.5 mmol/L [213 mg/dl] or intake of lipid-lowering agents), and renal dysfunction (serum creatinine 
level ≥2.0 mg/dl [177 µmol/L] or requirement of dialysis). HF was considered if a patient had a history of 
shortness of breath on exertion or at rest, decreased physical ability, or swelling of lower limbs proved 
clinically or at echocardiography upon medical consultation to be valid for signs of cardiac 
decompensation.2 Patients were assessed for cardiac medication use. BMI was calculated as body weight 
(kilograms) divided by height squared (meters). Accordingly, patients were grouped according to BMI 
classifications of the World Health Organization3 and the National Institutes of Health4 as underweight 
(BMI <18.5 kg/m2), normal weight (18.5 to 24.9 kg/m2), overweight (25 to 29.9 kg/m2), or obese (≥30 
kg/m2). 
End points were death from all causes and hard cardiac events (cardiac death or MI). Cardiac death 
was defined as death from any cardiac cause including sudden cardiac death, MI, congestive HF, cardiac 
arrhythmias, and death in which there is evidence of a primary cardiac cause that could not be classified 
as mentioned above. Sudden cardiac death was defined as unexpected natural death due to cardiac 
causes within 1 hour of onset of acute symptoms. Criteria of MI diagnosis included ≥2 of the following: 
high cardiac enzyme levels (creatine kinase [CK] level >190 U/L and CK-MB level >14 U/L, or CK-MB 
fraction >6% of total CK, or cardiac troponin T level >0.1 ng/ml), development of typical 
electrocardiographic changes (new Q waves >1 mm or >30 ms at electrocardiography), and typical chest 
pain. Events were verified by review of hospital records or contacting general practitioners, civil registry, 
or participants’ families (by questionnaires in telephone calls) if needed. 
Statistical analysis was performed using the syntax commands of SPSS 13.0 for Windows (SPSS, Inc., 
Chicago, Illinois). Categorical variables are expressed as percentages and were compared using 
Pearson’s chi-square test. Continuous variables are presented as mean ± SD and were compared using 
Student’s t test. Primary end points were all-cause mortality and hard cardiac events (cardiac death and/or 
nonfatal MI). Cox proportional hazards models were used to determine univariate and multivariate 
predictors of mortality. Results on all-cause mortality, cardiac death, and MI were generated by Kaplan-
Meier estimates and differences in mortality were compared using log-rank test. Hazard ratios (HRs) and 
95% confidence intervals (CIs) were derived from a Cox proportional hazard stepwise regression model. 
Assumptions of the proportional hazard model (proportional hazard, lack of interaction, and linearity of 
continuous variables) were tested and found valid unless otherwise indicated. Proportional hazards 
assumptions were tested by constructing interaction terms between variables and time to each end point. 
Cox regression analyses showed no statistically significant interactions with time (each p value >0.05). 
Model selection is based on the stepwise principle, where the limits for entering and removing variables 
were 0.05. BMI was divided into its quartiles in all statistical examinations. The group of normal weight 
patients served in analyses as the reference group (i.e., HR=1), and the risk of the other 3 BMI groups 
compared with this group was estimated by HRs from the proportional hazard models. Multivariate 
analysis was done by adjusting for all baseline characteristics including age, gender, and dobutamine 
stress echocardiographic results (to eliminate any significant interaction with other confounders). For all 























Distribution of BMI in the population was approximately normal, with a mean of 25.4 ± 4.0 kg/m2 (Figure 
1). Only 3% of the study population was underweight, 42% was normal or overweight, and 14% was 
obese. Clinical characteristics of the 4 BMI categories are presented in Table 1. Mean age was 60.8 ± 13 
years and was not different across different BMI subsets. There were more men in the normal and 
overweight groups and more women in the underweight group. Current smokers were more prevalent in 
the underweight group. Diabetes and hypertension were noted more frequently in obese patients. 
Distribution of coronary risk factors across different groups is presented in Figure 2. 
Patients were followed for a mean period of 6 ± 2.6 years. Minimum follow-up period was 6 months. In 
total, 3,828 of 5,950 patients (64%) were referred for dobutamine stress echocardiography after their initial 
visit. Stress-induced myocardial ischemia was assessed in 1,205 of 1,750 patients (69%) with known CAD 
and in 651 of 2,078 patients (31%) with suspected CAD. In total 1,786 of 5,950 patients underwent major 
vascular noncardiac surgery during the follow-up period. Of 1,786 patients, 38 (2.1%) died in the 
perioperative period. During follow-up, 1,697 patients (29%) died. Of these, 1,235 patients (21%) died 
from cardiac causes. Univariate associations between risk factors and long-term outcome are presented 
in Table 2. Underweight patients had a poor long-term outcome for all-cause and cardiac mortalities, 
whereas overweight and obese patients had more favorable long-term outcomes in terms of all-cause and 
cardiac deaths (Table 2). In a multivariable stepwise Cox regression model (Table 3), overweight and 
obese patients remained at significantly lower risk for all-cause mortality and cardiac mortality/MI. 
Underweight patients represented a high-risk category for all-cause mortality and cardiac death/MI. 
Kaplan-Meier survival curves of the 4 BMI categories for an average interval of 6 ± 2.6 years are 
presented in Figure 3. Incidences of long-term mortality in underweight, normal, overweight, and obese 
patients were 39%, 35%, 24%, and 20%, respectively. In the same order, incidences of cardiac death/MI 
were 33%, 26%, 17%, and 14%. As shown in Figure 3, mortality hazard was inversely proportional to BMI 
(p <0.001) for either type of mortality. Results were subsequently analyzed separately in patients with 
known CAD and in those with suspected CAD. An inverse relation between BMI and survival was 
observed in patients with suspected CAD (all-cause mortality, p <0.001; cardiac death, p <0.001) and in 
patients with known CAD (all-cause mortality, p <0.001; cardiac death, p <0.001; Figure 4). In patients 
with suspected CAD, the underweight group had 2 short temporary shifts of improved survival over the 
normal weight group (4.5 to 5.5 and 6.5 to 8.5 years of follow-up), but eventually followed the same inverse 
relation with BMI at the commencement of follow-up. Overweight and obese populations showed the same 
paradoxic trend with BMI over the normal weight and underweight populations.
Discussion 
The main finding of this study is that an inverse relation exists between BMI and incident all-cause and 
cardiac mortalities during long-term follow-up of patients with known or suspected CAD. Underweight 
patients had a greater than twofold increased risk of mortality compared with normal weight patients, with 
40% less mortality and 20% less cardiac death in the obesity group. This reversed trend persisted after 
adjustment for coronary risk factors and was observed in patients with known CAD and those with sus-
pected CAD. 
Our population represented a cohort of ambulatory patients with normal distribution of risk factors and 
clinical suspicion and/or presentation of CAD. This population was composed of a broader spectrum of 
patients in contrast to previous studies conducted in isolated groups or after acute event or specific 
interventions. Previous studies have pointed out the prognostic influence of BMI in moribund patients with 
very limited functional capacity and/or short expectancy.5-9 The effect of obesity on long-term outcomes 
in moribund patients with preserved functional capacity is an important issue. Our findings also show the 
contribution of coronary risk factors and other co-morbidities to the hazard of death in populations with 
different weights. In this regard, old MI remained a significant predictor of all-cause mortality (HR=1.5, 
95% CI=1.3 to 1.7) and for cardiac death (HR=2.0, 95% CI=1.7 to 2.3) after correction for all other 
confounders. 
In this population, crude death rate was 29% during a mean follow-up of 6 ± 3 years. Cardiac deaths 
were responsible for 73% of all deaths. Major risk factors (renal disease, diabetes, male gender, and 
smoking) were associated with increased long-term all-cause and cardiac mortality. As expected, co-
morbid conditions (e.g., diabetes and hypertension) were more prominent in the obese population, 
whereas smoking and renal dysfunction were more prevalent in the underweight population. 
As shown by Kaplan-Meier survival curves (Figure 4) patients with suspected CAD and those with 
proved CAD had similar long-term outcomes. The reason for this similar outcome might be related to the 
high incidence of asymptomatic CAD in patients with proved vascular disease.10 
The paradoxic relation, a “protective effect”, of obesity on survival had been observed recently in 
several patient populations, such as patients with chronic HF or renal disease.5,9,11 Curtis et al11 examined 
a cohort of 7,767 outpatients with an established history of HF controlled under digitalis treatment. Higher 
BMIs were associated with a lower mortality.11 These data confirmed previous survival data of 4,700 
hospitalized patients with congestive HF associating an increased BMI with lower mortality (p <0.0001).9 
Recently, Gruberg et al12 studied patients who underwent percutaneous coronary intervention or coronary 
artery bypass grafting. The long-term mortality risk was similar across all BMI categories irrespective of 
type of revascularization procedure. Thus, overweight or obesity had no effect on crude survival at 3 
years.12 Sierra-Johnson et al13 followed 389 patients undergoing cardiac rehabilitation and found an 
inverse relation between BMI and total and cardiovascular mortalities, although only the relation with 
cardiovascular mortality was statistically significant after adjustment for age and gender. Kragelund14 
examined the effect of BMI on survival in 6,676 consecutive patients with acute MI during 10-year follow-
up. Overall obesity was inversely related to mortality from all causes. There was no association between 
obesity assessed as BMI and mortality (men, adjusted relative risk 0.90, 95% confidence interval 0.85 to 
1.14, p = 0.3; women, adjusted relative risk 0.90, 95% confidence interval 0.74 to 1.10, p = 0.2).14 Similar 
results were reported by Kennedy et al15 who had examined BMI for all-cause mortality and cardiac death 
in 5,388 patients with complicated acute MI. Comparable results were assessed in patients with renal 
disease.5,16 When a large cohort of patients with renal failure requiring dialysis (n = 418,021) was 
examined for survival, overweight and obese patients using dialysis had longer survival than did those 
with lower BMI.7 
The reason for the paradoxic relation of BMI with mortality in the aforementioned patient populations 
is not understood. Although this pathomodulatory phenomenon is quite obscure, several influences can 
be suggested in our study. It had been previously demonstrated that peripheral adiposity (i.e., gynoid 
obesity) poses cardiovascular benefits due to secretion of adiponectin, which has anti-inflammatory, 
insulin-sensitizing, and antiatherogenic effects in addition to an association with lower total body fat 
content and the fact that subcutaneous body fat is relatively “inert” in metabolic and 
inflammatory/mediation terms.17 Abdominal obesity is associated with higher total body fat content, more 
insulin-resistance, more other co-morbid associations, and more metabolic activity and inflammatory 
cascading influences. Thus, an obesity paradox might be reflected from a higher prevalence of 1 obesity 
type (i.e., peripheral) over another (i.e., central), with its decelerating influences becoming more manifest 
as BMI increases to reach higher levels (i.e., >30 kg/m2). It had been suggested that hypercholesterolemia 
and high levels of serum low-density lipoproteins associated with obesity serve a scavenging action 
against unbound circulating lipopolysaccharides with consequent anti-inflammatory response and 
improved long-term outcomes.18 In the other extreme, it can be inferred from our population characteristics 
that active smokers were mostly in the normal BMI and underweight groups, an unsurprising finding 
knowing that those were the 2 groups with lowest survival. Loss of weight in geriatric patients, which might 
be related to malnutrition, multiorgan dysfunction, or unidentified occult malignancies (especially in the 
smoking population), had been identified as a significant predictor of mortality.19,20 In this instance, those 
patients who presented at the time of evaluation with a BMI <18.5 kg/m2 at ≥60 years of age represented 
a subcohort of patients at a higher risk of mortality. Most offending coronary risk factors were associated 
with a BMI >25 kg/m2. Those patients with symptomatic co-morbidities were expected to have had 
consulted medical care, with a high probability that they were maintained on drugs proved to improve 
survival in a CAD population such as β blockers, statins, α2 agonists and angiotensin-converting enzyme 
inhibitors. 
One limitation of the study is its retrospective design. Due to time limits, we could not extend our follow-
up beyond the date of conclusion. Data regarding waist circumference and waist/hip ratio that measures 
abdominal obesity were not routinely available. A more precise differentiation between peripheral 
adiposity and central compartment adiposity would have served to support the suggested hypothetical 
explanation about the role of a high BMI in prolonging survival in our patient population. Regarding the 
detection of our end points, a number of nonfatal asymptomatic MIs might have not been reported, 
especially if these occurred outside the hospital. Unfortunately, we have no data regarding a particular 
cause of cardiac death.
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Figure 2: Categorical distribution of clinical characteristics and identified cardiac 
risk factors according to BMI indicating underweight (black bars), normal weight 
(dotted bars), overweight (white bars), or obesity (bars with horizontal stripes). 
CABG (coronary artery bypass grafting); COPD (chronic obstructive pulmonary disease); DM 



































Figure 3. Kaplan-Meier survival curves of studied population showing mortality 
rate according to their BMI, in terms of; 
(A) Total (all-cause mortality): 
 
P<0.001 




Figure 4. Examination of patients with known versus suspected CAD for total 






















Table 1. Clinical characteristics of 5,950 patients according to body mass index
Variable No. of Patients (%)  BMI (kg/m2)      p Value
  
<18.5 
(n = 178, 3%)
18.5-24.9 (n = 2,499, 
42%)
25-29.9 
(n = 2,439, 41%) >30 (n = 834, 14%)
 
Age, mean ± SD 60.8 ± 12.6 60.7 ± 14.8 61.7 ± 13.3 61.7 ± 11.2 59.0 ± 11.3 0.7
Men 4,001 (67%) 98 (55%) 1,752(70%) 1,730(71%) 421 (50%) <0.01
Current smoker 1,741 (29%) 53 (30%) 839 (34%) 673 (28%) 176(21%) <0.01
Hypertension 2,737 (46%) 61 (35%) 1,050(42%) 1,173 (48%) 453 (54%) <0.01
Angina pectoris 1,369 (23%) 32(18%) 545 (22%) 560 (23%) 232 (28%) <0.01
Previous MI 1,964(33%) 53 (30%) 819 (33%) 841 (35%) 251 (31%) 0.13
Renal disease 363 (6%) 32(18%) 172 (7%) 108 (4%) 51 (6%) <0.01
Chronic obstructive pulmonary disease 313 (5%) 6 (4%) 163 (7%) 116(5%) 27 (3%) <0.01
History of HF 846 (14%) 20 (12%) 372 (15%) 332 (14%) 123 (15%) 0.51
Diabetes mellitus 883 (15%) 6 (4%) 267 (11%) 393 (16%) 217 (26%) <0.01
Hypercholesterolemia 2,093 (35%) 27 (15%) 800 (32%) 924 (38%) 342(41%) <0.01
Previous coronary by pass 929 (16%) 12 (7%) 359 (14%) 421 (17%) 137 (16%) <0.01
Previous percutaneous coronary 933 (16%) 16 (9%) 361 (14%) 394 (16%) 162 (19%) <0.01
intervention 
Known CAD 2,486 (42%) 51 (36%) 1,023 (41%) 1,085 (44%) 327 (39%) 0.01
Suspected CAD 3,464 (58%) 92 (64%) 149 (59%) 1,374(56%) 507 (61%) 0.01
Dobutamine stress echocardiography 
Wall motion abnormalities at rest 2,296 (38%) 98 (55%) 1,014(41%) 949 (39%) 235 (25%) <0.01
New wall motion abnormalities 1,857 (31%) 68 (38%) 827 (33%) 787 (32%) 175 (21%) <0.01
 
Table 2. Univariate association of clinical data with all-cause mortality and cardiac death/acute myocardial infarction mortality in univariate regression 
analysis 
Variable Total Mortality  Cardiac Death/Acute MI
No. of Patients HR 95% CI No. of Patients HR 95% CI
Age  1.05 1.05-1.07  1.03 1.02-1.04
Men 1,333 2.1 1.8-2.4 1,234 2.0 1.8-2.3
Current smoker 600 1.7 1.5-1.9 557 1.6 1.4-1.8
Hypertension 848 1.3 1.1-1.4 816 1.4 1.2-1.5
Angina pectoris 335 0.8 0.7-0.9 338 0.9 0.8-1.0
Previous MI 659 1.4 1.3-1.6 686 1.9 1.7-2.2
Diabetes mellitus 301 1.4 1.2-1.6 275 1.3 1.1-1.6
History of HF 356 2.1 1.8-2.5 312 1.8 1.6-2.2
Hypercholesterolemia 451 0.6 0.6-0.7 535 1.2 0.8-1.5
Treated with statins 92 0.8 0.6-1.0 141 1.8 1.4-2.2
Untreated 359 0.6 0.5-0.7 394 0.8 0.7-1.0
Chronic obstructive pulmonary disease 166 3.1 2.5-4.0 156 3.0 2.4-3.8
Renal disease 73 4.5 2.9-7.0 74 2.9 2.0-4.4
Coronary bypass surgery 254 1.1 0.9-1.3 252 1.3 1.1-1.6
<5 yrs 66 0.5 0.4-0.7 62 0.7 0.4-0.8
Percutaneous coronary intervention 134 0.4 0.3-0.5 174 0.7 0.6-0.9
< 5 yrs 72 0.6 0.4-1.0 92 0.8 0.5-1.4
Dobutamine stress echocardiography       
Wall motion abnormalities at rest 724 1.30 1.16-1.46 704 1.36 1.21-1.53
New wall motion abnormalities 608 1.37 1.21-1.54 604 1.50 1.33-1.69
BMI groups       
Underweight 69 1.69 1.21-2.38 58 1.53 1.08-2.16
Overweight 596 0.63 0.55-0.71 422 0.75 0.66-0.85













Table 3. Multivariable regression analysis of total (all-cause) mortality and cardiac death/acute myocardial infarction mortality hazard adjusted for all patient 
variables 
Variable  Total Mortality  Cardiac Death/Acute MI  
 No. of Patients HR 95% CI No. of Patients HR 95% CI
Age  1.04 1.04-1.05  1.02 1.02-1.03
Men 1,333 1.9 1.7-2.2 1,234 1.7 1.5-2.0
Current smoker 600 1.6 1.4-1.9 557 1.5 1.3-1.7
Hypertension 848 1.3 1.2-1.5 816 1.4 1.2-1.6
Previous MI 659 1.5 1.3-1.7 686 2.0 1.7-2.3
Diabetes mellitus 301 1.5 1.3-1.8 275 1.4 1.2-1.7
History of HF 356 2.0 1.7-2.4 312 1.6 1.4-2.0
Hypercholesterolemia 451 0.8 0.7-0.9 535 1.2 1.0-1.4
Using statins 92 0.9 0.7-1.2 141 1.8 1.5-2.2
Untreated 359 0.8 0.7-0.9 394 1.0 0.8-1.2
Chronic obstructive pulmonary disease 166 2.4 1.8-3.2 156 2.3 1.8-3.1
Renal disease 73 4.4 2.8-7.0 74 4.2 2.6-6.6
Coronary bypass surgery 254 1.0 0.8-1.1 252 1.0 0.8-1.1
< 5 yrs 123 0.6 0.5-0.8 111 0.8 0.5-0.9
Percutaneous coronary intervention 134 0.4 0.3-0.5 174 0.6 0.5-0.7
< 5 yrs 
Dobutamine stress echocardiography 88 
0.7 0.5-1.1 91 1.0 0.6-1.6 
Wall motion abnormalities at rest 724 1.6 1.3-1.9 704 1.7 1.4-2.0
New wall motion abnormalities 608 1.1 0.9-1.36 604 1.3 1.0-1.6
BMI groups       
Underweight 69 2.4 1.7-3.6 58 2.1 1.5-3.1
Overweight 596 0.7 0.6-0.8 422 0.8 0.7-0.9
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Abstract 
Background:  Cardiac events are the predominant cause of late mortality in patients with peripheral 
arterial disease (PAD). In these patients, mortality decreases with increasing body mass index (BMI). 
COPD is identified as a cardiac risk factor, which preferentially affects underweight individuals. Whether 
or not COPD explains the obesity paradox in PAD patients is unknown. 
Methods: We studied 2,392 patients who underwent major vascular surgery at one teaching institution. 
Patients were classified according to COPD status and BMIs (i.e., underweight, normal, overweight, and 
obese), and the relationship between these variables and all-cause mortality was determined using a 
Cox regression analysis. The median follow-up period was 4.37 years (interquartile range, 1.98 to 8.47 
years). 
Results: The overall mortality rates among underweight, normal, overweight, and obese patients were 
54%, 50%, 40%, and 31%, respectively (p < 0.001). The distribution of COPD severity classes showed 
an increased prevalence of moderate-to-severe COPD in underweight patients. In the entire population, 
BMI (continuous) was associated with increased mortality (hazard ratio [HR], 0.96; 95% confidence 
interval [CI], 0.94 to 0.98). In addition, patients who were classified as being underweight were at 
increased risk for mortality (HR, 1.42; 95% CI, 1.00 to 2.01). However, after adjusting for COPD severity 
the relationship was no longer significant (HR, 1.29; 95% CI, 0.91 to 1.93). 
Conclusions:  The excess mortality among underweight patients was largely explained by the 
overrepresentation of individuals with moderate-to-severe COPD. COPD may in part explain the 
“obesity paradox” in the PAD population. 
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ACE: Angiotensin-converting enzyme 
BMI: Body mass index 
DM: Diabetes mellitus 
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HR: Hazard ratio 
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Cardiac events are the predominant cause of late mortality in patients with peripheral arterial disease  
(PAD).1-3 Interestingly, in this population, unlike the situation in the general population, patients  who  
are  obese or overweight have better survival rates than those patients who are of normal weight.4 
Indeed,   the greatest mortality rates are observed in patients who are underweight. This phenomenon 
has been referred to as the “obesity paradox”. 4,5  To date, the reasons  underlying the obesity paradox 
have not been fully elucidated. Over the past decade, COPD has emerged as an independent risk factor 
for cardiovascular mortality.6,7 The effects of COPD on cardiovascular risk are amplified in the presence 
of another cardiac risk factor (e.g., smoking, hypercholesterolemia, or PAD).8  In  this study, we 
investigated the influence of COPD on the relationship between body mass index (BMI) and mortality in 















We studied 2,392 consecutive adult surgical patients who were admitted to the Department of Vascular 
Surgery of Erasmus University Medical Center (Rotterdam, the Netherlands) between January 1990 
and November 2006. Patients were evaluated for the presence and severity of COPD prior to their 
surgical intervention using spirometry. Vascular surgical interventions included abdominal aortic 
surgery, carotid endarterectomy, or lower limb arterial revascularization procedures. BMI was measured 
during preoperative evaluation using standard procedures. Ethics approval for data collection and 
cohort evaluation were obtained from the Medical Ethics Committee of the hospital. 
Baseline data included age, height, weight, and recorded medical history. The National Institutes 
of Health obesity classification10 was used to divide the study population into the following four BMI 
categories: underweight (BMI <18.5 kg/m2); normal weight (BMI, 18.5 to 24.9 kg/m2); overweight (BMI, 
25 to 29.9  kg/m2);  and  obese  (BMI ≥30 kg/m2).  The number of patients studied in each of these 
groups was 63 (2%), 1,101 (33%), 956 (28%), and 272 (8%), respectively. We differentiated the patients 
according to whether they had COPD (n=1,110; 46.4%) or did not have COPD (n=1,282; 53.6%) based 
on the definition of the Global Initiative for Chronic Obstructive Lung Disease (or GOLD) Committee 
(FEV1/FVC ratio following therapy with bronchodilators and symptoms of cough or dyspnea, <70%). 
Mild COPD was defined as an FEV1 of ≥80% predicted; moderate COPD was defined as an FEV1 of 
≥50% to <80% predicted; and severe COPD was defined as an FEV1 of <50% predicted.11 We 
considered patients without COPD as those without pulmonary function tests, those without symptoms 
(i.e., without pulmonary complaints and/or pulmonary medications), and those who had normal arterial 
blood gas levels (PCO2 <6.4 kPa; PO2 >10.0 kPa) at the time of assessment. 
Cardiac medical history included details of previous myocardial infarction, angina pectoris, heart 
failure (HF), and coronary artery revascularization (i.e., percutaneous coronary intervention or coronary 
artery bypass grafting). Comorbidities reported in the medical history included diabetes mellitus (DM), 
hypertension, smoking, dyslipidemia, and renal dysfunction. DM was defined as a fasting glucose 
concentration of ≥7.0 mmol/L or the use of a hypoglycemic agent. Hypertension was defined as a BP of 
≥140/90 mmHg or the use of antihypertensive medications. A diagnosis of HF was considered if the 
patient had a history of shortness of breath on exertion or at rest, decreased physical ability, swelling of 
lower limbs on physical examination, and echocardiographic signs consistent with cardiac 
decompensation.12 Dyslipidemia was defined as a fasting serum total cholesterol level of  ≥5.5 mmol/L, 
a triglyceride level of ≥1.7 mmol/L, or a high-density lipoprotein cholesterol level of  ≤1.0 mmol/L at 
assessment or the use of lipid-lowering agents. Renal dysfunction was defined as a serum creatinine 
level of >2.0 mg/dL (177 µmol/L) or a requirement for dialysis. In addition, the cardiac risk score was 
determined for each patient using the Lee revised cardiac risk index, which included information about 
vascular operations, history of ischemic heart disease, HF, cerebrovascular accidents, insulin therapy  
for DM, and renal disease with a serum creatinine level of >2.0 mg/dL.13 Patients were assessed for the 
use of cardiac medications including β-blockers, statins, angiotensin-converting enzyme (ACE) 
inhibitors, diuretics, aspirin, anticoagulants, nitrates, and calcium channel blockers. The use of 
pulmonary  medications, including bronchodilators and corticosteroids, was also captured. 
 
Study End Points 
The end of this study was all-cause mortality. The median duration of follow-up was 4.37 years 
(interquartile range, 1.98 to 8.47 years). Information about death was obtained and verified by reviewing 
the hospital record and linking with the national civil registry. 
 
Statistical Analysis  
Categoric variables are expressed as percentages and were compared using a Pearson ӽ2 test. 
Continuous variables are presented as the mean (±SD) and were compared using analysis of variance. 
We performed univariate and multivariate analyses of survival times using a Cox proportional hazard 
model for all-cause mortality from which hazard ratios (HRs) and 95% confidence intervals (CIs) were 
derived. In the regression analyses, we used BMI both as a continuous variable and as a categoric 
variable. When the categoric BMI variable was included in the model, patients with normal weight were 
taken as the reference group. In the multivariate models, we adjusted for baseline characteristics 
including age, gender, cardiac risk score, current smoking status, COPD severity, year of surgery, and 
use of pulmonary medications. In addition, we used stepwise regression models to investigate the 
association between the BMI categories and mortality, with stepwise adjustment made for clinical 
variables and subsequently for COPD severity and current smoking. Statistical significance was defined 
as a p value of <0.05. All statistical analysis was performed using a statistical software package (SPSS, 





















In the population that we studied, we found a relatively homogenous distribution of BMI (mean BMI, 
25.4±4.0 kg/m2). Of the 2,392 patients, only 2.6% were underweight and 11.4% were obese, while the 
majority was either normal (46%) or overweight (40%). Patient characteristics according to BMI 
classifications are presented in Table 1. Current smokers were more prominent in the underweight 
group (p=0.002). Moderate-to-severe COPD was more frequent among underweight patients (40%), 
while the frequencies of COPD in the overweight and obese groups were 25% and 22%, respectively (p 
<0.001). In contrast to the underweight group, patients in the obese group had more cases of 
hypertension, DM, and dyslipidemia, and were more likely to be treated with β-blockers, statins, aspirin, 
and ACE inhibitors (p<0.05 for all). During follow-up, 1,048 patients (43.8%) died; 56.8% of them had 
COPD. Mortality among patients in different BMI categories included 34 patients (54%) in the 
underweight group, 550 patients (50%) in the normal group, 380 patients (40%) in the overweight group, 
and 83 patients (31%) in the obese group (p <0.001). 
The   relationships among BMI categories and COPD classifications are shown in Figure 1. The 
prevalence of COPD showed an inverse relationship with BMI; COPD was present more often in 
patients with lower BMI (p <0.001). The percentage of COPD was highest in patients who were 
underweight (51%), which was largely driven by the increased prevalence of severe COPD in this 
group. In the underweight category, 19% of the patients had severe COPD; whereas, in the obese 
category only 2% of the patients had severe COPD. 
Moderate-to-severe COPD was independently associated with increased mortality (moderate 
COPD: HR, 1.67; 95% CI, 1.42 to 1.97; severe COPD: HR, 1.96; 95% CI, 1.50 to 2.55) [Table 2]. BMI, 
on the other hand, was inversely associated with mortality. The risk of mortality increased by 4% for 
each 1 kg/m2 reduction in BMI. After adjusting for the cardiac risk score, age, gender, year of surgery, 
current smoking status, and use of pulmonary drugs, patients who were underweight were 1.42  times 
more likely to die than individuals of normal weight (HR, 1.42; 95% CI, 1.00 to 2.01). In contrast, 
overweight and obese individuals had a reduced risk of mortality (overweight patients: HR, 0.73; 95% 
CI, 0.64 to 0.84; obese patients: HR, 0.68; 95% CI, 0.53 to 0.86) [Table 3, model 4]. When COPD 
severity was added to the multivariate model, the relationship between underweight status and mortality 
no longer remained statistically significant (HR, 1.29; 95% CI, 0.91 to 1.93). However, obesity and 
overweight remained significantly related to mortality (Table 3, model 5). 
 
Discussion 
In this study, we examined a large cohort of patients with PAD and found a high prevalence of COPD 
(46.4%), especially among patients who were underweight. We observed an inverse relationship 
between BMI and mortality, which is consistent with the obesity paradox described previously. However, 
when  we adjusted  for COPD  and  its severity, the relationship between underweight and mortality no 
longer remained significant, indicating that a substantial proportion of the excess deaths in patients with 
low BMI occur in subjects with COPD. This raises the possibility that the excess deaths in patients with 
low BMI are related to the patients’ underlying COPD. Our results are in accordance with those of 
Landbo et al.14 They studied the prognostic association of BMI in a similar population of COPD patients 
and observed that underweight patients, especially those with severe COPD, had an increased risk of 
mortality. 
Since spirometry is generally not part of a normal preoperative assessment for patients who are 
undergoing major vascular surgery at many institutions, COPD may remain undiagnosed and untreated 
in this group of patients, resulting in excess morbidity and mortality. Indeed, even in our population, only 
9% of the cohort was taking bronchodilators, though the overall prevalence of COPD was 47% and that 
for moderate-to-severe COPD was 27%. The findings in this study highlight the need for more 
aggressive use of spirometry and the institution of COPD interventions (including smoking cessation, 
treatment of exacerbations, and the use of maintenance drugs) for patients with peripheral vascular 
disease. 
The mechanisms responsible for the inverse relationship between BMI and mortality are 
uncertain. Previous studies15,16 have suggested that underweight patients demonstrate a higher 
metabolic rate, lower antioxidant capacity in skeletal muscles, and increased systemic inflammatory 
responses, which may contribute to excess weight loss and morbidity. Underweight status has also 
been associated with overt or occult malignancy. Our study findings suggest that in addition to the 
above factors, COPD may also be responsible for the obesity paradox (in the low BMI categories).  
Our finding that overweight and obesity are associated with improved survival is consistent with 
the obesity paradox of survival in HF patients. Previous studies have clearly demonstrated that HF 
patients who have a higher percentage of body fat17,18 and elevated  BMI19,20 have lower mortality than  
those with normal or reduced BMIs. However, the mechanism responsible for this observation remains 
elusive.21,22 Some investigators have suggested23-25 that increased BMI may confer protection against 
endotoxin and inflammatory cytokines by increasing the production  of “buffering” lipoproteins. HF may 
be diagnosed in obese patients at an earlier stage because they tend to be more symptomatic than HF 
patients with lean body mass. Thus, obesity may simply be a marker for less severe HF. 
Our finding that nearly 50% of patients undergoing major vascular surgery for PAD had COPD 
highlights the importance of using screening spirometry in this population. Over half of these patients in 
the underweight category had moderate-to-severe COPD. These data support the notion of more 
aggressive “screening” and treatment for COPD before and after surgery to optimize the health 
outcomes of these patients. 
There were certain limitations to the study. BMI has been recently questioned as a sensitive 
measure of body fatness.26 Other  anthropometric  measurements of body fat such as waist 
circumference  were not routinely performed  preoperatively and, hence, could not be included in our 
analysis. We also did not have complete lung function measurements for the cohort. Knowledge 
regarding total lung and inspiratory capacity as well as diffusing capacity may provide incremental 
information on mortality. Moreover, because we did not directly interview patients, we could not 
separate out purposeful from nonpurposeful weight loss.27 Thus, the underlying reasons for the low BMI 
in our population are unknown. Finally, because smoking is a more powerful risk factor in PAD patients 
than in patients with HF, ischemic heart disease, or stroke, it is uncertain whether our current findings 
can be generalized to other cardiovascular populations. 
 
Conclusion 
We found that nearly 50% of patients with PAD undergoing a surgical procedure had evidence of COPD 
and that BMI was inversely related to long-term mortality. Importantly, there was a disproportionate 
overrepresentation of COPD in patients with low BMI. Patients with low BMI had an increased risk of 
mortality, while obese and overweight patients had a reduced risk of mortality compared to individuals of 
normal weight. Adjustments for the severity of COPD abolished the significant relationship between BMI 
and mortality in those patients who were underweight, but not in those who were overweight or obese. 
These data suggest that COPD is a highly prevalent condition in PAD patients who are undergoing 
surgical procedures, and that COPD may be responsible for the obesity paradox associated with 
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Figure titles and legends: 
Figure 1: The cross-relationship between COPD status and BMI in our population: 
COPD classifications among BMI categories 
 














































Table 1. The Baseline Clinical Characteristics of 2392 Patients According to Body 




















Demographics       
   Mean age, year (SD) 66 (11) 64 (14) 67 (11) 67 (10) 63 (11) <0.001 
   Male gender (%) 1782 (75) 34 (54) 823 (75) 749 (78) 176 (65) <0.001 
   Type of surgery (%)      <0.001 
      AAA1 966 (40) 27 (43) 456 (41) 405 (42) 78 (29)  
      CEA2 561 (24) 6 (10) 217 (20) 254 (27) 84 (31)  
      LLR3 865 (36) 30 (47) 428 (39) 297 (31) 110 (40)  
Cardiac history (%)       
   Myocardial infarction 618 (26) 11 (18) 288 (26) 253 (27) 66 (24) 0.41 
   Revascularisation4 458 (19) 11 (18) 196 (18) 206 (22) 44 (16) 0.09 
   Heart failure 133 (6) 1 (2) 76 (7) 41 (4) 15 (6) 0.04 
   Angina 419 (18) 9 (14) 182 (17) 175 (18) 53 (20) 0.51 
Clinical variables (%)       
   Hypertension 1042 (44) 10 (16) 442 (40) 449 (47) 141 (52) <0.001 
   Diabetes Mellitus 362 (15) 0 (0) 127 (12) 155 (16) 80 (29) <0.001 
   Current smoker 781 (33) 26 (41) 395 (36) 288 (30) 72 (27) 0.002 
   Dyslipidemia 520 (22) 6 (10) 208 (19) 236 (25) 70 (26) <0.001 
   Mean BMI (SD) 25 (4) 17 (1) 23 (2) 27 (1) 33 (4) <0.001 
   Renal dysfunction 192 (8) 8 (13) 94 (9) 67 (7) 23 (9) 0.30 
   COPD         <0.001 
      No 1282 (53) 31 (49) 570 (52) 516 (54) 165 (61)  
      Mild 481 (20) 7 (11) 231 (21) 197 (21) 46 (17)  
      Moderate 494 (21) 13 (21) 229 (21) 196 (20) 26 (20)  
      Severe 135 (6) 12 (19) 71 (6) 47 (5) 5 (2)  
Cardiac medication (%)       
   Statins 719 (30) 12 (19) 298 (27) 315 (33) 94 (35) 0.02 
   Beta-blockers 1026 (43) 15 (24) 457 (42) 408 (43) 146 (54) <0.001 
   ACE-inhibitors 640 (27) 11 (18) 264 (24) 278 (29) 87 (32) 0.004 
   Calcium antagonists 602 (25) 12 (19) 271 (25) 242 (25) 77 (28) 0.41 
   Diuretics 502 (21) 10 (16) 218 (20) 214 (22) 60 (22) 0.36 
   Aspirin 1021 (43) 18 (29) 434 (39) 432 (45) 137 (50) <0.001 
   Anti-coagulants 937 (39) 30 (48) 431 (39) 375 (39) 101 (37) 0.50 
   Nitrates 307 (13) 6 (10) 134 (12) 129 (14) 38 (14) 0.63 
Pulmonary medication (%)       
   Bronchodilators 205 (9) 8 (13) 98 (9) 78 (8) 21 (8) 0.58 
   Corticosteroids 308 (13) 10 (16) 150 (14) 117 (12) 31 (11) 0.59 
     1Abdominal aortic surgery 
      2Carotid endarterectomy 
      3Lower limb arterial reconstruction 
      4Previous coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) 
       Continuous variables are shown as mean (SD), while dichotomous variables are shown as number (% of column totals) 






Table 2. The Relationship between Baseline Risk Factors and All-Cause Mortality.  
 
 Univariate analysis  Multivariate analysis § 
Variables HR 95% CI P value HR 95% CI P value 
COPD φ     
     Mild 1.45 1.23-1.71 <0.001 1.18 1.00-1.40 0.053 
     Moderate 2.21 1.91-2.56 <0.001 1.67 1.42-1.97 <0.001 
     Severe 2.52 1.99-3.18 <0.001 1.96 1.50-2.55 <0.001 
BMI 0,95 0.94-0.97 <0.001 0.96 0.94-0.98 <0.001 
 §  Adjustments were made for the Lee’s revised cardiac risk score, age, gender, year of surgery and use of pulmonary  
    drugs  
 φ Classification of COPD done according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)      







Table 3 Association between BMI (continuous and categories) and COPD severity and mortality  
 
Variables Model 1 Model 2 Model 3 Model 4 Model 5 
Cases, No. 2387 2387 2387 2387 2387 
Patients alive, No. 1340 1340 1340 1340 1340 
BMI  0.95 (0.94-0.97) 0.95 (0.94-0.97) 0.96 (0.94-0.97) 0.96 (0.94-0.97) 0.96 (0.94-0.97) 
Underweight 1.38 (0.98-1.96) 1.44 (1.02-2.04) 1.30 (0.92-1.40) 1.42 (1.00-2.01) 1.29 (0.91-1.93) 
Overweight 0.73 (0.64-0.83) 0.73 (0.64-0.83) 0.73 (0.64-0.84) 0.73 (0.64-0.84) 0.74 (0.65-0.84) 
Obese 0.68 (0.54-0.85) 0.67 (0.53-0.85) 0.67 (0.53-0.85) 0.68 (0.53-0.86) 0.68 (0.54-0.86) 
Mild COPD 1.19 (1.01-1.41)  1.19 (1.00-1.41)  1.18 (1.00-1.40) 
Moderate COPD 1.81 (1.55-2.10)  1.69 (1.43-1.99)  1.67 (1.42-1.97) 
Severe COPD 2.11 (1.67-2.68)  1.97 (1.51-2.57)  1.96 (1.50-2.55) 
 
Model 1: Age and gender adjusted 
Model 2: Multivariate in which age, gender, cardiac risk score, year of surgery and pulmonary medication were adjusted for 
Model 3: Multivariate in which all the variables in model 2 plus COPD severity were adjusted for 
Model 4: Multivariate in which all the variables in model 2 plus cigarette smoking were adjusted for 
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Objective: To evaluate the presence of the obesity paradox in a general surgery 
population, reporting both postoperative and long-term survival, including cause-
specific mortality. 
Background: The obesity paradox has been demonstrated postoperatively in 
several surgical populations. However, only few studies reported long-term 
outcome. 
Methods: This retrospective study included 10,427 patients scheduled for 
elective, non-cardiac surgery. Patients were classified as underweight (BMI < 18.5 
kg/m2); normal weight (BMI 18.5 - 24.9 kg/m2); overweight (BMI 25.0 - 29.9 
kg/m2); obesity class I (BMI 30.0 - 34.9 kg/m2); obesity class II (BMI 35.0 - 39.9 
kg/m2); and obesity class III (BMI ≥ 40.0 kg/m2). Study endpoints were 30-day 
postoperative and long-term mortality, including cause-specific mortality. 
Multivariate analyses were used to evaluate mortality risks in different BMI 
categories. 
Results: Within 30-days after surgery, 353 (3.4%) patients died. Only overweight 
was associated with postoperative mortality, showing improved survival (OR 0.7; 
95% CI 0.6-0.9). During the long-term follow-up 4884 (47%) patients died. 
Underweight patients had the highest mortality risk (HR 1.5; 95% CI 1.3-1.7), 
particularly caused by high cancer related mortality. In contrast, overweight and 
obese patients demonstrated improved survival (overweight: HR 0.8; 95% CI 0.7–
0.8; obesity class I: HR 0.7; 95% CI 0.6–0.8; obesity class II: HR 0.6; 95% CI 
0.5-0.8; obesity class III: HR 0.7; 95% CI 0.5-0.9), mainly because of a strongly 
reduced risk of cancer related mortality. 
		 	
Conclusions: In this surgical population the obesity paradox could be validated 





Overweight and obesity are major health conditions that currently affect more than 
two-thirds of the US population, and the prevalence of obesity still continues to 
increase.1, 2 In Europe obesity has also reached epidemic proportions, although 
there are large differences between European countries.3  
The obesity epidemic also affects surgery, not merely because of an increase 
in obese patients, but also because of an increase in obesity related disorders that 
require surgery.4, 5 Despite the medical hazards associated with obesity,5  recent 
literature has demonstrated that obese patients show improved survival, a 
phenomenon referred to as the obesity paradox. The obesity paradox has been 
described in various populations, including the general population,6 and in patient 
populations with heart failure,7 coronary artery disease 8 and dialysis,9 among 
others. Moreover, several surgical populations have shown a similar survival 
benefit for the obese patient in the postoperative period.10-13 However, the 
majority of these studies included specific surgical populations, and did not report 
long-term survival.  
Therefore, this study was undertaken to evaluate the presence of the obesity 
paradox in a general surgery population, reporting both postoperative and long-









Study Design and Patients  
This retrospective study included 10,427 patients who underwent non-
cardiac surgery between January 1991 and December 2008, in the Erasmus 
Medical Center, Rotterdam, the Netherlands. In all patients, height and weight 
measurements were obtained during preoperative evaluation at the anesthesia 
clinic. Body mass index (BMI) was calculated as weight in kilograms divided by the 
square of height in meters.  
Baseline clinical data were retrieved from medical records and included age, 
gender, ischemic heart disease (history of myocardial infarction or angina 
pectoris), heart failure, cerebrovascular disease (history of cerebrovascular 
accident and/or transient ischemic attack), diabetes mellitus (treatment with 
insulin and/or fasting blood glucose ≥ 7 mmol/L), renal dysfunction (serum 
creatinine > 2.0 mg/dL), chronic obstructive pulmonary disease (COPD), and 
smoking status.  
 
Classifications and Risk Stratification 
The World Health Organization (WHO) classification was used to divide the 
patient population into the following BMI categories: underweight (BMI < 18.5 
kg/m2); normal weight (BMI 18.5 – 24.9 kg/m2); overweight (BMI 25.0 – 29.9 
kg/m2); obese (BMI ≥ 30.0 kg/m2), further divided in obesity class I (mild obesity: 
BMI 30.0 -34.9 kg/m2); obesity class II (moderate obesity: BMI 35.0 -39.9 kg/m2); 
and obesity class III (morbid obesity: BMI ≥ 40.0 kg/m2).14 
Based on the guidelines of the European Society of Cardiology,15 the non-
cardiac surgical procedures were classified into expected low cardiac risk (breast, 
dental, endocrine, eye, gynecology, orthopedic and reconstructive), intermediate 
		 	
cardiac risk (abdominal, carotid, endovascular aneurysm, head and neck, 
neurologic, pulmonary, renal, urologic, and remaining), and high cardiac risk 
(aortic, peripheral vascular and other vascular). 
The Revised Cardiac Risk Index (RCRI), which is used to identify surgical 
patients at the highest risk for cardiovascular events, was determined for every 
patient. The RCRI assigns one point to each of the following characteristics: high-
risk surgery, diabetes mellitus, renal dysfunction, ischemic heart disease, heart 
failure, and cerebrovascular disease.16 
 
Study Endpoints 
The primary endpoints were 30-day postoperative mortality and long-term 
mortality. Length of hospital stay (LOS) was described as a secondary outpoint. 
Median follow-up duration was 5.4 years (interquartile range 2.2 – 9.7 years). 
Survival status was obtained from the hospital records and the civil registries. In 
74 patients follow-up was missing (0.7%). Cause of death was classified as 
cardiovascular, cancer or other (non-cardiovascular, non-cancer), and was 
ascertained by examining medical records and autopsy reports. For patients 
without a definite cause of death, an assumption was made based on prior history. 
If prior history showed no significant morbidities, cause of death was classified as 
‘unknown’ (6.6%). Cardiovascular mortality was defined as any death with a 
cerebro-cardiovascular cause and included death following myocardial infarction, 
cardiac arrhythmias, congestive heart failure, stroke and sudden unexpected 
death. Non-cardiovascular, non-cancer mortality included respiratory, infectious 





Continuous variables are reported as mean ± standard deviation (SD) or 
median and interquartile range (IQR), and categorical data as numbers and 
percentages. Continuous variables showing a normal distribution were compared 
using analysis of variance; otherwise, the Kruskal-Wallis and Mann-Whitney U test 
were applied. Categorical data were compared with chi-squared tests.  
Data on smoking status were available in 8887 (85%) patients and 
preoperative pulmonary function testing was performed in 9953 (96%) patients, 
which was used to identify patients with COPD. Missing value analysis was used to 
impute the missing data on smoking status (n=1540) and COPD (n=474). 
Regression substitution was performed to predict the values for smoking and 
COPD, using other variables without missing values (age, gender, height, weight, 
myocardial infarction, angina pectoris, heart failure, cerebrovascular accident, 
diabetes mellitus, and renal dysfunction) and available data on smoking status and 
COPD.  
Logistic regression analysis was used to study the association between BMI 
category and 30-day postoperative outcomes. Long-term mortality risk was 
evaluated using a Cox proportional hazard model. When the categorical BMI 
variable was included in the model, patients with normal BMI were taken as the 
referent group. Multivariate analyses were primarily adjusted for predefined 
potential confounders (age, gender, RCRI, COPD and smoking status, surgery risk, 
and year of surgery). Cumulative long-term survival was determined by the 
Kaplan-Meier method and compared with the log-rank test. 
Sensitivity analyses were performed in patients without missing values for 
smoking and COPD. Furthermore, to limit effects of pre-existing disease on 
		 	
baseline BMI, sensitivity analyses were performed excluding all person-years and 
deaths in the first 5 years of follow-up.17 
For all tests, a 2-sided p-value of < 0.05 was considered significant. All 
statistical analyses were performed using a statistical software package (SPSS, 
version 17.0 for Windows, SPSS Inc., Chicago, Ill). 
 
Results 
The study population consisted of 10,427 non-cardiac surgery patients. 
According to the BMI categories, 475 (5%) patients were classified as underweight, 
4,601 (44%) as normal weight, 3,500 (34%) as overweight, 1,851 (18%) as 
obese, with 1,311 (13%) patients with obesity class I, 368 (4%) patients with 
obesity class II, and 172 (2%) patients with obesity class III, respectively. Patient 
characteristics according to BMI classification are shown in Table 1. The BMI 
among the study population attained a normal distribution, with a mean BMI of 
25.8 (± 5.2) kg/m2. Mean age of the study population was 58 (± 16) years and 
59% were men. Underweight and obese class III patients were younger, whereas 
overweight patients were older than patients with a normal BMI. Gender also 
varied significantly by BMI category, with the underweight and obese patients 
more often being females, and overweight patients more often being males 
(p<0.001).  
Medical history revealed that the prevalence of diabetes mellitus increased 
from 30% in the lowest- to 49% in the highest BMI category (p<0.001). 
Furthermore, ischemic heart disease and cerebrovascular disease were more 
common in the overweight and obese class I and class II patients, with a 
prevalence of > 10% for angina pectoris and 7% for cerebrovascular disease 
		 	
(p<0.001 and p 0.005 respectively). On the other hand, smoking prevalence was 
highest in the underweight group (52%) (p<0.001).  
The majority (62%) of surgical procedures were classified as intermediate 
cardiac risk (Table 2). Low-risk surgery was most often carried out in obese class 
II and III patients (40%), whereas high-risk surgery was most often performed in 
overweight patients (16%) (p<0.001). 
Postoperative mortality differed between the BMI categories. Within 30-days 
after surgery, a total of 353 (3.4%) patients died. Underweight patients had the 
highest 30-day mortality rate (4.5%), compared to lower rates in the overweight 
(3.0%), obesity class I (3.1%), obesity class II (3.0%) and obesity class III 
patients (2.9%), although this difference was not significant (p=0.284). After 
adjusting for potential confounders (age, gender, RCRI, COPD and smoking status, 
surgery risk, and year of surgery), overweight patients showed a reduced 
postoperative mortality risk (OR 0.7; 95% CI 0.6-0.9), whereas other BMI 
categories showed no association with postoperative mortality risk (Figure 1). 
The LOS also varied significantly by BMI category. The median LOS was 7.0 
days (IQR 2.0-15.0 days) for normal weight patients, and 7.0 days (IQR 2.0-16.0 
days) for underweight patients (p=0.7). However, LOS was significantly shorter 
for overweight and obese patients, compared to normal weight patients 
(overweight: median LOS 6.0 days (IQR 2.0-13.0) (p=0.001); obesity class I: 
median LOS 5.0 days (IQR 1.0-12.0 days) (p<0.001); obesity class II: median 
LOS 4.0 days (IQR 1.0-9.0) (p<0.001); obesity class III: median LOS 4.0 days 
(IQR 1.0-10.0 days) (p<0.001); respectively). When the analysis was stratified by 
surgical risk, LOS was shorter for obese patients compared to normal weight 
patients, particularly in intermediate risk surgery (p<0.001) and high-risk surgery, 
		 	
although this difference was not significant (p=0.06). On the other hand, in low-
risk surgery LOS did not differ between BMI categories (p=0.5). 
During the long-term follow-up, 4884 (47%) patients died. Mortality rates 
varied significantly among BMI categories: 276 (58%) patients in the underweight 
category; 2361 (52%) patients in the normal weight category; 1606 (46%) 
patients in the overweight category; 481 (37%) patients in the obese class I 
category; 115 (31%) patients in the obese class II category; and 45 (27%) 
patients in the obese class III category (p<0.001) (Figure 4 and Table 3). 
Cumulative long-term survival according to BMI category is demonstrated in Figure 
2 (log rank p<0.001). Multivariate regression analyses, adjusting for age, gender, 
RCRI, COPD and smoking status, surgery risk, and year of surgery, demonstrated 
that in underweight patients all-cause mortality risk was increased (adjusted HR 
1.5; 95% CI 1.3–1.7), whereas overweight and obese patients showed improved 
survival (overweight: adjusted HR 0.8; 95% CI 0.7–0.8; obesity class I: adjusted 
HR 0.7; 95% CI 0.6–0.8; obesity class II: adjusted HR 0.6; 95% CI 0.5-0.8; 
obesity class III: adjusted HR 0.7; 95% CI 0.5-0.9, respectively) (Table 3).  
Sensitivity analyses in patients without missing values on smoking and 
COPD did not change these hazard ratios. However, sensitivity analyses excluding 
the first 5 years of follow-up yielded different results. In underweight patients 
mortality risk was still increased (adjusted HR 1.4; 95% CI 1.1-1.8), and 
overweight and obesity class I remained associated with improved survival 
(adjusted HR 0.9; 95% CI 0.8-1.0; and adjusted HR 0.8; 95% CI 0.7-1.0; 
respectively). On the other hand, obesity classes II and III were no longer 
associated with mortality (obesity class II: adjusted HR 0.8; 95% CI 0.6-1.1; 
obesity class III: adjusted HR 1.3; 95% CI 0.8-2.0). 
		 	
Cause-specific mortality among the BMI categories is represented in Figure 
4. Cardiovascular mortality accounted for 22% of deaths in underweight patients, 
and this increased to 42% in obesity class III patients (p=0.001). Despite the high 
cardiovascular mortality in the overweight and obese patients, multivariate 
analyses did not show independent associations with BMI and cardiovascular 
mortality risk (Table 3). 
Cancer related death was responsible for the majority (52%) of deaths in 
underweight patients, and this decreased to 24% in obesity class III patients (p < 
0.001). Underweight patients were 1.6 times more likely to die from cancer than 
normal weight patients (adjusted HR 1.6; 95% CI 1.3–1.9) (Table 3). In contrast, 
overweight and obese patients had a 30-70% reduced risk of cancer related 
mortality (overweight: adjusted HR 0.7; 95% CI 0.7-0.8; obesity class I: adjusted 
HR 0.5; 95% CI 0.4-0.6; obesity class II: adjusted HR 0.5; 95% CI 0.3-0.7; 
obesity class III: adjusted HR 0.3; 95% CI 0.2-0.6, respectively) (Table 3). 
 
Discussion 
In this large sample of general surgery patients from a single Dutch hospital, 
only overweight was associated with 30-day postoperative mortality, showing 
improved survival, whereas obesity was not associated with postoperative 
mortality. However, long-term survival was significantly better for obese patients, 
clearly showing the presence of the obesity paradox in this surgical population. 
Furthermore, cause-specific mortality differed significantly between BMI 
categories, with cardiovascular mortality accounting for more than one third of 
deaths in overweight and obesity, and cancer being responsible for the majority of 
deaths in underweight patients. 
		 	
Postoperative mortality risk was not associated with obesity in our study, 
and was even reduced in overweight patients. Postoperative complications, like 
wound infections, are related to obesity and can lead to a longer hospital stay,11, 
12 however, they do not affect survival. Although this study did not assess surgical 
complications, hospital stay was shorter in patients with obesity classes I and II. 
Mullen et al. reported similar postoperative outcomes for the overweight and the 
obese, including lower mortality risks and reduced length of stay.12 Increased 
awareness of the hazards of obesity by both surgeons and anesthesiologists,18, 19 
in combination with a decline in the prevalence of cardiovascular risk factors 
among the obese,20 might have led to improved perioperative care and lower 
postoperative (cardiac) complication rates. These improvements can be reflected 
by reduced length of hospital stay and no additional mortality risk for the obese 
patient. 
Although the current study did not demonstrate the obesity paradox at 30-
day postoperatively, its presence could be confirmed at long-term. One of the 
hypotheses to explain the obesity paradox in our study might be that a decrease 
in cardiovascular related mortality, similar to observations in the general 
population21, might have led to a decrease in all-cause mortality. Although the 
prevalence of cardiovascular risk factors and disease, including diabetes and 
ischemic heart disease, was high among the overweight and the obese, no 
independent association with cardiovascular mortality could be demonstrated. One 
of the explanations could be that the number of obese patients dying from 
cardiovascular causes was too small for meaningful subgroup analyses. However, 
considering that cardiovascular mortality was the leading cause of long-term 
mortality among the obese, this hypothesis might be less likely to explain the 
obesity paradox in the present study. Therefore, other explanations are probably 
		 	
warranted to explain the obesity paradox in our surgical population, which is 
mainly determined by decreased cancer related deaths among the obese.  
One of the explanations could be that obese oncology patients are not, or 
less often, referred for surgery, leading to selection bias and supposed improved 
survival. In addition, although several site-specific cancers are associated with 
obesity,22 particularly with visceral adiposity,23 BMI cannot distinguish between 
visceral and peripheral adiposity.  Visceral adiposity is less common in pre-
menopausal women.23 Therefore, visceral adiposity might have been less prevalent 
among the predominantly female obese patients in our study, particularly in obese 
class III patients, leading to a lower prevalence of cancer. Another hypothesis is 
that overweight and obese patients had less disseminated cancer, as some studies 
have reported,12, 24 in that way leading to improved survival.  
Although obesity is associated with several cancers, Calle et al. 
demonstrated an inverse association between overweight and obesity and death 
from lung cancer.25 Decreased mortality rates from lung cancer could have reduced 
total cancer mortality rates among the overweight and obese in the present study. 
However, similar to the current study, the population studied by Calle et al. 
included smokers. Smoking can be a potential confounder, because it is associated 
with both a decreased weight and an increased mortality risk.17 Furthermore, 
smoking is related to an increased incidence of cancer. The effects of smoking on 
mortality cannot be separated from the effects of BMI on mortality in smoking-
related diseases, like lung cancer.  
Besides smoking associated weight loss, chronic diseases can also cause 
weight loss. Chronic diseases that cause weight loss may remain unnoticed for 
months or even years, for example in the case of cancer and COPD. Consequently, 
reverse causation, which means that lower weight is not a cause but a result of 
		 	
chronic diseases that are related to poor outcome, can be another confounder 
associated with mortality.17 In order to limit the effects of smoking and reverse 
causation on mortality risks, deaths occurring in the first years of follow-up should 
be disregarded, and analyses should be restricted to persons without prior disease 
and to persons who never smoked.17 In the study by Calle et al. the apparent 
inverse association between obesity and lung cancer mortality risk disappeared 
after restricting analyses to persons who never smoked.  
In the present study, the prevalence of smoking was higher in the 
underweight population compared to other BMI categories. This could offer another 
explanation for the obesity paradox in this surgical population. Underweight 
patients displayed the worst long-term survival, with nearly 60% mortality during 
follow-up. Furthermore, more than half of deaths were attributable to cancer. After 
exclusion of the first 5 years of follow-up, in order to limit the effects of pre-existing 
disease on baseline BMI, the obesity paradox was still present, with highest 
mortality risk in the underweight and improved survival in the overweight and 
obesity class I. Unfortunately, in the present study analyses could not be restricted 
to persons without prior disease and never smokers, since information regarding 
cancer diagnosis and former smoking was not available.  
Several limitations of the present study have already been mentioned, 
including the inability of BMI to differentiate between visceral and peripheral 
adiposity, missing information on baseline cancer diagnosis and metastatic 
disease, and the unfeasibility to divide non-smokers into former and never 
smokers. In addition, information regarding medication use was not available. 
Furthermore, this is a retrospective observational study, and therefore causality 
between BMI and outcome cannot be established. Finally, data on smoking and 
COPD were incomplete. These patients were not excluded to prevent any bias, and 
		 	
established statistical methods were used to impute missing values. It was 
assuring that in sensitivity analyses excluding patients with missing values, 
reported hazard ratios did not change. 
In conclusion, in this large retrospective study of general surgery patients, 
postoperative mortality risk was reduced in overweight, and not associated with 
other BMI categories. At long-term the obesity paradox could be validated. 
Cardiovascular mortality remained the leading cause of mortality among the 
obese, whereas cancer related death was significantly decreased among the 
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Fig. 1 Adjusted odds ratios for 30-day postoperative mortality 
























































































































Obesity     Class I 
(N=1311) 
Obesity   Class II    
(N= 368) 




Age (mean ± SD) 52 (± 19) 57 (± 16) 60 (± 15) 58 (±14) 56 (±14) 53 (±12) 
< 
0.001
Male (%) 52 62 65 49 30 20 
< 
0.001
Medical history (%) 
Ischemic heart 




disease 3 6 7 7 7 4 0.005
Renal dysfunction 5 5 5 5 4 4 0.886
Heart failure 4 6 7 6 6 4 0.078
Diabetes Mellitus 30 36 41 45 48 49 
< 
0.001
Cancer 43 40 35 27 22 16 
< 
0.001
COPD 46 49 48 41 42 26 
< 
0.001




(%)             
< 
0.001
Low 26 23 23 30 39 40  
Intermediate 65 64 61 59 54 56  
High 9 13 16 11 7 4  
Revised Cardiac Risk Index (%)           
< 
0.001
None 61 54 48 46 45 47  
1 risk factor 32 34 37 38 39 40  
2 risk factors 6 9 11 11 11 13  
≥ 3 risk factors 1 3 4 5 5 1   
Abbreviations: COPD chronic obstructive pulmonary disease; SD standard deviation
 	 	 	
Table 2. Surgical procedures 
 N (%) 
Low Cardiac Risk * 2596 25 
Breast 132 1.3 
Dental 54 0.5 
Endocrine 121 1.2 
Eye 623 6.0 
Gynecology 579 5.6 
Orthopedic 939 9.0 
Reconstructive 148 1.4 
Intermediate Cardiac Risk * 6461 62 
Abdominal 2417 23.2 
Carotid 26 0.2 
Head and neck 1382 13.3 
Neurologic 338 3.2 
Pulmonary 814 7.8 
Renal and urologic 1022 9.8 
Other 462 4.4 
High Cardiac Risk * 1370 13 
Aortic 185 1.8 
Peripheral vascular 294 2.8 
Other vascular 891 8.5 
























Table 3. Mortality rates and Hazard Ratios for mortality from all-cause, 










all-cause mortality             
% 58 52 46 37 31 27 
unadjusted 
HR 1.2 1.0 0.9 0.6 0.5 0.4 
(95% CI) 1.0-1.3  0.8-0.9 0.6-0.7 0.4-0.6 0.3-0.6 
adjusted 
HR* 1.4 1.0 0.8 0.7 0.7 0.7 
(95% CI) 1.2-1.6  0.8-0.9 0.7-0.8 0.6-0.9 0.5-1.0 
cerebro-cardiovascular mortality 
% 13 15 18 14 13 12 
unadjusted 
HR 0.9 1.0 1.1 0.8 0.7 0.6 
(95% CI) 0.6-1.1  1.0-1.2 0.7-1.0 0.5-0.9 0.4-1.0 
adjusted 
HR* 1.2 1.0 0.9 0.8 1.0 1.3 
(95% CI) 0.9-1.5  0.8-1.1 0.7-1.0 0.7-1.3 0.8-2.0 
cancer mortality            
% 31 24 19 12 10 7 
unadjusted 
HR 1.4 1.0 0.8 0.5 0.4 0.2 
(95% CI) 1.1-1.6  0.7-0.8 0.4-0.6 0.3-0.5 0.1-0.4 
adjusted 
HR* 1.4 1.0 0.8 0.7 0.7 0.5 
(95% CI) 1.1-1.6   0.8-0.9 0.6-0.8 0.5-0.9 0.3-0.9 
* adjusted for age, gender, RCRI, COPD and smoking status, surgery risk, cancer related surgery and  
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Background: Obesity is a risk factor for atherosclerosis, a polyvascular process 
associated with reduced survival. In nonvascular surgery populations, a paradox between 
body mass index (BMI) and survival is described. This paradox includes reduced survival 
in underweight patients, whereas overweight and obese patients have a survival benefit. 
No clear explanation for this paradox has been given. Therefore, we evaluated the 
presence of the obesity paradox in vascular surgery patients and the influence of 
polyvascular disease on the obesity paradox. 
Methods: In this retrospective study, 2933 consecutive patients were classified according 
to their preoperative BMI (kg/m2) and screened for polyvascular disease and 
cardiovascular risk factors before surgery. In addition, medication use at the time of 
discharge was noted. Outcome was all-cause mortality during a median follow-up of 6.0 
years (interquartile range, 2-9 years). 
Results: BMI (kg/m2) groups included 68 (2.3%) underweight (BMI <18.5), 1379 (47.0%) 
normal (BMI 18.5-24.9, reference), 1175 (40.0%) overweight (BMI 25-29.9), and 311 
(10.7%) obese (BMI >30) patients. No direct interaction between BMI, polyvascular 
disease, and long-term outcome was observed. Underweight was an independent 
predictor of mortality (hazard ratio, 1.65; 95% confidence interval, 1.22-2.22). In contrast, 
overweight protected for all-cause mortality (hazard ratio, 0.79; 95% confidence interval, 
0.700-0.89). Cardioprotective medication usage in underweight patients was the lowest 
(P < .001), although treatment targets for risk factors were equally achieved within all 
treated groups. 
Conclusion: Overweight patients referred for vascular surgery were characterized by an 
increased incidence of polyvascular disease and required more extensive medical 
treatment for cardiovascular risk factors at discharge. Long-term follow-up showed a 
paradox of reduced mortality in overweight patients. 
 
INTRODUCTION 
The prevalence of obesity among adults has been increasing in epidemic proportions and has 
become a critical problem in developed countries.1 The American Heart Association and 
American College of Cardiology guidelines for secondary prevention in coronary artery disease 
(CAD) have listed obesity as a major modifiable cardiovascular risk factor.2 Obesity has an 
important role in the atherosclerotic process because it promotes endothelial dysfunction, 
systemic inflammation, and a prothrombotic state.3 More important, the process of 
atherosclerosis is often not limited to a single arterial location. The Reduction of Atherothrombosis 
for Continued Health registry showed that one of six patients with peripheral arterial disease 
(PAD), cerebrovascular disease, or CAD had involvement of one or two other arterial beds.4 
Moreover, the presence of polyvascular disease has been demonstrated as an independent 
predictor of long-term cardiovascular outcome in the general population.5-7 
Although obesity is associated with an increased risk of developing cardiovascular disease in 
the general population, evidence from population-based studies with established atherosclerotic 
disease has indicated an obesity paradox, whereby obesity appears to be protective against an 
adverse prognosis.8-10 No clear explanation for this discrepancy in survival rates between 
increased body mass index (BMI) and atherosclerotic disease has been found. Therefore, we 
performed the current study in a cohort of vascular surgery patients to evaluate (1) the prevalence 
of obesity and the association on long-term survival and (2) the association between polyvascular 
disease and medical treatment at time of discharge with respect to obesity, cardiovascular risk 
factor control, and long-term survival. 
 
Methods 
The study complies with the Declaration of Helsinki. Patient enrollment and approaching the 
municipal civil registries was performed after approval of the hospital’s Ethics Committee. 
 
Study design and population. This retrospective single-center study comprised a source 
population of 3612 consecutive major vascular operations, of which 254 (7%) were acute 
procedures and 3358 were elective (Fig 1). In the 3358 elective operations, 2933 unique patients 
were identified, and 425 repeated operations were performed in 311 (11%) of these 2933 
patients. Patients who had more than one operation were included only once, based on their first 
surgical procedure.11 All patients underwent a major vascular surgical procedure between 1990 
and 2008, which included open lower extremity revascularization, aneurysmatic abdominal aortic 
surgery, or carotid surgery. From 1990 until 2001, standard preoperative screening included a 
detailed cardiac history, physical examination, electrocardiogram, standard laboratory 
measurements, and additional stress testing if indicated. After 2002, standard preoperative 
echocardiography was added to the screening program. 
 
Body mass index. Before surgery, body weight (kg) and length (m) were measured in all 
patients, and BMI was calculated (kg/m2). The National Institutes of Health obesity classification12 
was used to divide the study population into the following four BMI categories (kg/m2): 
underweight (BMI <18.5), normal weight (BMI 18.524.9), overweight (BMI 25-29.9), and obese 
(BMI >30). 
 
Baseline characteristics. Medical records of every patient visit were reviewed by two authors 
(J.P.K. and W.J.F.) to determine the presence of documented CAD and cerebrovascular disease. 
CAD was defined as a documented history of ischemic heart disease (composite of angina 
pectoris, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass 
grafting). The presence of coronary ischemia was established by one of the following techniques: 
exercise electrocardiogram, exercise testing with echocardiography, or computed tomography.13 
Patients with stable or unstable angina pectoris were classified as having documented CAD. 
Documented cerebrovascular disease was defined as a history of cerebrovascular accident or 
transient ischemic attack (confirmed by a computed tomography scan). Lower extremity arterial 
disease was defined as current intermittent claudication with ankle-brachial index <0.9 or a history 
of intermittent claudication with a previous intervention. Polyvascular disease was defined as the 
presence of more than one affected vascular beds. 
 
Medication use and risk factors. The use of the following medication was recorded at 
discharge: aspirin, statins, β-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, 
calcium antagonists, and angiotensin-receptor blockers. According to the European Society of 
Cardiology guidelines, PAD patients have to be treated with aspirin (75-325 mg), statins (low- to 
intermediate-risk patients: target low-density lipoprotein-cholesterol [LDL-C] level <100 mg/dL, 
high-risk patients <70 mg/dL), and β-blockers in patients with ischemic heart disease, and those 
with a left ventricular ejection fraction <40% should receive ACE inhibitors.14 
Risk factors determined at baseline included age, gender, smoking status, hypertension 
(blood pressure >140/90 mm Hg in nondiabetics and >130/80 mm Hg in diabetics or requirement 
of antihypertensive medication), diabetes mellitus15 (fasting blood glucose >7.0 mmol/L or 
requirement for insulin or oral antidiabetic medication), hypercholesterolemia (LDL-C >135 mg/dL 
or the requirement of lipid-lowering medication, or both), chronic heart failure, and chronic 
obstructive pulmonary disease (COPD), according to the Global Initiative on Obstructive Lung 
Diseases classification.16 Control of cardiovascular risk factor was defined in line with the 
European Society of Cardiology guidelines,14 including systolic blood pressure <140 mm Hg, 
diastolic blood pressure <90mmHg, LDL-C <100 mg/dL (2.5 mmol/L), glycemia <110 mg/dL (6.1 
mmol/L), and smoking cessation >12 months. Good control was defined as three to five 
cardiovascular risk factors at target values and poor control was defined when zero to two 
cardiovascular risk factors were at targets.6 
 
End points. The median follow-up of all patients was 6 years (interquartile range, 2-9 years). The 
primary study end point was the occurrence of all-cause mortality. Survival was assessed by 
querying the municipal civil registries. Cause of death was ascertained by examining death certifi-
cates or by reviewing medical records. 
 
Statistical analyses. Dichotomous data are described as numbers and percentages. Continuous 
variables are described as means ± standard deviation. Continuous data were compared using 
analysis of variance, and categoric data were compared using a 2 test. Cumulative survival of 
the BMI groups was determined by the Kaplan-Meier method and compared using the log-rank 
test. Cox regression models were used to investigate the association between BMI groups 
(patients with normal BMI as reference group) and death during long-term follow-up. Censoring 
for the 311 patients with repeated surgery was performed at the second surgical procedure. 
 
All multivariate analyses were primarily adjusted for demographics (age and gender), 
cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia, chronic heart 
failure, and COPD), site of surgery (lower extremity, abdominal aortic, or carotid), year of surgery, 
repeated surgery during follow-up, history of malignancy, and medication use as recommended 
in PAD patients, including aspirin, statins, and β-blockers, in case of prior myocardial infarction, 
and ACE inhibitors in patients with heart failure.4 To evaluate the effect of discharge use of aspirin, 
statins, p-blockers, and ACE inhibitors on long-term outcome, multivariate Cox regression 
analyses were performed with propensity score adjustment for each medication. Separate 
propensity scores were developed with logistic regression analyses for each type of medication. 
Variables included in the propensity score were demographics (age and gender), cardiovascular 
risk factors (smoking, hypertension, diabetes mellitus, dyslipidemia, chronic heart failure, and 
COPD), site of surgery (lower extremity, abdominal aortic or carotid), year of surgery, repeated 
surgery during follow-up, and a history of malignancy. To study the influence of polyvascular 
disease on the BMI groups, we used interactions terms between BMI and polyvascular disease. 
Statistical analyses were performed using SPSS 15.0 software (SPSS Inc, Chicago, Ill). These 
models were used to calculate hazard ratios (HRs), along with their 95% confidence intervals 
(CIs). A value of P < .05 (two-sided) was considered statistically significant. 
 
RESULTS 
Description of the study population. The final study population consisted of 2933 patients 
referred for elective major vascular surgery (Fig 1). Abdominal aortic surgery was performed in 
1170 (40%), lower extremity revascularization in 1031 (35%), and carotid surgery in 732 patients 
(25%). At baseline, the 2933 patients were categorized into preoperative BMI groups and 
included 68 underweight (2.3%), 1379 normal-weight (47.0%; reference group), 1175 overweight 
(40.0%), and 311 obese patients (10.7%; Table I). A positive history of malignancies was less 
often observed in patients who were overweight (188 of 1175 [16%]) or obese (44 of 311 [14%]). 
The distribution of the surgical procedures is described in Fig 2. Patients with normal weight most 
often had lower extremity revascularization compared with the other groups (P < .01). In the total 
study population, coronary artery disease was detected in 1248 patients (43%) and 
cerebrovascular disease in 1037 patients (35%). 
 
Short-term and long-term outcome. Of the 2933 patients, 112 died during the first 30 
postoperative days, for a mortality rate of 4.0%. Mortality rates by BMI group were underweight, 
4% (3 of 68); normal-weight, 7% (97 of 1379); overweight, 3% (35 of 1175); and obese, 5% (16 
of 311). The difference in the mortality rates between these groups was not statistically significant 
(P=0.125). During long-term follow-up, there were 1389 deaths (47%; Table II). Mortality was 
69% in underweight patients (49 of 68) compared with 52% in normal-weight patients (717 of 
1379), which was significant (P<0.001). In contrast, overweight and obese patients had 
significantly lower mortality rates of43% (507 of 1175) and 38% (118 of 311, P<0.001), 
respectively. A non-cardiovascular cause of death occurred in 434 of 1389 patients (31%), of 
which 258 (59%) were cancer-related. Patients in the underweight group demonstrated a 44% 
rate (30 of 68) of cancer-related death compared with 23% for the normal-weight (317 of 1379), 
22% for the overweight (259 in 1175), and 18% for the obesity group (56 of 311), which was 
statistically significant (P<0.01). Univariate Kaplan-Meier curves for mortality, stratified according 
the BMI groups, demonstrated that underweight patients had lower survival rates than patients 
with a normal BMI (Fig 3). In contrast, overweight or obese patients had higher survival rates than 
patients with a normal BMI. A log-rank test was used to compare cumulative survival between 
underweight vs normal (P=0.002), overweight vs. normal (P< 0.001) and obesity vs. normal 
(P=0.01). 
 
After multivariate regression analyses, patients within the lowest BMI group had an increased 
risk for mortality (HR=2.10; 95% CI=1.45-3.03) compared with patients within the normal-weight 
BMI (Table III). In contrast, overweight patients had a reduced risk for mortality (HR=0.77; 95% 
CI=0.69-0.86). Other independent predictors for mortality were age (HR=1.05; 95% CI=1.04-
1.06), COPD (HR=1.30; 95% CI=1.14-1.48), diabetes mellitus (HR=1.25; 95% CI=1.08-1.45), and 
chronic heart failure (HR=1.47; 95% CI=1.21-1.79). 
 
Polyvascular disease and outcome. Polyvascular disease was present in 28 of 68 underweight 
(41%), in 703 of 1379 normal-weight (51%), and in 817 of 1486 overweight and obese patients 
(55%; P=0.02). When interaction terms were used to identify the direct influence of polyvascular 
disease on the relations between BMI and survival rates, no direct interaction was observed 
between the different BMI groups and polyvascular disease for long-term survival. In additional 
subgroup analyses, patients were subdivided into two groups with either BMI <25 kg/m2 or BMI 
>25 kg/m2. In both groups, the presence of polyvascular disease was associated with reduced 
long-term survival rates. Kaplan-Meier long-term survival estimates are demonstrated in Fig 4. In 
both groups, the presence of multiply affected vascular beds was associated with an increased 
mortality risk during long-term follow-up. In multivariate analyses, patients with BMI <25 kg/m2 or 
BMI >25 kg/m2 and concomitant polyvascular disease had an independent increased mortality 
risk (HR=1.22; 95% CI=1.051.42 and HR=1.33; 95% CI=1.13-1.58; respectively) compared with 
patients without polyvascular disease. 
 
Medication use and risk factor control. Medication use at discharge demonstrated an under-
treatment of underweight patients compared with overweight or obese patients. The standard 
cardioprotective medical treatment for PAD patients included aspirin, statins, β-blockers, and 
ACE inhibitors. Fig 5 provides an overview of the number of drugs per BMI category and shows 
that 34 of 68 (50%) of the underweight patients received no medical treatment at discharge. A 
significant trend for more use of these four types of drugs was observed in patients with higher 
BMI compared with patients with lower BMI (P<0.001). During the follow-up period, aspirin 
(HR=0.71; 95% CI=0.63-0.80) and statins (HR=0.69; 95% CI=0.59-0.80) were significantly 
associated with lower mortality rates in propensity-adjusted analyses. 
 
The atherosclerotic risk factors of hypertension, diabetes mellitus, and dyslipidemia were 
related to higher BMI because the prevalence in patients with obesity was significantly higher 
(P<0.001) compared with lower BMI. Mean preoperative systolic and diastolic blood pressure for 
the total were 148±48 and 82±25 mm Hg, and no significant differences between the BMI groups 
were observed (P=0.55). 
 
Preoperative mean high-density lipoprotein-cholesterol (HDL-C) was highest in the 
underweight group (53.0 ± 19 mg/dL [1.37 ± 0.50 mmol/L]) and lowest in the obesity groups 
(43±13 mg/dL [1.10±0.34 mmol/L]; P<0.001). Mean LDL-C of the total population was 123±48 
mg/dL (3.19±1.24 mmol/L), and no significant differences in mean preoperative LDL-C were 
observed among the BMI groups. 
 
Several important differences between gender, smoking habits, and the BMI groups were 
observed. Of the 30 underweight women, 15 (50%) were current smokers compared with 32 of 
the 101 obese women (32%). In addition, only 1 underweight woman (3%) stopped smoking 
compared with 136 of 714 women (19%) in the other BMI groups. In the men, the number of 
previous smokers showed a clear association with the increase in BMI: 8 of 38 (21%) of the 
underweight men and 65 of 210 (31%) of the obese men were previous smokers. The number of 
current smokers decreased from 17 of 38 (45%) in underweight men to 67 of 210 (32%) in obese 
men. Finally, in all patients, current smoking was not an independent predictor of increased 
mortality risk; however, those patients who stopped smoking had a significantly lower mortality 
risk (HR,=0.84; 95% CI=0.72-0.98) compared with those who continued smoking. There were no 
differences between the BMI groups regarding the number of controlled cardiovascular risk 
factors. Good control (3 to 5 risk factors controlled) was achieved in 53% (36 of 68) of the 
underweight group compared with 54% (745 of 1379) of the normal-weight, 53% (623 of 1175) 
of the overweight, and 55% (171 of 311) of the obesity group (P=0.88). In separate analyses for 
individual risk factors, significant differences were only detected for target LDL-C <100 mg/dL 
(2.5 mmol/L). Underweight patients had the lowest effect rate of statin therapy, as only 6 of 68 
(9%) received the target compared with 179 of 1379 (13%) normal-weight, 188 of 1175 (16%) 
overweight, and 62 of 311 (20%) obese patients (P =0.005). 
 
DISCUSSION 
The current study demonstrated that overweight patients had a reduced long-term mortality 
risk. We observed a low prevalence of polyvascular disease in patients with low BMI compared 
with a significantly higher prevalence in patients with BMI >25 kg/m2. The increased prevalence 
of polyvascular disease in overweight and obese patients was independently associated with an 
increased mortality risk; however, no direct interaction between BMI and polyvascular disease 
was observed. Medical treatment at time of discharge in overweight and obese patients was 
highest, because only 18% of these patients received no treatment. Remarkably, risk factor 
control was achieved equally in all treated BMI groups. 
 
In the pathogenesis and complications of obesity, the adipocyte has a substantial role acting 
as an endocrine organ.17 Food intake and energy metabolism is controlled by the hormone leptin, 
which is derived from adipocytes. Increased leptin levels have been related to the development 
of cardiovascular disease.18 On the one hand, obesity stimulates the development of leptin 
resistance, which in turn influences insulin resistance and eventually results in type-II diabetes 
mellitus. On the other hand, obesity promotes hyperleptinemia, which stimulates increasing blood 
pressure through adverse effects on the vascular wall.18 Several studies, however, have not been 
able to demonstrate a clear role for leptin. 
 
Other more recent studies have demonstrated the involvement of other adipokines and the 
immune system through low-grade inflammation of adipose tissue, reflected by C-reactive protein 
elevations.19,20 These pathophysiologic mechanisms are important in the atherosclerotic process, 
a systematic inflammatory disease with clinical presentations in multiple vascular beds. Obesity 
has been identified as an important risk factor for developing CAD; however, once this has been 
established, the correlation between obesity and mortality is paradoxic. Therefore, other factors, 
such as the presence of polyvascular disease or medical undertreatment, could be involved in 
the obesity paradox on long-term outcome. 
 
The obesity paradox has extensively been described in patient cohorts with established CAD. 
A meta-analysis by Romero-Corral and colleagues summarized these studies and demonstrated 
that patients with overweight and mild obesity had lower mortality rates than normal-weight 
patients.10 In contrast, patients who were underweight had an increased all-cause and 
cardiovascular mortality risk compared with normal-weight patients.10 The obesity paradox was 
also recently demonstrated in a cohort of almost 5000 patients undergoing percutaneous 
coronary intervention.8 Mullen et al21 demonstrated that overweight and moderately obese 
patients in the general surgery population have paradoxically lower crude and adjusted risks of 
mortality compared with normal-weight patients. Galal et al22 have shown an excess mortality 
rate among underweight patients with PAD, which was largely explained by the over-
representation of individuals with moderate-to-severe COPD. 
 
Our study results are in line with these studies regarding the paradoxically increased mortality 
rates in underweight patients during long-term follow-up. Short-term postoperative outcome was 
not associated with an increased mortality risk for one of the BMI groups compared with normal 
weight. The survival curves suggest an increased mortality risk for the underweight patients; how-
ever, this is very likely a result of the small number of patients in this group. 
 
Gulsvik et al23 demonstrated a U-shaped risk curve for total mortality in the elderly, which was 
confirmed by our results in high-risk vascular surgery patients. Furthermore, overweight was 
associated with a survival benefit compared with normal weight; however, obesity showed no 
relation with an increased or decreased mortality risk. In the present study, we used the National 
Institutes of Health obesity classification12 to study the associations with the obesity paradox. It 
could be argued that cohort should be defined into four equal BMI quartiles because this could 
have more statistical significance. However, the main purpose of the present study was to provide 
the clinician with a practical and easy applicable definition; therefore, we used the predefined BMI 
groups. 
 
More important, although several possible explanations for the obesity paradox have been 
suggested, the influence of polyvascular disease has not been investigated. We demonstrated 
that overweight and obese patients had a significant increased incidence of polyvascular disease 
compared with a low incidence in underweight patients. Remarkably, patients with BMI <25 kg/m2 
or BMI >25 kg/m2 and concomitant polyvascular disease had an increased mortality risk 
compared with those without polyvascular disease. Because no direct interaction between BMI, 
polyvascular disease and long-term mortality was observed, it cannot be concluded that 
polyvascular disease is an explanation for the obesity paradox. 
 
In the present study, patients with low BMI received less frequent medical treatment at 
discharge compared with overweight or obese patients. Results from the Get With The Guidelines 
Database in CAD patients showed that higher BMI was associated with increased use of standard 
medical therapies such as aspirin, β-blockers, ACE inhibitors, and lipid-lowering therapies.24 This 
relation between BMI and treatment rates may represent the response of physicians to a more 
visible risk factor compared with the less visible traditional risk factors such as hypertension and 
diabetes. However, because obese patients had an increased incidence of polyvascular disease, 
this could also be the reason for intensified treatment. 
 
In the present study, the low and normal BMI groups were consistently associated with a lower 
prevalence of established cardiovascular risk factors, with the exception of current smoking. 
Therefore, these BMI groups were less likely to receive effective secondary prevention therapies 
such as lifestyle interventions and medical treatment. In contrast, overweight and obese patients 
received more aggressive medical treatment. Because overweight and obese patients are 
younger at first presentation, a more aggressive treatment strategy may be performed. 
 
The importance of socioeconomic status and dietary habits also needs to be acknowledged. 
These are known risk factors for developing overweight and have been associated with adverse 
long-term outcomes.25,26 Although overweight seems to have a protective perioperative effect, 
and overweight patients are more likely to receive earlier and extended medical attention, they 
remain at increased risk for developing metabolic and cardiac complications due to their 
increased body weight. 
 
Even though low BMI patients received less intensive medical treatment at the time of 
hospitalization, risk factor control intensity in those patients who did receive treatment was 
comparable with the other BMI groups. Of note, statin therapy was an independent predictor for 
increased survival rates; however, LDL-C lowering could be less efficient in patients with low body 
weight. Our results emphasize the importance of risk factor stratification and modification in 
vascular surgery patients with a low BMI, while adequate medical treatment at discharge was 
associated with improved survival rates in all groups of patients. 
 
Potential limitations of the current study merit consideration. First, this study has the 
disadvantage of a retrospective design and included a patient population of vascular surgery 
referrals that might not be fully representative for the general population. 
 
Second, although suggested by the survival curves, short-term postoperative mortality (30 
days) was not significantly different among the BMI groups. This is very likely a result of the small 
number of patients in the underweight group, and these results need to be interpreted with some 
caution. 
 
Third, the results of this study showing significant associations between medical treatment at 
discharge and increased survival rates need to be interpreted with some caution because no 
evaluation of treatment adherence during follow-up was available. 
 
Fourth, because AAA development is not causally related to the presence of atherosclerotic 
disease, although there are many common risk factors, appropriate medical therapy could be 
underestimated in these patients. 
 
Finally, data on socioeconomic status and dietary habits were not available, and therefore, 
we cannot rule out the possibility of confounding by these factors. In addition, although we 
adjusted the multivariate analyses for possible confounders (smoking, cancer, medical treatment) 
of the primary end point, we cannot rule out the possibility of residual confounding. 
 
CONCLUSIONS 
In this population of vascular surgery patients, more than half were categorized as overweight 
or obese. The prevalence of polyvascular disease was significantly higher in patients who were 
overweight or obese. The high prevalence of polyvascular disease in overweight and obese 
patients was independently associated with increased mortality compared with patients with 
monovascular disease; however, no direct interaction between polyvascular disease and BMI 
was observed. A significant trend for less medical treatment at discharge in relation to decreasing 
BMI was observed. Underweight patients were at an increased long-term mortality risk, whereas 


















































































Table I. Baseline characteristics of the study population
Variables Underweight (n = 68) Normal (reference) (n = 1379) Overweight (n = 1175) Obese (n = 311) P 
Demographics 
Age, mean ± SD years 66 ± 12 67 ± 12 67 ± 10 64 ± 11 <.001
Male, No. (%) 38(56) 1040 (75) 901 (77) 210 (68) <.001
History, No. (%) 
Malignancies 33 (49) 359(26) 188(16%) 44 (14) <.001
CVA/TIA 11 (16) 469(34) 447 (38) 110 (35) <.001
Lower extremity PAD 24 (35) 389(28) 257 (22) 96 (31) <.001
Aortic aneurysmatic disease 3(4) 34(3) 25 (2) 5 (2) .50
Ischemic heart disease 22 (32) 557 (40) 535 (46) 134 (43) .02
Cardiovascular risk factors, No. (%) 
Smoking 
No 27 (40) 522 (38) 462 (39) 128 (41) .02
Current 32 (47) 546 (40) 415 (35) 99 (32)  
History 9(13) 311 (23) 298 (25) 84 (27)  
Hypertension 21 (31) 665 (48) 646 (50) 182 (59) <.001
Diabetes mellitus 8 (12) 178 (13) 208 (18) 97 (31) <.001
Dyslipidemia 10 (15) 347 (25) 334 (28) 107 (24) <.001
Chronic heart failure 3(4) 102 (7) 83 (7) 18 (6) .63
COPD 8 (12) 273 (20) 219 (19) 57(18) .38
Medication at discharge, No. (%) 
Aspirin 17(25) 670 (49) 621 (53) 194(62) <.001
Statin 15 (22) 454 (33) 501 (43) 161 (52) <.001
p-blocking agents 20 (29) 575 (42) 529 (45) 169(54) <.001
Diuretics 11 (16) 285 (21) 293 (25) 107(34) <.001
ACE inhibitors 9(13) 330 (24) 300 (26) 101 (35) .002
Calcium antagonists 15 (22) 317 (23) 300 (26) 79 (25) .45
Angiotensin receptor blockers 2(3) 49 (4) 77 (7) 29 (9) <.001



















Table III. Long-term survival of all patients 
Events No. (%) Univariate HR (95% CI) Multivariatea HR (95% CI)
All-cause mortality 
Underweight 49/68 (72) 1.60 (1.19-2.15) 2.10 (1.45-3.03)
Normal 717/1379 (51.9) Reference Reference
Overweight 507/1175 (43.1) 0.76 (0.68-0.86) 0.77 (0.69-0.86)
Obesity 118/311 (37.9) 0.78 (0.64-0.95) 0.93 (0.76-1.13)
CI, Confidence interval; HR, hazard ratio. 
aAdjustment for age, gender, polyvascular disease, smoking, hypertension, diabetes mellitus, hypercholesterolemia, heart failure, chronic obstructive pulmonary 
disease, site of surgery, year of surgery, aspirin, statins, and ^-blockers. 
 
Table II. Primary cause of death of the study population
Primary cause of death 
Patients No. (%)




Acute myocardial infarction 180(13)
Cardiovascular disease, unspecified 335(24)
Septicemia 36 (3)
Cancera 260(19)
Complications of surgical and medical care not 
elsewhere classifiedb 29 (2)
Chronic obstructive lung diseasec 85 (6)
Pneumonia and influenzad 22(1)
Symptoms, signs, and abnormal clinical or lab 
findings, not elsewhere classified 73 (5)
Ill-defined and unknown causes ofmortality 106 (8)
Total 1389 (100)
Of these groups, 35,a 14,b 12,c and 10d were classified as a secondary cause of
death due to secondary cardiac complications. 
 







Fig 2. Distribution of the sites of the surgical procedures are shown for the body mass 







Fig 3. Cumulative survival is shown by Kaplan-Meier analysis of the risk of all-cause 








































Fig 4. Kaplan-Meier estimates show cumulative survival stratified according to the presence of monovascular or 
polyvascular disease in patients with a (left) body mass index <25 kg/m2  or (right) >25 kg/m2 






Fig  5.  Number of drugs used at the time of discharge for each body mass index group, 
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The Obesity Paradox in the Surgical Population 
 
Abstract 
Background: Despite the medical hazards of obesity, recent reports 
examining body mass index (BMI) show an inverse relationship with 
morbidity and mortality in the surgical patient. This phenomenon is known 
as the ‘obesity paradox’. The aim of this review is to summarize both the 
literature concerned with the obesity paradox in the surgical setting, as well 
as the theories explaining its causation. 
Methods: PubMed was searched to identify available literature. Search 
criteria included obesity paradox and BMI paradox, and studies in which BMI 
was used as a measure of body fat were potentially eligible for inclusion in 
this review. 
Results: The obesity paradox has been demonstrated in cardiac and in non-
cardiac surgery patients. Underweight and morbidly obese patients displayed 
the worse outcomes, both postoperatively as well as at long-term follow-up. 
Hypotheses to explain the obesity paradox include increased lean body 
mass, (protective) peripheral body fat, reduced inflammatory response, 
genetics and a decline in cardiovascular disease risk factors, but probably 
unknown factors contribute too.  
Conclusions: Patients at the extremes of BMI, both the underweight and 
the morbid obese, seem to have the highest postoperative morbidity and 
mortality hazard, which even persists at long-term. The cause of the obesity 
paradox is probably multi-factorial. This offers potential for future research 






With advancement of medical care in modern societies, two distinct growing 
phenomena are observed, which pose new challenges to the surgeon. These 
are the overweight and obesity epidemic on the one hand, and the growing 
elderly population on the other hand.1-3 These two categories of patients 
share a number of risk factors and associated comorbidities that predispose 
them to cardiovascular and other life-threatening complications.4,5  
 Body mass index (BMI), formerly known as Quetelet’s index, has been 
introduced to public health science as a proxy of overall body fat content. It 
is calculated by dividing weight in kilograms by the square of height in 
meters. In late and even in upcoming years, much attention has been paid 
to this index and to other measures of total or abdominal fat, due to the 
increasing prevalence of overweight and obesity. Because of its simplicity, 
BMI has gained widespread acceptance and application in daily clinical 
practice. The World Health Organization (WHO) has defined different BMI 
categories (Table 1).6,7  
Clinical research in the surgical population frequently focused on the 
prognostic value of certain clinical variables obtained from the preoperative 
assessment and the perioperative course.8-11 Some of these variables are 
incorporated in guidelines regarding preoperative cardiovascular 
management in non-cardiac surgery,12 which have been shown to reduce 
postoperative cardiac events and improve long-term outcomes. Furthermore, 
recognition and optimization of other, non-cardiac, chronic ailment 
conditions prior to surgery can also be beneficial, both in the perioperative 
stage as well as for the long-term.13 Although several preoperative risk-
scoring systems exist,14 BMI has not been included, since it was not 
considered as an independent (preoperative) risk factor or predictor for 
postoperative and long-term outcomes. 
 The purpose of this article is to give an overview of the relationship 
between BMI and outcome in the surgical population, reporting both 
postoperative and long-term outcomes. Furthermore, the literature 
regarding the inverse relationship between BMI and outcome, known as the 





We performed a PubMed search to identify available literature up to January 
1st, 2012. Search criteria included obesity paradox and BMI paradox, each of 
which was subsequently combined with additional search criteria including 
surgery, general surgery, cardiac surgery, outcome, and survival to narrow 
search results. Search criteria were restricted to English language, humans, 
and adults (age > 19 years). Original articles (observational, cohort, case-
control, cross-sectional, longitudinal and experimental), systematic reviews 
and meta-analyses were considered for inclusion in the review. Eligible 
studies were first identified by title, and abstracts in which BMI was used as 
a measure of body fat were retrieved as full-text papers. Additional studies 
were identified after reviewing related PubMed citations and references of 
the included papers.  
 
 
The risks of obesity in the surgical patient 
 
The worldwide broadening of the obesity epidemic has also affected surgery, 
not only because more surgical patients are obese, but also because of an 
increase in obesity related diseases that require surgery.1,4 Substantial data 
from literature showed the preponderance of cardiovascular risk factors in 
the overweight and obese population.1,4,15 Moreover, increased body mass 
was found to be a predictor of increased cardiac risk, independent of 
cardiovascular risk factors.16 Obesity is also known to be related to left-
ventricular morphological changes and impaired diastolic function.17 
Therefore, the observation of a strong association between obesity and long-
term mortality in several studies was not unexpected.18,19  
However, the perioperative risks associated with obesity might have 
been overestimated. Increased anesthetic and surgical interest in obesity, 
particularly in bariatric surgery, might have led to better care of obese 
patients and lower perioperative complication rates.20,21 Several prospective 
cohort studies with strict definitions of postoperative morbidity, 
demonstrated that in general (non-bariatric) surgery, postoperative 
complications like surgical site infections are related to obesity,22-27 with the 
highest rates in morbid (class III) obese patients.22,24,26,27 In addition, 
morbidly obese patients had the highest postoperative mortality 
rates.23,24,26,27 On the other hand, the lowest postoperative mortality risk 
was reported in the overweight and obese class I and class II patients.23,24,27 
In several surgical oncology populations the postoperative mortality rates 
did not differ between normal weight and overweight and obese 
patients.25,28-30 However, most data regarding the risks of obesity in the 
(non-bariatric) surgical population are obtained from large-scale studies in 
cardiac surgery patients. Since overweight and obesity are known to 
promote the progression of coronary heart disease,7 it is not surprising that 
around two thirds of all coronary artery bypass grafting (CABG) surgery is 
performed in overweight and obese patients.31,32 Similar to non-cardiac 
surgery, several prospective studies in CABG surgery demonstrated that 
obesity was shown to be related to postoperative morbidity, with the highest 
rates of deep sternal wound infection and prolonged ventilation and 
hospitalization in moderate (class II) and morbid (class III) obese 
patients.33-35 However, the majority of cardiac surgery studies, including 
CABG studies, did not report adverse associations with postoperative 
morbidity31,32,36 or mortality in obese patients.31,32,35-38 It is important to 
notice that current studies in various surgical populations do not make a 
distinction between obese surgical patients with normal metabolic profiles 
and those with diabetes, although it is widely known that diabetes adversely 
affects postoperative outcomes.  
Despite the large body of evidence showing that postoperative 
mortality is not increased in the majority of obese patients undergoing 
surgery, much attention has been paid to the association with postoperative 
morbidity, which might have led to a negative attitude towards obesity as a 
co-morbid condition in patients requiring surgery. 
 
 
The obesity paradox 
 
Recent epidemiological studies in the general population have shown a 
longer life expectancy in modern societies with prevalent overweight and 
obesity, compared to those that did not join the obesity epidemic.39,40 The 
inverse relationship between body fat composition, particularly defined by 
the BMI, and all-cause mortality, is frequently referred to as the obesity 
paradox. The more comprehensive term reverse epidemiology also 
comprises the obesity paradox. It represents the unexplained 
counterintuitive relationship of traditional cardiovascular risk factors and 
mortality in various (patient) populations.41-44  
Many studies in surgical populations have demonstrated a similar 
paradoxical relationship between BMI and postoperative mortality, with the 
highest postoperative mortality risks in the underweight and morbid (class 
III) obese patients (Figure 1). The obesity paradox has been shown in 
various surgical populations, both in cardiac31,32,34,36-38 and in non-cardiac 
surgery.23,24,26,27  
The majority of studies examining the effects of BMI on surgical 
outcome merely studied short-term (i.e. postoperative) mortality; however 
some also reported long-term survival.25,29,30,33,37,45-48 Underweight patients 
displayed the worse long-term survival, both in non-cardiac45 and in cardiac 
surgery.33,46,48 Overweight and obese patients showed conflicting results 
regarding long-term survival. Studies in vascular surgery,45 oncology 
surgery29,30 and cardiac surgery37 reported survival benefit for overweight 
and obese patients, whereas other studies in oncology surgery25 and cardiac 
surgery47 did not demonstrate any association with long-term survival.  
Table 2 gives an overview of different patient populations in which an 
inverse relationship between BMI and mortality was demonstrated. Most of 
these studies were conducted in Western populations; however, the obesity 
paradox has recently been described in East Asians as well.59 
 
 The paradox theories 
 
Since the first observation of the obesity paradox, several suggestions were 
made to overcome the unexpected survival benefit of the overweight and 
obese. One suggestion was that the values of BMI cut-offs representing the 
categories defined by the WHO should be revised, so that overweight 
patients showing survival improvement should merge into the control group 
i.e. the normal BMI population.60 However, it is important to consider that 
BMI does not discriminate between fat mass and lean mass, and as a result, 
BMI does not adequately reflect adiposity.61,62 Therefore, it might be that 
overweight and (mild) obese persons do not have more fat, but instead have 
a preserved or increased lean body mass, which would offer a possible 
explanation for the survival benefit in these groups. Consequently, it has 
been suggested to omit the BMI completely as an index of body fat and 
replace it with more accurate indices such as waist circumference, waist-to-
hip ratio and waist-to-height ratio, and with computed tomographic 
measurement of intra-abdominal fat content.63-65   
Conversely, others have tried to find explanations for the occurrence 
of the obesity paradox, which was first recognized in chronic disease 
populations. Moreover, the obesity paradox has also been described in the 
general population.19,60 Studies of BMI and cause-specific mortality in the 
general population, excluding persons with prior cardiovascular disease, 
cancer and chronic obstructive pulmonary disease (COPD), revealed that 
overweight was not associated with an increased risk of cancer or 
cardiovascular disease, and appeared to be relatively protective for 
survival.66 However, excess mortality in the obese population was mainly 
attributable to cardiovascular disease and obesity-related cancers, including 
colon cancer, breast cancer, esophageal cancer, pancreatic cancer, uterine 
cancer, ovarian cancer and kidney cancer.66,67 In contrast, upper 
aerodigestive cancers, COPD and other respiratory diseases could explain 
excess mortality in the underweight population.66,67 Chronic diseases, 
including cardiovascular disease, cancer and COPD, are characterized by 
wasting and increased inflammatory responses, thereby offering possible 




The benefits of obesity 
 
Adipose tissue is a potential endocrine organ capable of secreting a variety 
of cytokines with opposing actions.4 Tumor necrosis factor-α (TNF-α) is a 
pro-inflammatory and atherogenic macrophage-derived cytokine, and is 
known to promote cardiac and endothelial injury through its apoptotic and 
negative inotropic effects.68 Adipocytes release soluble TNF-α receptors, 
which can neutralize TNF-α in various inflammatory wasting states.69 
Moreover, adipocytes secrete adipokines, of which adiponectin plays a key 
role in regulating inflammation and endovascular homeostasis and increasing 
insulin sensitivity in peripheral tissues.70 Particularly visceral (abdominal) 
adiposity is associated with chronic inflammation, insulin resistance and 
enhanced progression of atherosclerosis.4 On the other hand, peripheral 
(lower-body) fat has a protective effect.71 These differences between visceral 
and peripheral adiposity are irrespective of gender.71 However, since BMI 
cannot distinguish between visceral and peripheral adiposity, this might offer 
an explanation for the observed survival benefit in the obese population.  
Inflammatory responses in obesity can also be reduced by the toxin-
scavenging ability of adiposity. Lipopolysaccharides (LPS) are potent 
endotoxins that induce the release of pro-inflammatory cytokines.72 Plasma 
concentrations of LPS are higher in chronic debilitating disorders.73-75 In 
overweight and obesity the negative effects of lipopolysaccharides are 
neutralized by the toxin-scavenging effect of adiposity, in which lipophilic 
end products of increased catabolism are sequestrated.57 Furthermore, 
increased levels of lipoproteins, which are often observed in overweight and 
obesity, may offer a survival advantage in chronic diseases, because 
lipoproteins can actively bind to and neutralize circulating endotoxins, the 
so-called endotoxin-lipoprotein hypothesis.76  
In addition, the prevalence of cardiovascular risk factors among the 
overweight and obese has declined in the past decades.77 Although 
cardiovascular disease remains the leading cause of death among the obese, 
this decline in cardiovascular risk factors might have led to a decrease in 
cardiovascular related mortality, and therefore to a decrease in total 
mortality.19 These findings are consistent with declining mortality rates from 
ischemic heart disease.78,79 However, it may take several years to decades 
for obesity and its related cardiovascular disease to have its full impact on 
mortality.80 Consequently, in studies without long-term (e.g. more than 15 
years) follow-up, the effects of obesity on mortality might have been 
underestimated, suggesting survival benefit for the obese. 
Finally, genetics might offer a different explanation for the survival 
advantage of the overweight and obese. The thrifty genotype theory is an 
old theory explaining obesity. This genotype emerged as an adaptive and 
selective gene-environment interaction in times of famine, and led to obesity 
when famines no longer occurred in the modern era.81 This theory would 
explain the survival advantage of the overweight and obese, however, it is 
not supported by any substantial scientific evidence.82 On the other hand, 
genetic polymorphism in systems related to food intake, energy expenditure 
and BMI definition can result in variable effects on body composition, which 
might lead to differential effects on survival among the obese population.83-
85 Figure 2 gives an overview of the multi-factorial causation of the obesity 
paradox. In addition to the various aforementioned explanations, there 
might be currently unknown factors that also contribute to its’ causation, as 
presented in the figure.  
 
 
The hazards of underweight 
 
The association of increased mortality in the underweight population might, 
at least in part, be attributable to reverse causation, which means that lower 
weight is not a cause but a result of chronic diseases that are related to poor 
outcome.86 Chronic diseases that cause weight loss may remain unnoticed 
for months or even years, for example, in the case of cancer, chronic 
respiratory or cardiac diseases. Smoking is another potential confounding 
factor, because it is associated with both a decreased weight and an 
increased mortality risk.86 In order to minimize the effects of reverse 
causation and smoking on mortality rates, deaths occurring in the initial 
follow-up period should be disregarded, and analyses should be restricted to 
patients without preexisting disease and to persons who had never smoked. 
However, studies that addressed these potential confounders still show 
increased mortality rates in the underweight population.18,19,67  
COPD and other respiratory diseases are responsible for the vast 
majority of mortality in the underweight population.66,67 This may be due to 
weight loss associated with COPD (reverse causation). However, low BMI in 
COPD has also been shown to be a risk factor for mortality, irrespective of 
disease severity.87 In addition, skeletal muscle dysfunction is a common 
feature in COPD, and can be caused by muscle loss due to wasting and by 
intrinsic muscular alterations, in which the proportions of skeletal muscle 
fiber types change.88 Skeletal muscle dysfunction is recognized to be an 
independent predictor of mortality in patients with COPD.89 In underweight 
patients with COPD the intrinsic muscular alterations are aggravated,90 and 
this could also explain the increased mortality risk in this group. 
 Wasting and inflammation could offer additional explanations for the 
mortality hazard of the underweight population. Improper nutrition and 
wasting in chronic illness can result in catabolic changes in skeletal muscle in 
lean subjects having minimal stores of fat, leading to cachexia.91 Oxidative 
stress may be an important underlying cause for both wasting and 
inflammation.92 Accumulation of oxidants results from a reduction in anti-
oxidant capacity in the face of elevated metabolic requirements. These 
oxidants have pro-inflammatory effects, which eventually will lead to fatal 
complications. This cascade is called the “malnutrition-inflammatory-
cachexia complex”.93 The deleterious effects of the malnutrition-
inflammatory-cachexia complex occur rapidly, and the short-term risks of 
underweight outweigh the long-term (cardiovascular) risks associated with 
obesity.93 The malnutrition-inflammatory-cachexia complex clearly explains 
the increased mortality risk in the underweight population.  
 
 
Implications for the surgical population 
 
As previously described, the obesity paradox has also been shown in the 
surgical population. The mechanisms explaining the survival benefit of the 
obese in the general population might also be applicable to the obese 
surgical patient. Moreover, it is speculated that overweight and mild obese 
patients have a more appropriate inflammatory and immune response to the 
stress of surgery than their leaner and morbid obese counterparts.26,27 There 
is a close relationship between the immune and metabolic response systems, 
and proper function of each is dependent on the other.94 Compared to 
normal weight patients, overweight and obese patients have a more 
sufficient nutritional reserve and might be functioning in a more efficient 
metabolic state, and as a result, the inflammatory and immune response to 
surgery might be more adequate. In contrast, both underweight and morbid 
obese patients are inefficient in energy expenditure, due to underlying 
malnutrition and metabolic excess. The inflammatory response to the stress 
of surgery is aggravated, which leads to further metabolic dysfunction and 
immunosuppression.  Consequently, these patients suffer from adverse 
outcomes following surgery.26,27  
In addition, recent weight loss of more than 10% of body weight and 
lower mean albumin levels, due to protein-energy malnutrition, are common 
in underweight patients and are indicators of malnourishment. Both 
conditions are well-known risk factors for adverse outcomes following 
surgery.95-98 Several nutrition-screening tools can adequately assess 
malnourishment, and are able to identify patients who should benefit from 
nutritional support.99 Peri- and postoperative nutritional support in 
malnourished underweight patients can improve outcomes following major 
surgery.100-103 On the other hand, preoperative nutritional support in obese 
patients is not recommended,101,102 although in obese patients nutritional 
deficiencies like iron deficiency, resulting in a higher prevalence of anaemia, 
are common.21 Weight loss in obese patients prior to surgery is not 
recommended as well, because studies that evaluated this strategy showed 
conflicting evidence regarding postoperative outcomes.21 In obese patients 
undergoing surgery, the highest priority should be on the recognition and 
adequate treatment of underlying cardiopulmonary comorbidities that 
negatively influence postoperative outcomes, including obstructive sleep 







Despite the feeling that obese patients requiring surgery are at increased 
risk for adverse postoperative outcomes, surgery can be relatively safely 
performed in the higher BMI categories. However, patients at the extremes 
of BMI, both the underweight and the obese class III, seem to have the 
highest postoperative morbidity and mortality hazard, which even persists at 
long-term. The inverse relationship between BMI and mortality is referred to 
as the obesity paradox, and has been observed both in the general 
population as well as in several disease specific populations. Cancer and 
respiratory diseases, including COPD, are responsible for excess mortality in 
the underweight population, exerting its effects at relatively ‘short’ long-
term, i.e. within years. On the other hand, cardiovascular disease accounts 
for the majority of deaths among the obese, particularly at longer follow-up. 
Cancer, COPD and cardiovascular disease are characterized by wasting and 
inflammation, thereby offering possible explanations for the obesity paradox. 
Moreover, it is important to consider that BMI is not a measure of body fat 
distribution. Likely, the cause of the obesity paradox is multi-factorial. It is 
suggested that future research should be directed at more accurate indices 
of body fat, such as waist circumference or computed tomographic 
measurement of intra-abdominal fat content and its’ relation with 
inflammation, in order to examine the association with survival and to 
evaluate whether the obesity paradox remains valid, not only in the general 
population, but also in disease specific populations. This provides more 
insight into the hazards of both underweight and (morbid) obesity and might 
lead to a more tailored approach, including dietary and drug strategies, in 
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Table 1 BMI classification according to the WHO6  
  
 BMI (kg/m2) 
Underweight < 18.5 
Normal 18.5 – 24.9 
Overweight (pre-obese) 25.0 – 29.9 
Obese ≥  30.0  
   Obese class I (mild obese) 30.0 – 34.9 
   Obese class II (moderate obese)  35.0 – 39.9 
   Obese class III (morbid obese) ≥  40.0 
 





Table 2 Populations showing the obesity paradox  
 
Non-surgical Populations Surgical Populations 
Cardiac Disease  Vascular surgery 
 Acute coronary syndromes50,51  Peripheral arterial disease23,45 
 Percutaneous coronary interventions 
(PCI)37 
 Abdominal aortic aneurysm24 
 Coronary artery disease55  
 Chronic atrial fibrillation49 Cancer surgery 
 Chronic heart failure44,54   Pancreaticoduodenectomy30 
   Gastrectomy29 
Chronic obstructive pulmonary 
disease44,52 
   
 Orthopedic surgery 
Renal disease   Arthroplasty58 
 Chronic kidney disease43   
 Maintenance dialysis57  Cardiac surgery 
  Coronary artery bypass 
grafting31,32,34,36-38 
Rheumatoid arthritis44  Left-ventricular assist device 
placement46 
  
Acquired immunodeficiency44  
  
Intensive care unit patients56  
  
Hospitalized patients53  
  
Advanced age44  
 
Legends to Figures 
 
Figure 1. Odds ratios (adjusted) for 30-day mortality after (non-bariatric) 
general surgery displayed by obesity class, with normal BMI class used as 







Figure 2. Schematic representation of possible causes of the obesity 
paradox, showing its’ multi-factorial origin with several (overlapping) 
hypotheses. 


























Relation between Preoperative and Intraoperative New Wall 
Motion Abnormalities in Vascular Surgery Patients: A 
Transesophageal Echocardiographic Study 
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Aims. This study evaluated the prevalence of left-ventricular (LV) dysfunction 
in vascular surgery patients and pharmacological treatment, according ESC 
guidelines. 
 
Methods. Echocardiography was performed preoperatively in 1,005 
consecutive patients. Left-ventricular ejection fraction (LVEF) ≤50% defined 
systolic LV dysfunction. Diastolic LV dysfunction was diagnosed based on 
E/A-ratio, pulmonary vein flow, and deceleration time. Optimal 
pharmacological treatment to improve LV function was considered as: (i) 
angiotensin-blocking agent (ACE-I/ABR) in patients with LVEF ≤40%; (ii) 
ACE-I/ABR and β-blocker in patients with LVEF ≤40% + heart failure 
symptoms or previous myocardial infarction; and (iii) a diuretic in patients with 
symptomatic heart failure, regardless of LVEF.   
 
Results. Left-ventricular dysfunction was present in 506 patients (50%), of 
whom 209 (41%) had asymptomatic diastolic LV dysfunction, 194 (39%) had 
asymptomatic systolic LV dysfunction, and 103 (20%) had symptomatic heart 
failure. Treatment with ACE-I/ABR and/or β-blocker could be 
initiated/improved in 67 (34%) of the 199 patients with asymptomatic LVEF 
≤40%. A diuretic could be initiated in 32 patients (31%) with symptomatic 
heart failure (regardless of LVEF). 
 
Conclusion. This study demonstrated a high prevalence of LV dysfunction in 
vascular surgery patients and under-utilization of ESC recommended 
pharmacological treatment. Standard preoperative evaluation of LV function 
could be argued based on our results to reduce this observed care gap. 
INTRODUCTION 
 
Patients undergoing vascular surgery are known to be at increased risk of 
perioperative complications due to frequently underlying (a)symptomatic 
coronary artery disease. Coronary artery disease is the aetiology of heart failure 
in 60–70% of patients, predominantly in the elderly population.1, 2. Coupled to 
the growing prevalence of heart failure and the elderly population, is the 
increase in surgical procedures. In addition, many invasive surgical 
interventions (such as major vascular surgery) are increasingly performed in 
elderly patients. Worldwide, about 100 million adults undergo noncardiac 
surgery every year and by the year 2020 the number of patients eligible for 
surgery will increase by 25%, with the largest group of patients aged >65 
years.3  
 
Considerable improvements have been made in the treatment of heart 
failure. Guidelines of the European Society of Cardiology (ESC) recommend 
treatment with angiotensin-converting enzyme inhibitors (ACE-I) in patients 
with systolic left-ventricular (LV) dysfunction, defined as LV ejection fraction 
(LVEF) ≤40%,  irrespective of the presence of heart failure symptoms to 
improve ventricular function.4 An angiotensin-receptor blocker (ARB) is 
recommended in case of ACE-I intolerance.4 Patients with asymptomatic 
systolic LV dysfunction and a myocardial infarction (MI) in past history are 
recommended to receive a β-blocker as well. A diuretic is recommended next 
to these agents in patients with symptomatic heart failure.4  
 
The aim of the current study was to evaluate the prevalence and 
pharmacological treatment for asymptomatic systolic LV dysfunction or 
symptomatic heart failure, according to the ESC guidelines, in the vascular 





Study population and baseline characteristics 
The patient population consisted of 1,005 consecutive vascular surgery patients 
at the Erasmus Medical Center (Rotterdam, the Netherlands) during 2002-2008. 
The study was approved by the hospital’s ethics committee and performed with 
the informed consent of all patients. A detailed history was obtained from every 
patient and clinical data included age, gender, ischemic heart disease (history of 
angina pectoris, coronary revascularization, or myocardial infarction),  
cerebrovascular disease (history of ischemic or hemorrhagic stroke), renal 
dysfunction (serum creatinine >2 mg/dL), diabetes mellitus (fasting blood 
glucose ≥7.0 mmol/L or requirement for anti-diabetic medication), 
hypertension (blood pressure ≥140/90 mmHg in non-diabetics and ≥130/80 
mmHg in diabetics or requirement for antihypertensive medication), 
dyslipoproteinemia (low-density lipoprotein cholesterol >3,50 mmol/L or 




Preoperatively, transthoracic echocardiography was performed in all patients 
using a handheld Acuson Cypress Ultrasound System (7V3c transducer). 
Standard images were obtained at rest with the patient in the left lateral 
decubitus position as recommended.5 Left-ventricular end-systolic and end-
diastolic volumes were determined and LVEF was calculated using the biplane 
Simpson’s technique.6 Systolic (S) and diastolic (D) pulmonary vein flow, 
deceleration time, and mitral inflow E/A ratios of peak velocities (at early rapid 
filling E and late filling due to atrial contraction A) were determined in apical 
4-chamber view as recommended 7.  An LVEF ≤50% was defined as reduced 
and an LVEF ≤40% was eligible for pharmacological treatment.4 Diastolic LV 
dysfunction was confirmed in patients with E/A-ratio <0.8 or >2.8 Abnormal 
pulmonary vein flow (S/D <1) was used to distinguish normal and pseudo-
normal diastolic LV function in patients with E/A-ratio between 0.8 and 2.9 
Deceleration time >220 or <140 ms defined diastolic LV dysfunction in 
patients with atrial fibrillation.9 Patients with both systolic and diastolic LV 
dysfunction were classified as systolic LV dysfunction. The presence of LV 
dysfunction in combination with heart failure symptoms (shortness of breath, 
fatigue, exercise intolerance, signs of fluid retention)4 defined symptomatic 
heart failure. Two experienced investigators performed off-line assessments of 
the obtained ultrasound images. When there was disagreement between the 
two assessors, a third investigator viewed the images without knowledge of the 
previous assessment and a majority decision was reached.  
 
European Society of Cardiology treatment recommendations  
During the first preoperative visit to the outpatient clinic, the use of the 
prescription medications was recorded and included ACE-Is, ARBs, β-
blockers, diuretics, statins, aspirin, oral anticoagulants, and nitrates. In the 
current study the following ESC treatment recommendations were used:  (i) 
treatment of  all patients with an LVEF ≤40% with at least ACE-I/ARB, (ii) 
treatment of patients with an LVEF ≤40% and a history of myocardial 
infarction with ACE-I/ARB and a β-blocker, (iii) treatment of heart failure 
symptoms with a diuretic, regardless of LVEF, and (iv) treatment of LVEF 
≤40% in combination with heart failure symptoms with ACE-I/ARB in 
combination with a β-blocker and diuretic.   
 
Contraindications for ACE-I/ARB were confirmed in patients with 
known ACE-I/ARB intolerance, history of angio-oedema, bilateral renal artery 
stenosis, serum potassium concentration >5.0 mmol/L, serum creatinine >2.5 
mg/dL, and severe aortic stenosis.4 Contraindications for β-blocker treatment 
were confirmed in patients with known β-blocker intolerance, sinus bradycardia 
<50 beats per minute, second- or third degree heart block, sick sinus syndrome, 
or asthma.4 In addition, contraindication for diuretic treatment was confirmed 
in patients with known diuretic intolerance, renal failure, clinical signs of 
hypovolemia or dehydration, serum potassium concentration <3.5 mmol/L, 
serum magnesium concentration <1.2 mmol/L, or serum sodium 
concentration <135 mmol/L.4  
 
Follow-up 
Long-term mortality was assessed by approaching the municipal civil registries. 
Survival status and medication use was completed by approaching the referring 
physician. All surviving patients received a mailed questionnaire (80% response 
rate) addressing medication use. Medication use in patients who died or 
patients who did not respond the questionnaire, was completed by approaching 
the referring physician. Mean follow-up was 2.2 ± 1.8 years.  
 
Statistical analysis 
Dichotomous data are presented as numbers and percentages and categorical 
data are compared using the χ2 test. The continuous variables age, blood 
pressure, and heart rate are described as means ± standard deviation (SD) and 
compared using ANOVA. The relation between ACE-I/ARB use in patients 
with an LVEF ≤40% and long-term mortality was evaluated with Cox 
regression analyses with propensity score adjustment for treatment with ACE-
I/ARB. Multivariate analyses were adjusted for demographics (age and gender), 
cardiovascular risk factors (ischemic heart disease, cerebrovascular disease, 
renal dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, 
chronic obstructive pulmonary disease, and smoking status) and medication 
use (β-blockers, statins, and aspirin). We report (crude and adjusted) hazard 
ratios with their 95% confidence interval. For all tests, a p-value <0.05 (two-
sided) was considered significant. All analyses were performed using SPSS 






The baseline study population consisted of 1,005 vascular surgery patients, of 
which the majority were males (77%) and the mean age was 67 (SD ± 10) 
years. Patients with LV dysfunction were older and more often male compared 
with patients with normal LV function. In addition, LV dysfunction was 
associated with ischemic heart disease, renal dysfunction, hypertension, and 
chronic obstructive pulmonary disease (Table 1).  
 
Prevalence of left-ventricular dysfunction 
Left–ventricular dysfunction was diagnosed in 506 (50%) patients (Figure 1), of 
which 403 (80%) patients had asymptomatic LV dysfunction and 103 (20%) 
patients had symptomatic heart failure. Of the patients with asymptomatic LV 
dysfunction, 209 (52%) had asymptomatic isolated diastolic LV dysfunction 
and 194 (48%) had asymptomatic systolic LV dysfunction. In total, 130 (67%) 
patients with asymptomatic systolic LV dysfunction had an LVEF ≤40% 
(Figure 2). In this group, a medical history of myocardial infarction could be 
appointed as a cause of LV dysfunction in 63 (49%) patients. In addition, 
valvular stenosis and/or regurgitation could be appointed in 33 (25%) patients 
as a possible cause of LV dysfunction.  
 
Of the 103 patients with symptomatic heart failure, 72 (70%) patients 
had NYHA II, 28 (27%) patients had NYHA III, and 3 (3%) patients had 
NYHA IV. In addition, 69 (67%) patients had an LVEF ≤40%. In this group, 
a medical history of myocardial infarction could be appointed as a cause of LV 
dysfunction in 52 (75%) patients. In addition, valvular stenosis and/or 
regurgitation could be appointed in 10 (15%) patients as a possible cause of LV 
dysfunction.  
Left-ventriccular (LV), standard deviation (SD). 
Table 1 









[N=499] [N=506]  
Demographics  
  Age in years (± SD) 65 (11) 70 (10) <0.01 
  Male (%)    363 (73) 406 (80) 0.005 
Medical history (%)  
  Ischemic heart disease   165 (33) 265 (52) <0.01 
  Cerebrovascular disease 169 (34) 184 (36) 0.407 
  Renal dysfunction 61 (12) 114 (23) <0.01 
  Diabetes mellitus 98 (20) 117 (23) 0.178 
  Hypertension 294 (59) 364 (72) <0.01 
  Hypercholesterolemia 233 (47) 249 (49) 0.425 
  Chronic obstructive pulmonary disease 145 (29) 222 (44) <0.01 













Left-ventricular (LV), left-ventricular ejection fraction (LVEF). 
 
 
Figure 2: Distribution of the different types of left-ventricular dysfunction.  
Deceleration time (DT), left-ventricular (LV), left-ventricular ejection fraction (LVEF). 
 
Pharmacological treatment at first presentation  
Medication use was recorded during the first presentation at the outpatient 
clinic. Most frequently, we observed the use of (i) statins (N=527 or 52%), (ii) 
aspirin (N=430 or 43%) (iii) β-blockers (N=366 or 36%), (iv) ACE-I (N=310 
or 31%), (v) diuretics (N=253 or 25%) (vi) oral anticoagulants (N=164 or 
16%), (vii) ARB (N=144 or 14%) and (viii) nitrates (N=101 or 10%). 
Medication use stratified according to LV function is demonstrated in Table 2. 
The use of ACE-I, ARB, β-blockers, diuretics, oral anticoagulants, and nitrates 
was associated with LV dysfunction.  
 
Angiotensin-converting enzyme (ACE), left-ventricular (LV). 
 
Pharmacological treatment to improve left-ventricular function 
As demonstrated in Table 3, 71 patients with an LVEF ≤40% and NYHA = 1 
did not have a myocardial infarction in their past history. Of these patients, 31 
Table 2 
Medication use stratified according to left-ventricular function 

























 [N=499] [N=209] [N=194] [N=103]  
ACE inhibitors 129 (26) 65 (31) 63 (33) 53 (52) <0.001
Angiotensin-receptor 67 (13) 28 (13) 28 (14) 21 (20) 0.005 
β-blockers 138 (28) 80 (38) 81 (42) 67 (65) <0.001
Diuretics  95 (19) 54 (26) 57 (29) 47 (46) <0.001
Statins  249 (50) 108 (52) 114 (59) 564 (54) 0.433 
Aspirin  165 (33) 83 (40) 102 (53) 80 (78) <0.001
Oral anticoagulants 61 (12) 35 (17) 41 (21) 27 (26) <0.001
Nitrates  32 (6) 19 (9) 20 (10) 30 (29) <0.001
(44%) patients received no treatment and 25 (35%) patients received optimal 
treatment with ACE-I/ARB to improve LV function. In addition, 128 patients 
with an LVEF ≤40% did have a myocardial infarction and/or had current 
NYHA ≥2. Of these patients, 31 (24%) patients received no treatment and 52 
(41%) patients received optimal treatment with ACE-I/ARB in combination 
with a β-blocker to improve LV function. Of the patients who received no or 
suboptimal treatment to improve LV function, 55 (28%) patients had a 
contraindication to ACE-I/ARB and/or β-blockers. Therefore, 
pharmacological treatment to improve LV function could be initiated or 
















     
 
a Treatment for LV function should at least contain ABA, b  Treatment for left ventricular function 
should at least contain an ABA in combination with β-blocker. Angiotensin blocking agent (ABA), 




Pharmacological treatment to reduce heart failure symptoms 
In total 103 patients had heart failure symptoms with a severity of NYHA class 
2 or more during the first presentation at the outpatient clinic (Table 4). Of 
Table 3 
Patients with left-ventricular ejection fraction 
≤40%, treatment with angiotensin blocking agents 




No previous MI 
and 






 [N=71] [N=128] 
ABA- β-blocker  -        (%) 31 (44) 31 (24) 
ABA+ β-blocker  - (%) 17 (24) 24 (19) 
ABA- β-blocker + (%) 15 (21) 21 (16) 
ABA+ β-blocker + (%) 8 (11) 52 (41) 

















(%) 13 (18) 15 (12) 
these, 47 (46%) patients received a diuretic. After adjustment for 
contraindications, initiation of diuretic treatment was possible in 32 (31%) of 
the patients. In addition, of the patients with an LVEF ≤40% and heart failure 
symptoms NYHA ≥2 (N=65), 19 (29%) patients received optimal treatment 
with ACE-I/ARB in combination with a β-blocker and a diuretic. Of the 
patients who received no or suboptimal treatment to reduce heart failure 
symptoms, 28 (43%) patients had a contraindication to ACE-I/ARB, β-
blockers or diuretics. Pharmacological treatment to reduce heart failure 
symptoms could therefore be initiated or improved in 18 (28%) patients with 
and an LVEF ≤40% and heart failure symptoms NYHA ≥2. 
Table 4 
Patients with symptomatic heart failure, treatment 
with diuretics for symptom relief 
 
NYHA ≥2 LVEF ≤40% 
 
LVEF >40% 
 [N=68] [N=35] 








(%) 16 (34) 8 (23) 









Pharmacological treatment at time of discharge 
In total, 199 patients with an LVEF ≤40% were recommended to receive at 
least ACE-I/ARB treatment to improve their LV function. Of these patients, 
139 (70%) patients were treated with an ACE-I/ARB, and 187 (94%) patients 
with a β-blocker at time of discharge. Multivariate analyses demonstrated that 
ACE-I/ARB treatment was independently associated with a reduced risk of 




We have found that LV dysfunction was present in around half of the patients 
undergoing vascular surgery and the majority (80%) of LV dysfunction was 
asymptomatic. Of the patients with asymptomatic LV dysfunction, around half 
the patients had asymptomatic systolic LV dysfunction. In addition, we found 
that in approximately one-third of the patients with LV dysfunction 
(asymptomatic or symptomatic), pharmacological treatment, as recommended 
in ESC guidelines, could be initiated or improved.  
 
In countries represented by the ESC, the prevalence of LV dysfunction 
is suspected to be around 4% in the general population. In septo- and 
octogenarians, the prevalence is between 10 and 20%.4 In our sub-population, 
of patients undergoing vascular surgery (mean age 67 years), we found a 
prevalence of LV dysfunction of around 50%. With respect to adherence of 
ESC recommendations, the EuroHeart Failure Survey provided information 
on the state of implementation of the guidelines.10 The following prescription 
rates in patients with LVEF <40% were reported: (i) ACE-I: 80%, (ii) ARB: 
6%, (iii) β-blocker: 49% and (iv) diuretics: 88%.10 Drechsler et al. assessed 
pharmacological treatment in 747 patients with symptomatic heart failure 
(LVEF ≤40%) and found that 84% received ACE-I, 72% received ACE-I + β-
blocker, and 38% received ACE-I + β-blocker + diuretic.11  
 
The above-mentioned studies included patients with symptomatic heart 
failure and concluded that there is insufficient adherence to the ESC 
guidelines. All patients included in the present study received routine 
preoperative echocardiography, which allowed the evaluation of asymptomatic 
LVEF ≤40% as well. We found that half of the patients with symptomatic 
LVEF ≤40% and one-third of patients with symptomatic diastolic LV 
dysfunction received a diuretic. In addition, less than one-third of the patients 
with symptomatic LVEF ≤40% received an ACE-I/ARB + β-blocker + a 
diuretic. Therefore, we found that optimal treatment for symptomatic heart 
failure was lower in our vascular surgery population, compared with the 
population described by Drechsler et al.11 Understandably, the under-use of 
ACE-I/ARB and β-blockers was more pronounced in patients with 
asymptomatic LVEF ≤40%. 
 
Peripheral arterial disease patients have a three to six-fold increased risk 
for cardiovascular mortality compared with patients without peripheral arterial 
disease.12, 13 There is growing awareness of the systemic vascular risk of patients 
with peripheral arterial disease. However, the Reduction of Atherothrombosis 
for Continued Health registry demonstrated that peripheral arterial disease 
patients do not receive adequate risk factor control, compared with individuals 
with coronary artery or cerebrovascular disease. In addition, it demonstrated 
that improved risk factors control is associated with a positive impact on 1 year 
cardiovascular event rates.14, 15 
 In the latest ESC perioperative guidelines, heart failure symptoms are a 
well-acknowledged risk factor for cardiac events.16 In addition, preoperative 
cardiac risk indices identify symptomatic heart failure to be an important risk 
factor.17-19 Asymptomatic LV dysfunction is considered a precursor of 
symptomatic heart failure, which is associated with high mortality.4 Currently, 
routine echocardiography is not recommended for preoperative evaluation of 
LV function. However, echocardiography may be performed in asymptomatic 
patients undergoing high-risk surgery, such as vascular surgery.16 We found that 
one out of four vascular surgery patients were eligible for pharmacological 
treatment of LV dysfunction,4 and more than half of these patients appeared to 
be asymptomatic. With more routine use of preoperative echocardiography in 
vascular surgery patients, pharmacological treatment of asymptomatic LV 
dysfunction could be improved.  
 
Based on cost-effectiveness considerations, preoperative 
echocardiography might not be applicable for all vascular surgery patients. 
However, these days biochemical markers such as N-terminal pro-B-type 
natriuretic peptide, are increasingly used to detect or exclude LV dysfunction.20 
Therefore, standard measurements of this biochemical marker may play an 
important role in detecting asymptomatic LV dysfunction in vascular surgery 
patients. In patients with increased levels of N-terminal pro-B-type natriuretic 
peptide, LV dysfunction could be confirmed with echocardiography.   
 
Potential limitations of these data merit consideration. First, although 
we included 1005 patients, the sample size eligible for ESC recommended 
treatment was relatively small. Second, although experienced investigators 
performed off-line assessments of the ultrasound images, we cannot rule out 
interobserver variability to have had minor influence on our results. Third, the 
evaluation of diastolic LV function was limited, not including E/E’ ratio, 
isovolumetric relaxation time, or Tissue Doppler Imaging. Finally, our 
population consisted of patients referred to a tertiary referral center and may 
not fully represent the general vascular surgery population. 
 
In conclusion, the current study demonstrates that one-third of 
vascular surgery patients with LV dysfunction do not receive optimal 
pharmacological treatment, as recommended in ESC guidelines. More routine 
use of echocardiography prior to vascular surgery could reduce the observed 
care gap in vascular surgery patients, with subsequent initiation of ESC 
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Abstract 
Background: Coronary revascularization of suspected culprit coronary lesion 
assessed by preoperative stress testing is not associated with improved 
outcome in vascular surgery patients.  
 
Objectives: To study the correlation between the location of the 
preoperative assessed new wall motion abnormalities (NWMAs) by 
dobutamine echocardiography (DE) and those assessed by transesophageal 
echocardiography (TEE) during vascular surgery.  
 
Methods: Fifty-four major vascular surgical patients underwent preoperative 
DE and intraoperative TEE. The locations of left ventricular (LV) rest wall 
motion abnormalities and NWMAs were scored using a seven-wall model. 
During 30-day follow-up, postoperative cardiac troponin release, myocardial 
infarction and cardiac death were noted. 
 
Results: Rest wall motion abnormalities were noted by DE in 17 patients 
(31%), and TEE was noted in 16 (30%). NWMAs were induced during DE in 
17 patients (31%), whereas NWMAs were observed by TEE in 23 (43%), κ 
value = 0.65. Although preoperative and intraoperative rest wall motion 
abnormalities showed an excellent agreement for the location (κ value = 
0.92), the agreement for preoperative and intraoperative NWMAs in different 
locations was poor (κ value = 0.26-0.44). The composite cardiac endpoint 
occurred in 14 patients (26%).  
 
Conclusions: There was a poor correlation between the locations of 
preoperatively assessed stress-induced NWMAs by DE and those observed 
intraoperatively using TEE. However, the composite end-point of outcome 
was met more frequently in relation with intraoperative NWMAs.  
 
Key words: dobutamine echocardiography, perioperative myocardial 
ischemia, transesophageal echocardiography, new wall motion abnormalities. 
 
Condensed abstract 
The correlation between the locations of preoperative assessed new wall 
motion abnormalities by dobutamine echocardiography (DE) with 
intraoperatively assessed new wall motion abnormalities by transesophageal 
echocardiography (TEE) was studied in patients undergoing major vascular 
surgery. DE could predict patients who developed postoperative cardiac 

























cTnT: cardiac troponin-T  
DE: dobutamine echocardiography  
ECG: electrocardiography  
κ: kappa estimate (coefficient)  
LV: left ventricular  
MAP: Mean arterial pressure (invasive)  
MI: myocardial infarction  
NWMA: new wall motion 
abnormality/abnormalities 
 
Rest WMA: rest wall motion 
abnormality/abnormalities 
 
TEE: Transesophageal echocardiography  
   
   
   
   
   




Vascular surgical patients represent a population at  increased risk for 
developing postoperative (PO) adverse cardiac outcomes. 1, 2 Cardiac stress 
testing prior to surgery is widely used to identify patients at increased risk of 
PO cardiac events. Recently, prophylactic coronary revascularization was 
studied in vascular surgery patients. 3 However, revascularization of the 
suspected intraoperative culprit coronary lesion, assessed by preoperative 
testing, was not associated with an improved outcome.  
Although, the pathophysiology of perioperative myocardial infarction 
(MI) is not entirely clear, it is now well accepted that coronary plaque 
rupture, leading to thrombus formation and subsequent vessel occlusion, is 
an important cause. This is similar to the non-operative setting. The surgical 
stress response includes a catecholamine surge with associated 
hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet 
activation, and consequent hypercoagulability. 4 In patients with significant 
coronary artery disease (CAD), MI may also be caused by a sustained 
myocardial supply/demand mismatch due to tachycardia and increased 
myocardial contractility. The association of PO MI with myocardial ischemia 
and nontransmural or circumferential subendocardial infarction supports this 
mechanism. Although, transmural ischemia is considered to be relatively 
uncommon, half of all fatalities have direct evidence of plaque disruption 
defined as fissure or rupture of plaque and hemorrhage into the plaque 
cavity. 5-7  
The use of intraoperative transesophageal echocardiography (TEE) had 
recognized a high prevalence of transient myocardial ischemic episodes 
causing regional wall motion abnormalities (WMA) in patients undergoing 
major non-cardiac surgery and requiring vigilant monitoring for serious 
cardiac outcomes. 8-10 Those transient events reflect the balancing effects of 
coronary reserve and myocardial viability versus a multifactorial 
perioperative ischemic load (burden). Different detection modalities like 
persantine-thallium scintigraphy and electrocardiography were compared to 
intraoperative TEE in detecting ischemia with inconclusive results. 11, 12 
However, the location of ischemic events has never been a primary goal in all 
previous investigations. 
Our hypothesis is that although dobutamine echocardiography (DE) 
can identify the patients at risk, the location of the cardiac event is difficult to 
foresee because of the unpredictable plaque rupture of non-significant, 
vulnerable, coronary artery lesions. In the present study we matched 
preoperative assessed ischemic left ventricular (LV) territories using DE and 
intraoperatively observed new wall motion abnormalities (NWMA) using TEE 
to examine the chance of reproducibility of a NWMA at the same location 
preoperatively and intraoperatively as well. This matching correlation would 





Materials and Methods 
Study participants 
In this prospective cohort study, patients over 40 years of age 
scheduled for non-cardiac vascular surgery at Erasmus University Medical 
Center, Rotterdam, the Netherlands, between June 2005 and September 
2008 were candidates for inclusion in the study. Patients had to be scheduled 
for abdominal aortic aneurysm repair, abdominal aortic stenosis surgery or 
lower limb arterial reconstruction. We used the Lee’s revised cardiac risk 
index which included history of ischemic heart disease, heart failure, 
cerebrovascular accidents, insulin therapy for diabetes mellitus and renal 
disease with serum creatinine > 2.0 mg/dL to abbreviate the cardiac risk 
factors, to identify patients at risk. 13 All patients underwent DE prior to 
surgery. Exclusion criteria for the study was the inability to retrieve adequate 
echocardiographic views pre or intraoperatively. After approval of the Medical 
Ethics Committee board and obtaining a patient informed consent, we 
included 54 consecutive adult patients.  
Dobutamine echocardiography  
All patients underwent DE to evaluate LV wall motion using 
dobutamine (± atropine) as a stressor. Two-dimensional echocardiography 
was performed at rest using Hewlett-Packard Sonos 1000 echo apparatus 
(Hewlett-Packard, Andover, MA, USA) with 2.5 and 3.5 MHz transducers. The 
technique yielded standard para-sternal and apical echocardiographic views 
under basal conditions and throughout graded dobutamine infusion. A 
stepwise incremental dose of dobutamine was administered, beginning at 10 
μg/kg/min, increased by 10 μg/kg/min every 3 min until a definite end-point 
was attained. 14-16 During the dobutamine infusion, heart rate, blood 
pressure and electrocardiography were monitored. When the target heart 
rate (85% of maximum age and gender predicted heart rate) was not 
obtained at the maximum dobutamine dose (40 μg/kg/min), atropine (0.25-
1.0 mg) was administered. 15, 17 Test end-points were achievement of target 
heart rate, maximal dose of dobutamine and atropine, extensive NWMA, 
>2mV downsloping ST-segment depression measured 80 ms after the J-point 
compared with the baseline, hypertension (blood pressure > 240/120 
mmHg), a decrease in systolic blood pressure of > 40 mmHg compared with 
at rest, significant arrhythmias, or any intolerable adverse effects considered 
to be the result of dobutamine or atropine. An intravenous beta-blocker 
(metoprolol 1 to 5 mg) was available to reverse the adverse effects of 
dobutamine/atropine. The test was completed only after all ischemic regions 
had returned to baseline.  
Transesophageal echocardiography 
 After induction of anesthesia and endotracheal intubation, the 
TEE probe was inserted. We based our TEE examination on the 
recommendations of the American Society of Echocardiography Council for 
Intraoperative Echocardiography and the Society of Cardiovascular 
Anesthesiologists guidelines for performing a comprehensive intraoperative 
multiplane transesophageal echocardiography examination. 18 The LV wall-
motion was monitored in 6 views; namely; 3 mid-esophageal views (the 4-
chamber mid-esophageal view, the mid-esophageal 2-chamber view, and the 
mid-esophageal long-axis (LAX) view), and 3 trans-gastric views (basal, mid-
papillary and apical trans-gastric views). Baseline images of the LV in short 
and long-axis were acquired and tape-recorded for offline analysis. The TEE 
probe depth and imaging planes of the basal views were noted to reproduce 
equivalent views intraoperatively. To improve the detection of intraoperative 
NWMA, we adopted a semi-continuous method keeping the TEE probe in the 
transgastric position with the mid-papillary left ventricular short-axis view 
continuously displayed and repeating the whole set of the examination views 
every 10 minutes and whenever there was echocardiographic suspicion of 
NWMA, hemodynamic change or surgical maneuver requiring special 
attention. For safety reasons, echocardiographic monitoring was freezed 
whenever the probe temperature exceeded 37.5˚C which allowed the probe 
to cool down shortly. 
TEE images were obtained using a standard adult 5 MHz multiplane 
transesophageal probe (GE LOGIQ 500 Probe, model H4552TB; General 
Electric) and the VingMed® System 5 echocardiographic imaging system 
(General Electric-VingMed Ultrasound, Horton, Norway). The main 
investigator was responsible for intraoperative image acquisition and passed 
a comprehensive training in transesophageal echocardiography in the study 
institute and performed 150 comprehensive TEE examinations as 
recommended by the American society of Echocardiography Council for 
Intraoperative Echocardiography and the Society of Cardiovascular 
Anesthesiologists. 18 The occurrences of LV NWMA, as well as the segmental 
location of each abnormality were recorded for each patient. The training 
physicians (anesthesiologists and surgeons) were blinded to intraoperative 
echocardiographic findings except if significant NWMA (involving > 4 
segments) necessitating immediate management were apparent on the 
screen. 
Interpretation of echocardiographic views 
DE test results and intraoperative TEE recordings were scored for rest 
WMA and new wall motion abnormalities (NWMA) using a 17-segment model 
as proposed by the American Society of Echocardiography and interpreted 
accordingly into a 7-wall LV model. 19-21 Transcription of LV segments to their 
LV wall involvement was done as shown in figure 1 redrawn based on the 
illustrations of LV wall in the TTE reports recommended by our institute and 
in the recommendation of the American society of Echocardiography Council 
for Intraoperative Echocardiography and the Society of Cardiovascular 
Anesthesiologists for the comprehensive TEE examination. 18 
A 5-point scale was used for wall motion analysis: 1 = normal; 2 = 
mild-moderate hypokinesis; 3= severely hypokinetic; 4 = akinesis; 5 = 
dyskinetic, as employed earlier. 14-17 Recorded echocardiographic loops were 
displayed simultaneously with resting images in a cine-loop format for 
interpretation. All images were analyzed at one time by two experienced 
readers blinded to clinical, electrocardiography, or other perioperative patient 
data. A NWMA was interpreted whenever a new or worsening regional LV 
motion was observed. Normal wall motion or an unchanged rest WMA were 
not considered for myocardial ischemia. Disagreements in interpretation were 
resolved by consensus.  
Definition of end-points 
All patients were monitored postoperatively for the development of 
adverse cardiac events. Standard electrocardiography and cardiac troponin-T 
(cTnT)) were serially measured after surgery on days 1, 3, 7, and 30 or at 
discharge. Tests were repeated when patients has had symptoms and/or 
signs of clinical myocardial ischemia. Troponin T level was measured by an 
electrochemiluminescence immunoassay on the Elecsys 2010 (Roche 
Diagnostics, Mannheim, Germany). The recommended lower limit of 0.03 
ng/ml was used to define positive troponin T levels because lower levels do 
not meet the imprecision criteria of <10%. 
The study end-point was the combination of elevated cTnT, MI, and 
cardiac death. Criteria of MI diagnosis included at least two of the following: 
cTnT ≥ 0.1 ng/ml, typical electrocardiographic changes (new Q waves >1 
mm or >30 ms in electrocardiogram), and typical chest pain complaints. 
Cardiac death was defined as fatal MI (postmortem evidence of acute MI or 
definite criteria for MI within the 24 hr before death) and sudden cardiac 
death. Sudden cardiac death was defined as unexpected natural death due to 
cardiac causes, within one hour of the onset of acute symptoms. 
Statistical Analysis 
Categorical variables are expressed as percentages and were 
compared using the Pearson's chi-square test. Continuous variables are 
presented as mean (± SD) and were compared using the unpaired Student t-
test. Correlation between DE and intraoperative TEE results in different LV 
locations was tested by means of kappa statistic (κ), to verify if a paired rest 
WMA or NWMA locality, estimated by both techniques, might differ from 
agreement that could occur by chance alone. The κ measure of agreement 
between two observations ranges between 0 and 1 (0 is chance agreement, 
less than 0.4 poor agreement, 0.4 to 0.75 fair to good agreement, and over 
0.75 excellent agreement). The measured κ value is presented in table or 
text. 
For all tests, a P value <0.05 (two-sided) was considered significant. 
All analyses were performed using the syntax commands of SPSS® v15.0 
statistical package for Windows® (SPSS Inc., Chicago, Illinois). 
 
Results 
 Fifty-four consecutive patients were enrolled in the study. 
Preoperative baseline clinical characteristics are shown in table 1 including 
baseline echocardiographic variables. None of the examined patients had 
pacing devices. Operative characteristics are shown in table 2. We excluded 
six eligible patients from our study: two due to inability to insert the TEE 
probe which encountered resistance and four cases due to improper 
visualization of standard echo-views mentioned in the methods. 
 Dobutamine echocardiography and TEE showed rest WMA in 17 
(31%) and 16 (30%) patients respectively, κ value on patient base = 0.92. 
The agreement for location of rest WMA was excellent, κ range = 0.77-1.0. 
Stress-induced NWMA during DE occurred in 17 patients (31%), whereas 
intraoperative NWMA were observed by TEE in 23 patients (43%), κ value on 
patient base = 0.65. However, the agreement for location of NWMA, using a 
7-wall model was poor, κ range = 0.26-0.44. Echocardiographic locations of 
NWMA were presented in figure 2 and table 3. κ value for inter-observer 
variability for the different LV walls ranged between 0.91-0.98. A random 
sample of 10 patients were selected and re-scored for LV wall motion by each 
scoring investigator. Intra-observer κ value for the different LV walls ranged 
between 0.97-1.00. 
 During 30-day follow-up the composite endpoint occurred in 15 
(28%) patients; cTnT release in 14 (26%), MI in 6 (11%), and cardiac death 
in 3 (6%); (Table 4). In these 15 patients, 10 (67%) experienced both pre 
and intraoperative NWMA, while in 4 (27%) only intraoperative NWMA were 
observed. In only one patient (7%) without pre- and intraoperative NWMA, 
troponin release was observed. This patient did not experience ischemic 
symptoms or electrocardiographic abnormalities. The relation of preoperative 
and intraoperative NWMA and PO outcome is presented in table 4. In all 6 
patients who experienced a PO MI, the location of electrocardiographic 
changes matched with the intraoperatively observed NWMA by TEE, while in 
2 (33%) there was an agreement with the preoperative induced ischemia 
during DE. 
 Figure 3 represented the sub-division of the total population 
according to preoperative and intraoperative development of NWMA and PO 
cardiac outcome. The presence of multi-vessel CAD as detected by DE and 
intraoperatively by TEE was in favor of a composite outcome (P < 0.05 for DE 
and P = 0.001 for intraoperative TEE) but not a single-vessel disease 
(P=NS). In table 5, we presented the calculated diagnostic indices of both 
preoperative DE and intraoperative TEE for the study outcomes.  
 
Discussion  
 In this study we used echocardiography to observe the location of 
NWMA induced preoperatively during DE and those developed 
intraoperatively by TEE monitoring in 54 high-risk vascular surgical patients.  
Using the κ coefficient, we observed an excellent correlation between 
preoperative and intraoperative rest WMA (κ range 0.8-1.0), indicating 
concordance between preoperative and intraoperative echocardiographic 
recordings. However poor agreement correlations were found between 
preoperative and intraoperative locations of NWMA (κ ≤ 0.4). 
  While patients with severe and unstable coronary disease are 
warranted to undergo preoperative stress testing to direct toward the optimal 
prophylactic strategy, those who have stable coronary disease do not show 
much benefit from stress testing over clinical stratification. Dobutamine 
echocardiography; among other stress tests; accurately determine reversible 
ischemic regions. However, those tests have stronger negative than positive 
predictive power particularly in the stable coronary disease population. 
Perioperative beta-blockade had proven to be a sufficient prophylactic regime 
in such patients. In the present investigation, approximately 45% of our 
population presented with established coronary artery disease, 14% 
presented with two and 43% showed three or more risk factors among the 
Lee’s revised cardiac risk index with fair LV function in average estimated by 
mean ejection fraction. This stratification puts this population in the grey 
zone of where optimized medical therapy is weighed against coronary 
revascularization. The purpose of this study was to determine which of the 
two prophylactic measures is optimal in order to provide better PO cardiac 
outcome. 22, 23 
Autopsy studies had shown the pathologic similarity of perioperative 
MI to that occurring in the non-operative setting, however, they were 
unsuccessful at the predictability of the site of vulnerable plaque rupture in 
most instances of perioperative MI based on the severity of coronary 
stenosis. 6, 7 This means that selective targeting of isolated culprit plaque(s) 
by means of a focused revascularization techniques, as a prophylactic 
measure cannot be employed with adequate results. 
 Due to the high propensity of CAD in the peripheral arterial disease 
population requiring elective surgical intervention, preoperative cardiac 
evaluation might suggest an indication for coronary revascularization in those 
presenting with severe coronary stenosis. 5, 24, 25 Pooled data from previous 
studies were not favor of preoperative coronary revascularization prior to 
major non-cardiac surgery. In the CARP trial, coronary arterial 
revascularization in 258 symptomatically stable; but severe CAD patients did 
not confer beneficial outcomes on perioperative or long-term than in the 
control group (252 patients) prior to major vascular operations. 3 Similar 
findings were shown in the DECREASE-V randomized pilot study in 101 high-
risk vascular surgical patients randomized either to no intervention (n=52) or 
coronary revascularization before vascular surgery (n=49). 26 The CASS trial 
investigators suggested similar conclusions, when equivocal long-term 
outcomes were observed between coronary artery bypass graft surgery and 
intensive medical treatment patient groups. 27 These findings remained the 
same after 10 years of follow-up. Comparable results were shown by medical 
treatment, surgical treatment, or PCI. 28 Finally, reports of unwanted 
outcomes had been addressed for PCI prior to non-cardiac surgery in the at-
risk CAD population. 29, 30 Indeed, the reason that coronary artery bypass 
graft was found superior to PCI prior to vascular surgery in one study was 
the more extensive revascularization in the coronary artery bypass graft 
group. 31 
 We reported PO cardiac outcomes as 26%, 11% and 6% for PO cTnT 
release, MI and cardiac death respectively. These events were predictable by 
the induction of NWMA by a DE stress test and even better predicted by the 
occurrence of intraoperative NWMA. In our population, NWMA induced during 
DE or detected intraoperatively by TEE presented more with multi-vessel CAD 
form, which was also correlated with the combined cardiac outcome 
(P=0.003 for multi-vessel reversible ischemia by preoperative DE, and 
P=0.001 for multi-vessel reversible ischemia by intraoperative TEE) but not a 
single coronary vessel’ related NWMA (P=NS). This indicated the more 
extensive nature of coronary vascular disease they had.  
 We found perfect matching of intraoperative NWMA location with PO 
electrocardiographic locality of MI indicating the accumulation of most 
perioperative stressors on the vulnerable myocardium of the vascular surgical 
patient in the intraoperative phase exhausting the moribund coronary 
reserve around the end of surgery which would hence yield most fatal MI’s in 
the immediate PO phase up to 12 hours PO. This coincides with the well-
established knowledge that > 50% of perioperative MI’s do occur in the 
immediate PO period and led to recommending twice daily 
electrocardiography in the first PO day. Additionally, we reported PO cTnT 
release in 14 patients (26%). In 8 (57%) of them, troponin release was not 
associated with MI. LeManach and colleagues found earlier in a larger cohort 
of vascular surgical patients that PO abnormal troponin (14% of 1136 patient 
population). Elevated cardiac troponins were related to PO MI (in 35% of the 
elevated troponin patients) in two distinct fashions (early and late) indicating 
two different sets of myocardial stressors nearer and later from the end of 
surgery. 32 Our incidence of elevated PO troponin is similar to or even 
reduced to that reported in other research in similar populations. 25, 33, 34 
Silent myocardial ischemic events would result from the effects of 
perioperative stressors in a myocardial demand/supply mismatch insufficient 
to progress to evident myocardial damage. This is supported by the finding 
that perioperative cTnT is related to poor long-term cardiac outcomes. This 
would explain the higher rates of sub-clinical ischemic events (elevated cTnT 
or transient NWMA) over harder cardiac events in our and other populations. 
23, 25, 35 
 Intraoperative TEE showed an additional incremental value on the 
prediction of PO cardiac events. Both preoperative NWMA during DE and 
intraoperative NWMA detected by TEE had a significant association with the 
composite cardiac outcome (P < 0.001). No events of cardiac death or PO MI 




We had several limitations in the present study. Some cases were excluded 
for either technical difficulty in image acquisition at any stage or 
inappropriate views to judge LV wall motion. We could not continue to enroll 
more patients for time factors limiting the level of power of our significant 
results especially those related to the regression analysis. Some NWMA were 
probably missed particularly prior to probe insertion following the start of 
anesthesia induction. Coronary angiography was not clinically indicated 
preoperatively in the studied patients and hence we could not relate our 
findings to the more pathognomonic angiographic data. Some reversible 
segmental LV wall motion abnormalities could have been missed in some 
views while obtaining others for offline analysis. Nevertheless, concomitant 
mechanical effects like tethering by a coexisting myocardial scarring or 
ballooning effect during aortic cross-clamping would have influenced our 
judgment for a NWMA. Finally, Kappa measurement is a useful statistic to look for 
the chance of agreement between two sets of readings. However, it has some flaws 
particularly its vulnerability towards difference in prevalence regardless a fixed specificity 
and sensitivity between the two readings particularly when sophisticated variables and 





In patients undergoing major vascular surgery, preoperative 
dobutamine echocardiography and intraoperative transesophageal 
echocardiographic monitoring of wall motion changes had good correlation 
with PO cardiac troponin-T release and myocardial infarction. 
Transesophageal echocardiography; however; had a stronger association 
with all PO cardiac events. Reproducibility of wall motion abnormalities in the 
same myocardial wall locations at different perioperative times was not 
achievable. This suggests the superiority of optimized medical therapies over 
the invasive interventions focused on particular culprit lesions for the 
prophylaxis against perioperative myocardial ischemia. In our population 
receiving beta-blocking medications, the higher predictive power of 
intraoperative TEE over preoperative DE for PO outcomes further emphasizes 
the importance of optimized medical treatments over preoperative cardiac 
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Fig. 1. Left ventricular (LV) myocardial segmentation for echocardiographic 
wall motion analysis with corresponding distribution of coronary arterial blood 
supply, showing segmental distribution of the seven LV walls in dobutamine 
echocardiography (A) and in transesophageal echocardiography (B). Cx = 
circumflex artery; LAD = left anterior descending coronary artery; RCA = 
right coronary artery. 
 
 
 Fig. 2. Agreement for location in ischemic left ventricular (LV) walls between 









Fig. 3. Composite cardiac outcome according to perioperative new wall 











Table 1. Baseline and Perioperative Patient Characteristics in All and Sub-populations 




Preoperative DSE Intraoperative TEE
NWMA No NWMA 
P value 
NWMA No 
A P value N=54  N=17  (31) N=37  (69) N=23  (43) N=31  (57) 
Patient Demographics:   
Mean age (± SD) 65.5±12.1 69.7±12.1 63.6±11.7 NS 71.0±11.9 61.4±10.7 < 0.05 
Male sex 48 (89) 15 (88) 33 (89) NS 20 (87) 28 (90) NS 
Angina pectoris 13 (24) 6 (46) 7 (54) NS 10 (44) 3 (10) NS 
Previous myocardial infarction 24 (44) 10 (59) 14 (38) NS 14 (61) 10 (32) < 0.05 
Previous coronary revascularization € 14 (26) 6 (43) 7 (57) NS 7 (30) 7 (23) NS 
Previous stroke 11 (20) 5 (29) 6 (16) NS 7 (30) 4 (13) NS 
Diabetes mellitus £ 12 (22) 8 (47) 4 (11) < 0.05 6 (26) 6 (19) NS 
Renal dysfunction Ω 8 (15) 5 (29) 3 (8) < 0.05 6 (26) 2 (7) < 0.05 
Hypertension ¥ 34 (63) 11 (65) 23 (62) NS 15 (65) 19 (61) NS 
Hypercholesterolemia 29 (54) 13 (77) 16 (43) < 0.05 15 (65) 14 (45) NS 
Chronic obstructive pulmonary disease 22 (41) 8 (47) 14 (38) NS 13 (57) 9 (29) < 0.05 
Congestive heart failure 3 (6) 0 (0) 3 (8) NS 3 (13) 0 (0) < 0.05 
Echocardiographic features§        
Left ventricular hypertrophy  23 (43) 9 (53) 14 (38) NS 14 (61) 9 (29) NS 
Ejection Fraction (mean ± SD) 47.1±8.6 44.8±9.6 47.7±6.5 NS 44.9±5.8 44.7±5.2 NS 
Fractional Area Change (mean ± SD) 43.9±8.2 44.3±7.9 43.3±8.3 NS 45.0±8.8 43.1±8.1 NS 
Fraction Shortening (mean ± SD) 26.9±5.2 25.2±5.1 28.4±5.0 NS 25.9±3.6 27.4±5.8 NS 
        
ASA Physical Status classification:        
            ● ASA Class I 3 (6) 0 (0) 3 (8) NS 0 (0) 3 (10) NS 
            ● ASA Class II 13 (24) 4 (24) 9 (24) NS 5 (22) 8 (26) NS 
            ● ASA Class III 29 (54) 8 (47) 21 (57) NS 12 (52) 17 (55) NS 
            ● ASA Class IV 9 (17) 5 (29) 4 (11) NS 6 (26) 3 (10) NS 
LEE RCRI:        
            ● I 17 (32) 0 (0) 17 (46) 0.001 2 (9) 15 (48) < 0.05 
            ● II 14 (26) 3 (18) 11 (30) NS 6 (26) 8 (26) NS 
            ● ≥ III 23 (43) 14 (61) 9 (39) < 0.001 15 (65) 8 (26) < 0.01 
Medication:        
Beta-blockers 54 (100) 17 (100) 37 (100) NS 23 (100) 31 (100) NS 
Statins 29 (54) 14 (82) 15 (41) < 0.05 16 (70) 13 (42) < 0.05 
ACE-inhibitors 13 (24) 7 (41) 6 (16) < 0.05 9 (39) 4 (13) < 0.05 
Calcium-channel blockers 9 (17) 6 (35) 3 (8) < 0.05 6 (26) 3 (10) NS 
Aspirin 35 (65) 11 (65) 24 (65) NS 14 (61) 21 (68) NS 
Nitrates 2 (4) 1 (6) 1 (3) NS 2 (9) 0 (0) NS 
Diuretics 12 (22) 5 (29) 7 (19) NS 8 (35) 4 (13) NS 
Continuous variables are shown as mean (SD), while dichotomous variables are shown as number (% of 
column totals). 
€ Coronary artery bypass graft surgery and/or percutaneous coronary intervention procedures. 
£ Fasting blood sugar ≥ 7 mmol/L or use of hypoglycemic agents. 
Ω  Serum creatinine level ≥ 2.0 mg/dl [177 mmol/L] or requirement of dialysis. 
¥ Arterial blood pressure ≥ 140/90 mmHg or use of antihypertensive drugs. 


















Table 2. Population Operative Characteristics with respect to the distribution of 





NWMA No NWMA 
P value 
N=54  N=23 (43) 
N=31  
(57) 
Anesthetic technique:     
General anesthetic 31 (57%) 10 (44%) 21 (68%) NS
Combined general and epidural 
anesthesia 23 (43%) 13 (57%) 10 (32%) NS 
    NS
Surgical procedure:     
● Open aortic prosthetic repair 34 (63%) 17 (74%) 17 (55%) NS
       - Clamping duration  (min) 49.4±54.6 52.4±45.1 47.9±55.7 NS
     
● LLR 20 (38%) 6 (26%) 14 (45%) NS
     
● Procedure duration (min) € 267.6±72.1 275.1±45.4 264.6±64.1 NS
● Operative blood loss (L)€ 0.5 (0.6-1.9) 0.6 (0.2-1.9) 0.5 (0.4-1.8) NS
     
Intraoperative fluid 
administration 
    
  ● Crystalloids (L) € 4.0 ± 0.2 4.6±2.9 3.8±1.9 NS
  ● Colloids (L) € 1.5±0.8 1.6±0.8 1.4±0.7 NS
  ● Packed cells (units) € 4.3±1.5 3.8±1.8 4.5±1.2 NS
  ● Plasma (units) € 3.0±1.0 2.5±1.1 3.1±0.8 NS
  ● Cell-saver blood £ 0.4 (0.3-1.2) 0.4 (0.2-1.0) 0.6 (0.3-1.4) NS
     
Hemodynamic variables     
Heart Rate € 67.1±11.9 69.6±11.5 66.5±7.7 NS 
Mean Arterial Pressure € 77.7±13.4 80.5±11.5 73.2±15.4 NS 
     
Intraoperative urine output (L) £ 0.5 (0.4-0.7) 0.7(0.5-0.8) 0.6 (0.4-0.7) NS 
     
Continuous variables are shown as mean ± standard deviation (€) or mean ± interquartile range (£), while 
dichotomous variables are shown as number (% of column totals). 
Abbreviations:- LLR: lower extremity arterial revascularizations, NWMA: New wall motion 
abnormalities, TEE: Transesophageal echocardiography. Abbreviated units of measurement provided; (L): 





















Table 3. Agreement for the association and locality distribution of resting 
“(a)” and ischemic “(b)” LV walls presenting with WMA’s in preoperative 
DSE and intraoperative TEE. 
 




N (%) K 
Patients with Rest WMA 
17 (31) 16 (30) 0.917 
* Locality of the Rest WMA:    
  • Anterior Wall 7 (41) 9 (56) 0.821 
  • Antero-septal Wall 10 (59) 12 (75) 0.843 
  • Septal Wall 11 (65) 11 (69) 1.0 
  • Lateral Wall 7 (41) 9 (56) 0.821 
  • Posterior Wall 7 (41) 7 (44) 1.0
  • Inferior wall 9 (53) 9 (56) 1.0
  • Apical 13 (76) 10 (63) 0.769






Patients with NWMA 
17 (31) 23 (89) 0.653 
* Locality of the NWMA:    
  • Anterior Wall 5 (29) 6 (26) 0.292 
  • Antero-septal Wall 8 (47) 14 (61) 0.440 
  • Septal Wall 9 (53) 13 (57) 0.321 
  • Lateral Wall 5 (29) 9 (39) 0.351
  • Posterior Wall 4 (24) 5 (22) 0.260
  • Inferior Wall 4 (24) 8 (35) 0.395
  • Apical 9 (53) 4 (17) 0.351
    
Single vessel reversible ischemia 7 (41) 8 (35) 0.233 
Multi-vessel reversible ischemia 10 (69) 15 (65) 0.336 
 
Abbreviations:- DE: dobutamine echocardiography, K : Kappa measurement value, 
NWMA: New wall motion abnormalities, TEE: Transesophageal echocardiography, 




Table 4. Postoperative Patient Outcomes According to Ischemia Wall 




Preoperative DE Intraoperative TEE 
NWMA No NWMA 
P value 
NWMA No NWMA 
P value N=54  N=17 (31) N=37 (69) N=23  (43) N=31 (57) 
Postoperative Outcomes:        
PO cTnT release 14 (26) 9 (53) 5 (14) < 0.05 13 (57) 1 (3) < 0.001 
PO MI 6 (11) 6 (35) 0 (0) < 0.001 6 (26) 0 (0) < 0.05 
Cardiac Death 3 (6) 2 (12) 1 (3) NS 3 (13) 0 (0) < 0.05 
Composite outcome 15 (28) 10 (59) 5 (14) 0.001 14 (61) 1 (3) < 0.001 
        
Abbreviations:- DE: dobutamine echocardiography, NWMA: New wall motion 
abnormalities, PO cTnT: Postoperative cardiac troponin-T, PO MI: Postoperative 
















Table 5. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of preoperative dobutamine echocardiography (DE) 
and intraoperative transesophageal echocardiography (TEE) for the study 
outcomes. 













DE  61% 64% 100% 67% 67% 
TEE - 93% 100% 100% 93% 
  













DE  90% 80% 77% 71% 82% 















DE 82% 53% 35% 12% 59% 















DE 76% 87% 100% 97% 87% 
TEE - 97% 100% 100% 97% 
Abbreviations:- DE: dobutamine echocardiography, NWMA: New wall motion 
abnormalities, PO cTnT: Postoperative cardiac troponin-T, PO MI: Postoperative 
myocardial infarction, PPV: positive predictive value, NPV: Negative predictive value, 


















This  thesis  consists  of  two  sections:  one  linking  preoperative  patient  bodily  composition  status 
(termed  as  body  mass  index)  to  long‐term  outcomes  and  the  other  links  preoperative  and 
intraoperative echocardiographic  testing  to major postoperative  (cardiac)  complications.  In view of 
the first part, one can say that a reflective image of expected outcome can be related to a patient’s 
original  body  mass  when  presenting  prior  to  a  surgical  intervention.  As  the  association  between 
preoperative  factors  and mortality were not  uncommon  to nowadays health  risk  stratification  and 
prognosis, a simple reaction would be a logic intervention to influence these outcomes by measures 
of prevention. Nevertheless,  the unexpected risk association within our research between BMI and 
mortality  witnessed  a  long  debate  in  the  medical  community.  This  unexpected  finding  would  be 
“conditionally”  expressed  as  the  changing  relationship  between body mass  index  and mortality.  In 
addition,  our  data  represent  the  first  published  studies  to  report  an  inverse  relationship  between 





Cardiovascular  complications  remain  a  major  concern  in  vascular  surgical  patients  who 
present with propensity of cardiac risk factors. 1,2 The association of peripheral vascular disease with 
coronary  artery  disease  is  also  known  to  affect  chances  of  survival.  3  Projection  of  perioperative 
patient  risk  estimates  to  long‐term  adverse  events  is  becoming  more  and  more  of  clinical 
importance.  Overweight  and  obesity  are  among  factors  researched.  By  advancements  in  early 













As a conclusion  form  this part, BMI definitely  showed an altered  relationship with mortality  in our 




severe  burden  of  associated  co‐morbidities.  A  survival  advantage  of  BMI  was  shown  in  the 
overweight  and moderate  obesity,  whereas  being  underweight  always  showed worsened  survival. 
The relationship was shown for both short‐term and long‐term mortality (i.e. in chapter 3, we found 
this  relationship  [partially]  true  in  overweight  patients  for  short‐term  mortality  within  30‐days 




Our  series  of  studies  joined  an  ongoing  debate  in  the  medical  literature  regarding  the 
apparent  conflict  between  this  observation  and  the  common and  acknowledged perception  about 
the health‐related risks of obesity. Consequently, a careful interpretation of research findings might 
guide  us  towards  a  better  understanding  of  this  phenomenon  and  its  implication  in  today’s 






the  life  expectancy  in  Western  societies  could  be  interpreted  as  a  proof  for  success  in  adopting 
extensive primary care regimes to prevent and early manage major diseases and risk factors such as 
hypertension,  diabetes,  coronary  artery  disease,  stroke  and  COPD.  However,  smoking,  alcohol 
consumption  and  cancer  occurrence  remain  little  influenced.  BMI  is  known  for  a  preferential 
incidence of certain types of cancer such as colo‐rectal, breast and ovarian cancers in obesity, while 
being underweight is known for others such as lung and gastric cancers. Therefore, to avoid biasing 
our  knowledge  from  studies  on  populations  with  particular  cancer‐types,  these  studies  were  not 
taken  into  consideration  during  this  discussion.  We  claim  that  at  least  three  specific  causes  of 
mortality  are  responsible  for  explaining  the  BMI  paradox  based  on  our  examined  populations;  i.e. 
cardiovascular mortality (Chapter 1), respiratory causes (chapter 2) and cancer (Chapter 3). In a study 
General discussion of the thesis 
of  re‐vascularized  coronary  artery  disease  patients,  underweight  patients  were  susceptible  for 
cardiovascular  death  and  myocardial  infarction,  whereas  overweight  patients  had  low  affinity  to 
acquire cardiovascular death. 9 In an analysis of cause‐specific mortality in a pooled population from 





found  to be  associated with  increased mortality  from diabetes  and  kidney disease,  and decreased 
mortality from other non‐cancer, non‐cardio‐vascular causes. Obesity was associated with increased 
mortality  from  cancers  considered  obesity‐related,  but  not  from  other  cancers.  10  We  tested  the 
assumption  that  the  general  surgical  population  risk  of  cancer  death  can  influence  the  altered 
relation  between  BMI  and  long‐term  mortality.  We  found  significantly  higher  cancer‐death  rates 
among  the  underweight,  while  higher  BMI  categories  showed  lower  mortality  from  cancer  when 
compared to normal weight subjects. The association between cerebro‐cardiovascular mortality and 











is  thought  that  increased  leptin  secretion  from white  adipocytes  plays  a major mediator  of  these 
metabolic  effects.  16,  17  As  fat  loss  occurs  first,  followed  by muscle  protein  catabolism,  we  would 
suggest a concept of critical body mass entailing the percentage of total body weight  (or BMI)  loss 
prior  to  the  point  at  which muscle  breakdown  ensues.  It  has  been  suggested;  in  cancer  patients 
receiving chemotherapy, that this critical point is 5% from the original BMI. 18, 19 The higher the initial 
BMI,  the wider would be  this critical gap and the more stable would be the status of  the patient’s 
metabolism. Moreover,  there  is  an  evidence  that  ageing  associated with  overweight  and/or  early 
obesity with re‐distribution of  fat cells  in  favor of  the subcutaneous  fat  implicates a state of  leptin 






of ageing  is probably an expression of  loss of muscle mass  (and hence weight  loss)  and decreased 
exercise  tolerance.  This  weight  change  over  time  was  considered  as  a  shortcoming  of  studies 
accounting for a single BMI measurement. However, if this were true, then the same would apply for 
studies  involving  other  variables  measured  once  like  bioelectrical  impedance  and  other  specific 
anthropometric  surrogates of adiposity. More appropriate scientific consideration  is  to account  for 
weight  change as  a unique  risk  factor  corrected  for BMI  (i.e.  lean or  fat mass).  This  is  functionally 
expressed by the higher mortality risk to remain un‐fit or to have deteriorating CRF over‐time. 22 A 
more complicating element of weight loss is the importance to differentiate intentional weight loss; 






weight  loss  is associated with  increased adverse cardiovascular events, while presumed  intentional 
weight  loss  is  associated with  lower  clinical  events.  24  The  same  findings were  found  among  4869 




intentional weight  loss had a benefit  from reduction  in all‐cause mortality.  In an older study which 
collected prospective data from a survey on 49,337 overweight white men aged 40‐64 years over 12 
years interval, the mortality effects of intentional weight loss was measured. 26 In the sub‐cohort of 
36,280  participants  with  no  reported  health  conditions,  intentional  weight  loss  of  more  than  20 
pounds  increased diabetes‐associated mortality  by  48%. Whereas,  in  13,057  overweight men with 
initially  reported health  conditions,  intentional weight  loss more  than 20 pounds  increased  cancer 
mortality by  25%, and decreased diabetes‐associated mortality by 32%.  In  fact,  healthy  individuals 
who were overweight or obese, were advised to change their  life‐style and CRF profile rather than 
losing weight in order to impact longevity. 27 In a population of 6,492 congestive heart failure patients 










Although  our  observations  seemed  unusual,  the  counterintuitive  relationship  between  BMI  and 
mortality is not completely new to the medical literature. Epidemiologic studies in Western societies 
from  the  era  before  discovering  the  obesity  paradox  showed  a  longer  life  expectancy  in  the 
overweight and obese over those, who did not join the obesity epidemic. 30‐32 In their study, Kalmijn 
and colleagues  investigated the association between BMI, waist‐to‐hip ratio  (WHR) and the sum of 
the subscapular and  triceps skinfold thickness  in a cohort of 3741 elderly  Japanese‐American men, 
between 1991 and 1993, aged between 71 and 93 years. 33 Follow‐up period was 4.5 years in average 
and  they  clearly  showed  that BMI  and  skinfold  thickness  had  consistent  inverse  relationships with 
mortality.  However,  the  idea  was  totally  surprising  and  confusing  particularly  when  they  found  a 
direct  association  between  WHR  and  mortality.  In  2000,  Landi  and  colleagues  found  in  18,316 
hospitalized  elderly  individuals  that  the  lowest  mortality  rate  was  associated  with  BMI  ranging 
between  25.0  through  27.4  kg.m‐2.  34  Plotting  the  life‐table  of  the  younger  group  produced  a 
hyperbolic  curve  with  increased  mortality  at  the  lowest  and  highest  BMI’s.  For  the  older  group, 
increased  mortality  was  associated  with  being  underweight,  whereas  high  BMI  showed  slight 
increase in mortality hazard. Others endorsed the BMI paradox in patients with chronic heart failure 
and  in  dialysis  patients  .  35,  36  Following  these  reports,  a  surge  of  publications  proved  the 





Obesity  is  a  known  risk  factor  for  cardiovascular  atherosclerotic  disease  and  particular  obesity‐
related  cancers  among  the  general  population.  However,  substantial  evidence  from  large 
observational  studies  supports  the  existence  of  the  BMI  paradox  in  particular  chronic  disease 
populations.  Patients  with  chronic  heart  failure  and  coronary  artery  disease  and  end‐stage  renal 
disease were among the first and most extensively studied. In a recent meta‐analysis of 14 studies on 
23,967 heart  failure patients38  the obesity paradox was present both  in patients with  and without 
preserved  left  ventricular  function.  However,  it was  better  demonstrated  in  those with  preserved 
ejection  fraction.  Similar  results  as  found  in  chapter  2 were  reported  in  very  large meta‐analyses 
concerning  patients  with  chronic  heart  failure,  acute  coronary  syndromes,  and  patients  who 
underwent  revascularization  procedures.  38‐42  All  the  mentioned  meta‐analyses  showed  increased 
risk  of  mortality  in  the  underweight  group  of  patients.  They  also  report  overweight  and  obese 








bodily  fat.  Reis  et  al  examined  the  risk  association  between  measures  of  adiposity  and  overall 






the  Tokyo Gas Company, who were  followed up  for  cancer mortality  to  the  year  of  2003.  45  They 
found an  inversely proportional relation of cardiorespiratory fitness (CRF) to cancer mortality. They 
based  CRF  definition  on  a  submaximal  exercise  test  on  a  cycle  ergometer.  Through  subgrouping 
patients according to their CRF profile, they could explain the causes of decreased cancer mortality 
among higher BMI category as of having better cardiorespiratory  fitness profile. Surprisingly,  these 














and  distribution  of  body  fat  might  differ  from  one  individual  to  another.  Central  (i.e.  visceral, 
android) adiposity was suggested to be associated with atherosclerotic and cardio‐metabolic disease 
risk mediated by leptin and other mediators causing insulin‐resisting, pro‐inflammatory cascade. This 
is  opposed  by  the  anti‐inflammatory  and  insulin  sensitizing  actions  of  peripheral  (i.e.  gynoid) 
adiposity  secreting  adiponectin  and  other  mediators.  A  complex  genetic,  gender,  racial,  habitual, 
adipokine and perhaps neuro‐hormonal factors play regulatory roles to define this. Not confined to 
adiposity, BMI also reflect  the  important component of muscle  (fat‐free) mass, which undoubtedly 




53,  54 More  accurate  estimates  of  adiposity  particularly  bioelectric  impedance  showed  the  gapping 
misses given by BMI in comparative studies. 54 Thus, it limits the identification of obesity and includes 
other cases inside its set range. This is one element explaining how the risk of increasing BMI might 









However,  two  challenging  questions  about  the  extent  and  range  of  involvement  in  this  dynamic 
phenomenon were  still  unanswered.  For  the  first, we  conducted a  trial  in  chapter 3  to evaluate  a 
broad‐spectrum general  surgical population  for  the possibility  to  find  the BMI paradox correlation. 
Our population was moderate with respect to the severity of co‐existing morbidities, with a variable 
burden of risk factors making this population representative of the wider general medical population. 
In  January 2013,  Flegal  and his  colleagues published a meta‐analysis  in  JAMA, which enrolled 2.88 
million individuals from 97 studies, examined for mortality association with BMI. 60 Overweight and 
class  I obesity were associated with  lower hazard of death from all‐causes, whereas overall‐obesity 
as well  as  obesity  class  II  and  III were  associated with  increased mortality  hazard. Analysis  by  age 
shows a better form of the paradox for patients aged 65 years and higher, and in such case severe 
forms of obesity carry insignificant relationship with mortality. These findings point to other factors 





predict outcome at  a  short  follow‐up  such as  the post‐procedural  and hospital  stay outcome? We 




118,707  non‐bariatric  general  surgical  patients.  In  their  study,  the  correlation  between  BMI  and 
short‐term  mortality  represented  a  unique  shape  with  highest  risk  among  those  who  were 
underweight,  and with  risk  reduction  among  overweight  and  obesity  type  I  and  II  patients.  Other 
studies  showed  a  similar  correlation  between  BMI,  perioperative mortality  and  length  of  hospital 





and  obese,  and  attributed  to  better  intraoperative  and  postoperative  hemostasis,  better 
hemodynamic tolerance and absence of increased early postoperative mortality; against the former 




Several  studies  revealed  limitations  caused  by  grouping  patients  according  to  the WHO  standard 
categorization. 73, 74 Specific population and ethnic features must be considered. 45, 75‐80 For example 














BMI  is  the  result  from  dividing  weight  by  the  second  exponential  power  of  height.  Many 
mathematicians  advocated  that  the  weight  exponent  of  two  should  better  be  raised  to  a  value 
between  two  and  three  in  order  to  reflect  bodily  mass  more  accurately.  This  had  led  to  the 






In  an  ageing world,  loss  of  a  few  centimeters  of  height  in  geriatrics  adds  another  variable  to  the 
criticized equation. However, this new assumption required correlation studies to prove its value as 
compared to the standard BMI. In contrast to what is expected from this assumption, a recent study 





became  important  to distinguish  the difference between  risk association of a  single  factor  such as 
BMI with a certain disease condition, and fatality from such disease. This is probably due to the fact 
that  treatment  of  diseases  prone  to  become  clinically  evident  at  an  earlier  age would  ameliorate 








Another  aspect of  the paradox may be due  to  the  sensitivity  and  specificity  of BMI  for  associated 
risks and prediction power. The composition of BMI consisting in two different types of tissues (i.e. 
muscles  (lean  fat‐free  mass)  and  fat)  and  two  metabolically  active  types  of  fat  (i.e.  central  and 
peripheral)  is making  this more complicated  . BMI  is criticized of being a sensitive but non‐specific 
indicator of central adiposity. A group of researchers studied a large European patient population for 




their  analysis  for  all‐cause  mortality,  the  same  relationship  was  shown.  Whereas  all  other 
anthropometric  measurements  attained  directly  proportional  linear  fashions  with  all‐cause  and 
cardiovascular mortalities, the BMI plots were J‐shaped. 81 This has been confirmed in patients older 
than 60 years. 50 A meta‐regression analysis of 18 prospective cohort studies yielding 689, 465 total 
number of participants  and 48, 421 deaths during 5‐24  years of  follow‐up  showed a hyperbolic U‐
shaped  relationship  between  BMI  and  mortality,  whereas  WHR,  WC  and  WHtR  had  a  linear 
relationship. 85 A meta‐analysis of 31 articles used a receiver operating characteristics (ROC) curves 
for  assessing  the  discriminatory  power  of  BMI,  WC  and  waist‐to‐height  ratio  (WHtR)  for  cardio‐
metabolic risk and general cardiovascular outcomes (CVD). Using data on all outcomes in more than 














we  can  measure  the  longitudinal  consequences  of  BMI  in  different  populations  in  retrospective 
analyses.  The  longitudinal  advantage  of  healthy  life‐style,  CRF  exercises  and  proper  nutrition  are 
undoubted;  the  same  as  the  disadvantages  of  gathered  adiposity.  Other  classical  explanations 
mentioned  in our review article  in chapter 5 are widely accepted  in  the medical community. Being 


































reducing  risk  factors  and  optimization  of  chronic  co‐morbidities.  The  initiation  of  secondary 
prevention  of  atherosclerotic  disease  prior  to  and  after  elective  (vascular)  surgery  is  in  this 
perspective  of  particular  importance.  Anesthesiologists  have  now  to  extend  their  activities  from 





the peri‐operative management of  the vascular  surgical patient. We have shown  the superiority of 
intraoperative  transesophageal  echocardiography  over  preoperative  dobutamine  stress 
echocardiography  in  predicting  the  location  of  intraoperative  and  postoperative  ischemic  events. 
These  findings  and  the  lack  of  significance  of  the  anesthetic  technique  used,  intraoperative  fluid 
management  and  hemodynamic  variables  suggest  that  imbalance  between  oxygen  supply  and 
demand  is  not  the mechanism  of  perioperative myocardial  ischemia  in  peripheral  arterial  disease 
patients.  The  value  of  ischemia‐targeted  echocardiography  was  evident  over  mere  resting 
echocardiographic  results.  The  high  incidence  of  clinically  detected  and  subclinical  myocardial 
ischemia  in  this  population  warrants  a  stronger  emphasis  on  the  myocardial  ischemic  risk  in  this 
population. Our results match with results from other prospective controlled studies 90 examining the 
efficacy of coronary interventions prior to non‐cardiac surgery. All studies indicate the superiority of 
global  anti‐ischemic  management  over  invasive  “focal”  interventional  management  in  prophylaxis 
against later myocardial ischemia and/or infarction in high‐risk populations.  
 
  In  the  second  chapter  of  this  part  (i.e.  Chapter  7),  utilization  of  preoperative  resting 
echocardiography  showed  the  high  prevalence  of  left  ventricular  dysfunction  in  the  peripheral 
arterial disease population mounting to 50%. Whereas only one‐fifth (20%) of these affected patients 
was symptomatic, the rest was divided between asymptomatic LV systolic or diastolic dysfunctions. 
Unfortunately,  and  as  a  natural  consequence,  the  implementation  of  the  European  Society  of 
Cardiology (ESC) and the European Society of Anaesthesiology (ESA) guidelines on the perioperative 
medical  management  of  such  patients  was  far  from  optimal.  So  there  is  room  for  improvement 
probably leading to a better outcome. 
General discussion of the thesis 




management.  Due  to  the  variety  of  intraoperative  anesthesia  and  surgery‐related  stressors 
influencing  the  homeostatic mechanisms  in  the  vascular  patient,  the  intraoperative  setting  can  be 
considered as an ultimate stress test for myocardial ischemic events. Monitoring such effects on the 
vascular patient myocardium can yield important information about the occurrence of perioperative 
myocardial  ischemia  and  infarction.  Dobutamine  stress  echocardiography  is  an  established  risk 
estimate  and  accepted  stress  testing method  in  high‐  risk  vascular  surgical  patients  If  the  surgical 
setting could be utilized  to analyze perioperative  ischemic events, additional  imaging by CT or MRI 






events  can  occur  both  intraoperatively  as  well  as  postoperatively,  intraoperative  transesophageal 
echocardiography may complete the range of electrical and biochemical detection methods for those 
events occurring  in the  immediate perioperative phase. The appropriate management  in subclinical 


































































































































































































































































































































































































































































Preoperative  evaluation  and  perioperative management  play  a  key  role  in  postoperative  outcome. 
However,  this  link  is  not  always  clear  and  often  difficult  to  reveal.  Many  correctable  risk  factors  must  be 





mass  index  paradox”.  It  mainly  included  subjects  suffering  from  peripheral  artery  disease,  coronary  artery 
disease,  and polyvascular  disease  (Chapters  1,  2  and 4). However,  the  existence of  the  phenomenon  in  the 




its  nature,  prevalence,  affected  patient  populations  and  influencing  factors.  The  field  of  anesthesiology  can 




In  the  second  part,  two  studies  were  conducted  to  demonstrate  the  value  of  perioperative 
echocardiography  as  a  powerful  tool  in  the  hands  of  perioperative  anesthesiology  physician,  applying  and 
interpreting  the  recommendations of  the  respective echocardiography and cardiology  societies  including  the 
European  Society  of  Cardiology  (ESC),  the  American  Society  of  Echocardiography  (ASE)  and  the  Society  of 





















However,  the  overweight  category  of  patients  showed  the  highest  prevalence  of  polyvascular  disease  and 




In  Chapter  4  the  phenomenon  of  BMI  paradox  differed  in  short‐term  from  long‐term  follow‐up. 
Although  only  overweight  patients  showed  improved  survival  at  short‐term,  nevertheless,  BMI  was 
paradoxically associated with the length of hospital stay. The existence of BMI inverse relationship to long‐term 
overall  mortality  was  clearly  shown  in  this  population.  Further  examination  of  the  causes  of  mortality  in 




population. Patients at  the extremes of BMI, both  the underweight and  the morbid obese seem to have the 
highest  postoperative  morbidity  and  mortality  hazard,  which  even  persists  at  long‐term.  The  cause  of  the 






6  showed  a  higher  rate  of  inducible  ischemia  during  Dobutamine  Stress  Echocardiography  (DSE)  than 
intraoperatively  detected  by  TEE, with  poor  agreement  in  the  location of myocardial  ischemia  of  respective 
patients undergoing major vascular surgery. The rate of subclinical ischemia in this small population detected 







ischemic  patients  over  focused  therapy  with  coronary  interventions  attacking  particular  culprit  lesions  or 
particular coronary artery branches prior to vascular surgery. 
 
Finally,  Chapter  7  showed  that  left  ventricular  dysfunction  is  present  in  one‐half  of  patients 
undergoing  vascular  procedures.  Of  those  only  20%  were  symptomatic  and  the  remaining  80%  were 
asymptomatic  and  equally  divided  between  systolic  and  diastolic  dysfunctions.  Adherence  to  the  ESC 
recommended  therapy  was  found  in  only  one  third  of  those  patients  as  identified  by  the  utilization  of 


























Preoperatief onderzoek en perioperatief management zijn belangrijke factoren  die de 
postoperatieve uitkomst bepalen. De relatie tussen de factoren en de uitkomst is niet altijd 
duidelijk en soms lastig te leggen. De anesthesioloog moet vele corrigeerbare factoren 
beschouwen bij het uitvoeren van het preoperatief onderzoek. Dit moet voor de chirurgische 
patiënt leiden tot een verbeterde uitkomst van het intraoperatieve proces en de postoperatieve 
follow-up periode. 
Dit proefschrift bestaat uit twee delen. In het eerste deel wordt het fenomeen van de 
omgekeerde relatie tussen het preoperatief bepaalde BMI en de lange termijn sterfte bij 
chirurgische patiënten bestudeerd: de body mass index paradox. Er is specifiek  onderzoek 
gedaan naar patiënten die leden aan perifeer arterieel vaatlijden, coronarialijden en 
gegeneraliseerd vaatlijden. (hoofdstukken 1,2, en 4). Het optreden van dit fenomeen in een 
populatie van patiënten die algemeen chirurgische operaties ondergingen, was tot nu toe niet 
vastgesteld (hoofdstuk 3).  Deze retrospectieve studie werd uitgevoerd in een grote algemeen 
chirurgische populatie om de relatie vast te stellen tussen BMI enerzijds en de lengte van 
verblijf in het ziekenhuis en de mortaliteit anderzijds vast te stellen. 
De BMI-mortaliteit paradox is een fenomeen dat epidemiologisch gevalideerd dient te worden 
om vast te stellen wat de oorzaak, de prevalentie en de beïnvloedende factoren zijn en welke 
patiënten populatie het betreft . De anesthesiologie kan hierbij de epidemiologische studies 
ondersteunen, omdat lengte en gewicht naast ander relevante gegevens  immers routinematig 
opgenomen worden in het preoperatieve dossier . Abusievelijk is de BMI-paradox meer 
bekend bij het publiek en ook bij medici als de obesity paradox ondanks het feit dat de 
paradox nog het sterkst voordoet bij patiënten met ondergewicht. 
In het tweede deel worden twee studies beschreven die de waarde aantonen van perioperatieve 
echocardiografie, als een belangrijk hulpmiddel  voor de perioperatief werkzame 
anesthesioloog.  Met gegevens verkregen met echocardiografie kunnen de richtlijnen  van de 
respectievelijke cardiologische, echografische en anesthesiologische verenigingen, zoals de 
European Society of Cardiology (ESC), American Society of Echocardiography (ASE) en de 
Society of Cardiovascular Anesthesiologists (SCA),  beter geïmplementeerd worden. Het 
opvolgen van deze richtlijnen die op klinisch bewijs gestoeld zijn, zou naar verwachting 
moeten leiden tot een verlaging van het aantal complicaties en een verbetering van de 
klinische uitkomst, te weten kwaliteit van leven en overleving. Deze richtlijnen gaan primair 
Summary 
meer over het perioperatieve anesthesiologisch beleid dan over de wijze waarop een 
chirurgische ingreep gefaciliteerd moet worden.   
 
Deel I: de body mass index paradox. 
Ons onderzoek begon met het de vraag of de BMI paradox aanwezig was bij 5950 patiënten 
bekend met of verdacht van coronarialijden (hoofdstuk 1). Wij vonden inderdaad een 
omgekeerde relatie tussen BMI en lange termijn mortaliteit ten gevolge van alle 
doodsoorzaken, maar ook van cardiale doodsoorzaken. De patiënten met een lage BMI 
hadden een hoger risico op lange termijn sterfte door alle oorzaken en hartdood dan de 
patiënten met een hogere BMI. 
In hoofdstuk 2 toonden wij aan dat de mortaliteit bij patiënten met perifeer arterieel 
vaatlijden die vooraf aan hun operatie een longfunctie onderzoek ondergingen, duidelijk 
afnam met de toename van de BMI. Verdere sub-classificatie van onze patiënten naar ernst 
van de COPD liet zien dat patiënten met ondergewicht vaker aan een ernstiger vorm van 
COPD leden. Correctie voor de ernst van de COPD in de multivariate analyse elimineerde de 
significante associatie tussen patiënten met ondergewicht en mortaliteit, maar niet de 
associatie tussen toegenomen overleving en een hoger BMI.  
Hoofdstuk 3 richt zich op de risico’s van gegeneraliseerd vaatlijden en de invloed op de BMI 
paradox. Hoewel voor alle risico factoren in alle BMI categorieën dezelfde streefwaarden 
voor de  medicamenteuze therapie gehanteerd werden, bleek ondergewicht een onafhankelijke 
voorspeller voor afgenomen overleving maar ook voor het laagste gebruik van cardiale 
medicatie. De groep met overgewicht toonde, daarentegen, niet alleen de hoogste prevalentie 
van gegeneraliseerd vaatlijden en gebruik van cardiale medicatie, maar ook een toegenomen 
overleving wanneer naar overlijden ten gevolge van alle doodsoorzaken gekeken wordt. De 
relatie tussen BMI, gegeneraliseerd vaatlijden en lange termijn uitkomsten was in de groep 
patiënten niet significant. 
In hoofdstuk 4 blijkt het fenomeen van de BMI paradox verschillend te zijn met betrekking 
tot korte en lange termijn overleving. Hoewel uitsluitend de patiënten met overgewicht op 
korte termijn een toegenomen overleving hadden, was daarentegen BMI paradoxaal 
gerelateerd aan de lengte van het verblijf in het ziekenhuis. Het bestaan van een omgekeerde 
relatie tussen BMI en lange termijn mortaliteit door alle doodsoorzaken was in deze groep 
patiënten duidelijk aanwezig. Verder onderzoek naar de doodsoorzaken bracht aan het licht 
dat een lagere BMI was geassocieerd met dood ten gevolge van kanker, terwijl patiënten met 
overgewicht een toegenomen overleving op cardiovasculair gebied toonden. 
 In hoofdstuk 5 hebben wij een review van de literatuur over de BMI paradox in de algemeen 
chirurgische populatie geschreven. Patiënten aan de uiteinden van het spectrum, zowel die 
met ondergewicht als de morbide obese, blijken de hoogste postoperatieve morbiditeit en 
mortaliteitsrisico’s te lopen. Ook op lange termijn blijkt dit het geval. De oorzaak van de BMI 
paradox  is waarschijnlijk multifactorieel. Dit geeft weer mogelijkheden voor toekomstig 
onderzoek om de uitkomsten van patiënten aan de uiteinden van het BMI spectrum te 
verbeteren. 
 
Deel II: De uitbreiding van het gebruik van perioperatieve en intraoperatieve 
echocardiografie. 
Dit deel presenteert 2 prospectieve studies. De studie in hoofdstuk 6 toont aan dat er vaker  
ischemie geprovoceerd wordt bij dobutamine stress echocardiografie (DSE) dan er ischemie 
tijdens operaties vastgesteld wordt met behulp van transoesophageale echocardiografie. 
Bovendien is er bij patiënten die grote vaatchirurgische ingrepen ondergaan een slechte 
correlatie tussen beide onderzoeken met betrekking tot de locatie waar de ischemie 
vastgesteld wordt. De frequentie van subklinische ischemie in deze patiëntengroep 
aangetoond door uitsluitend een stijging van het serumtroponine bedraagt 15% terwijl 
myocardinfarct in 11% voorkomt. De cardiale mortaliteit bedraagt 6%. DSE kan het optreden 
van intraoperatieve en postoperatieve ischemische veranderingen en blijvende wand 
bewegingsstoornissen in het hart voorspellen, maar niet de plaats waar dit op zal treden. Bij 
alle patiënten met een postoperatief hartinfarct werd de lokalisatie van het infarct met behulp 
van TEE in 100% correct voorspeld, terwijl DSE maar in een derde van de gevallen een juiste 
voorspelling van de lokalisatie opleverde. De studie geeft steun aan de gedachte dat algemene 
medicamenteuze behandeling van cardiale ischemie beter is dan lokale behandeling van 
laesies in de coronair arteriën voorafgaand aan een vaatchirurgische operatie. 
Tot slot laat hoofdstuk 7 zien dat dysfunctie van de linker hartkamer voorkomt in de helft van 
de patiënten die een vaatoperatie ondergaan. Hiervan is 20% van de patiënten symptomatisch. 
De 80% asymptomatische patiënten zijn gelijk verdeeld over systolische en diastolische 
dysfunctie. Slechts in een derde van de patiënten werden de ESC behandelrichtlijnen gevolgd. 
Het volgen van de richtlijnen werd afgeleid uit het gebruik van angiotensin converting 
enzyme remmers, en/of diuretica. Deze bevindingen tonen aan dat er sprake is van 
onderbehandeling van deze patiëntengroep ten opzichte van de ESC richtlijnen ondanks het 




 ، ﻭﻣﻊ ﺫﻟﻚﺮﺍﺣﺔ . ﻣﺎ ﺑﻌﺪ ﺍﻟﺠ ﻧﺘﺎﺋﺞ ﺩﻭﺭﺍ ﺭﺋﻴﺴﻴﺎ ﻓﻲ ﺗﻠﻌﺐ ﺍﻟﻤﺤﻴﻄﺔ ﺑﺎﻟﺠﺮﺍﺣﺔﺍﻟﻄﺒﻴﺔ  ﻭﺍﻹﺩﺍﺭﺓ ﻗﺒﻞ ﺍﻟﺠﺮﺍﺣﺔ ﺗﻘﻴﻴﻢ ﺍﻟﻤﺮﺿﻰ
 ﺓ ﻭﺭﻮﺍﻟﻌﺪﻳﺪ ﻣﻦ ﻋﻮﺍﻣﻞ ﺍﻟﺨﻄ ﻳﺠﺐ ﺍﻟﻨﻈﺮ ﻓﻲ ﻭ ﺍﻟﻜﺸﻒ ﻋﻨﻪ . ﻏﺎﻟﺒﺎ ﻣﺎ ﻳﺼﻌﺐ ﻭ ﺩﺍﺋﻤﺎ ﻭﺍﺿﺤﺎ  ﻳﻜﻮﻥﻻ ﻫﺬﺍ ﺍﻟﺮﺍﺑﻂ
 ﻭﺃﺛﻨﺎء ﺍﻟﺠﺮﺍﺣﺔ ﺍﻟﻄﺒﻴﺔ  ﺩﺍﺭﺓﺍﻹﻋﻤﻠﻴﺔ  ﻟﺘﻮﺟﻴﻪ ،ﻗﺒﻞ ﺍﻹﺟﺮﺍء  ﺩﻗﻴﻖ ﺗﻘﻴﻴﻢ ﺧﻼﻝ ﻞ ﺍﻟﺠﺮﺍﺣﺔﻗﺒ ﻁﺒﻴﺐ ﺍﻟﺘﺨﺪﻳﺮ ﻣﻦ ﻗﺒﻞ ﺎﺗﺼﺤﻴﺤﻬ
  . ﺍﻟﺠﺮﺍﺣﻲ ﻟﻠﻤﺮﻳﺾﺃﻛﺜﺮ  ﻣﺮﺿﻴﺔﻭ ﺃﻓﻀﻞ  ﻧﺘﺎﺋﺞ ﻧﺤﻮﺔ  ﺑﻌﺪ ﺍﻟﺠﺮﺍﺣﻣﺘﺎﺑﻌﺔ ﺍﻟﻤﺮﺿﻰ 
 
ﺍﻟﺬﻱ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﺑﻴﻦ  ﺔﻌﻜﻮﺳﻤﺍﻟ ﻌﻼﻗﺔﺍﻟ ﻅﺎﻫﺮﺓ ﺩﺭﺍﺳﺔ ﺖﺗﻤ ﺍﻟﺠﺰء ﺍﻷﻭﻝﻓﻲ  ﻣﻦ ﺟﺰﺋﻴﻦ ، ﻫﺬﻩ ﺍﻷﻁﺮﻭﺣﺔ ﻭﺗﺘﻜﻮﻥ
ﻣﺆﺷﺮ ﻛﺘﻠﺔ  ﻣﻔﺎﺭﻗﺔﺃﻭ ﻣﺎ ﻳﺴﻤﻰ " ﻟﻌﻤﻠﻴﺎﺕ ﺟﺮﺍﺣﻴﺔﺍﻣﺮﺿﻰ  ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞ ﻓﻲﻓﻴﺎﺕ ﻣﻌﺪﻝ ﺍﻟﻮﻭ ﻗﺒﻞ ﺍﻟﺠﺮﺍﺣﺔ ﺗﺤﺪﺩ
ﺔ ﺍﻟﺘﺎﺟﻴﻦ ﻭﻣﺮﺽ ﺍﻟﺸﺮﺍﻳﻴ ، ﺔ ﺍﻟﻤﺤﻴﻄﻴ ﻦﻴﻳﺍﺍﻟﺸﺮ ﺽﺍﻣﺮﺃﻣﻦ  ﻳﻌﺎﻧﻮﻥ ﺮﺿﻰﻣ ﺑﺸﻜﻞ ﺭﺋﻴﺴﻲ ﻀﻤﻨﺖﺗ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺎﺕ " . ﺍﻟﺠﺴﻢ
ﻫﺬﻩ ﻭﺟﻮﺩ ﺇﺛﺒﺎﺕ ، ﻓﺈﻥ  ﻭﻣﻊ ﺫﻟﻚ ( . ﺍﻷﻭﻝ ﻭ ﺍﻟﺜﺎﻧﻲ ﻭ ﺍﻟﺮﺍﺑﻊ ﺼﻮﻝﺍﻟﻔ) ﺍﻟﻤﺘﻌﺪﺩﺓﺍﻟﻤﺤﻴﻄﻴﺔ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ ﻣﺮﺽ  ، ﻭ
ﻫﻲ ﺩﺭﺍﺳﺔ ﺪﺭﺍﺳﺔ ﺍﻟ ﻫﺬﻩ ( . ﺍﻟﺜﺎﻟﺚ ﺍﻟﻔﺼﻞﺇﺛﺒﺎﺗﻪ ) ﻣﻄﻠﻮﺏﻫﻮ ﺃﻣﺮ  ﻋﻤﻮﻣﺎ ﻛﺜﺮﺍﻷ ﻴﻦﺍﻟﺠﺮﺍﺣﻴ ﻤﺮﺿﻰﺩ ﺍﻟﺍﻌﺪﺗﻓﻲ  ﺍﻟﻈﺎﻫﺮﺓ
ﺔ ﻣﻦ ﻤﺠﻤﻮﻋﺔ ﻭﺍﺳﻌﻟ ﻮﺍﺧﻀﻌ ﻴﻦ ﺍﻟﺬﻳﻦﺠﺮﺍﺣﻴﺍﻟ ﻤﺮﺿﻰﺍﻟﺿﺨﻢ ﻣﻦ ﺩ ﺍﻌﺪﺗﻓﻲ  ﺃﺟﺮﻳﺖ، ﻣﻦ ﺣﻴﺚ ﺍﻟﻨﻮﻋﻴﺔ  ﺍﺳﺘﻌﺎﺩﻳﺔ
ﺑﻌﺪ  ﺍﻹﻗﺎﻣﺔ ﻓﻲ ﺍﻟﻤﺴﺘﺸﻔﻰ ﻓﺘﺮﺓ ﻭﻁﻮﻝ، ﻣﻦ ﺟﻬﺔ  ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﺍﻟﻌﻼﻗﺔ ﺑﻴﻦ ﻟﺪﺭﺍﺳﺔ، ﻭ ﺫﻟﻚ  ﺔ ﺍﻟﻌﺎﻣﺔﻴﺍﻟﺠﺮﺍﺣ ﺟﺮﺍءﺍﺕﺍﻹ
  ﻭ ﻣﻌﺪﻝ ﺍﻟﻮﻓﻴﺎﺕ ﺑﻴﻨﻬﻢ ﻓﻲ ﺗﻠﻚ ﺍﻟﻔﺘﺮﺓ ﻭ ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﺒﻌﻴﺪ . ﺇﺟﺮﺍء ﺍﻟﺠﺮﺍﺣﺔ
 
ﻣﺎ ﻫﻴﺘﻬﺎ ﺗﺘﻄﻠﺐ ﺍﻟﺘﺤﻘﻖ ﻣﻦ ،  ﻧﺔ ﺍﻷﺧﻴﺮﺓﻓﻲ ﺍﻵﻭ ﺖﻟﻮﺣﻈ ﻅﺎﻫﺮﺓﻫﻲ  ﻓﻴﺎﺕﻭ ﻣﻌﺪﻝ ﺍﻟﻮ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﺍﻟﻤﻔﺎﺭﻗﺔ ﺑﻴﻦ  ﻭ
 ﻣﻔﻴﺪﺓ ﻣﻨﻄﻘﺔﺃﻧﻪ  ﺜﺒﺖﻳﻳﻤﻜﻦ ﺃﻥ  ﺍﻟﺘﺨﺪﻳﺮ ﻣﺠﺎﻝﺇﻥ  ﻓﻴﻬﺎ .  ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﺆﺛﺮﺓﻭﺑﻬﺎ ،  ﻴﻦﻤﻨﺍﻟﻤﺘﻀ ﻫﺎ ، ﻭﺍﻟﻤﺮﺿﻰ، ﻭﺍﻧﺘﺸﺎﺭﻭﺑﺎﺋﻴﺎ 
ﺱ ﺍﻟﻮﺯﻥ ﻘﻴﺎﻟﺍﻟﺮﻭﺗﻴﻨﻲ  ﺩﺭﺍﺝﺍﻟﺠﺮﺍﺣﻴﻴﻦ . ﺇﻥ ﺍﻹ ﺍﻟﻤﺮﺿﻰ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﻓﻲ ﺎﻭﻗﻮﻋﻬ ﺛﺒﺖ ، ﺣﻴﺚ ﺎﻭﺑﺎﺋﻴ ﻫﺬﻩ ﺍﻟﻈﺎﻫﺮﺓﺪﺭﺍﺳﺔ ﺟﺪﺍ ﻟ
 ﻣﻦ ﻗﺒﻞ ﻫﺬﻩ ﺍﻟﻈﺎﻫﺮﺓ ﺩﺭﺍﺳﺔ ﻳﺠﻌﻞ ﺍﻟﺠﺮﺍﺣﻴﺔ ﻬﻢﻤﻠﻴﺎﺗﺇﺟﺮﺍء ﻋ ﻗﺒﻞ ﻴﺎﺕﺍﻟﻤﺴﺘﺸﻔ ﻓﻲ ﻣﺮﺿﻰﻭ ﺑﺴﺎﻁﺔ ﻫﺬﺍ ﺍﻟﻘﻴﺎﺱ  ﻭﺍﻟﻄﻮﻝ
ﻋﻠﻰ ،  "ﺍﻟﺒﺪﺍﻧﺔ ﻣﻔﺎﺭﻗﺔ" ﺑﺎﺳﻢ، ﻋﻤﻮﻣﺎ  ﺍﻟﻤﻌﺮﻭﻑﻛﻤﺎ ﻫﻮ ،  ﺧﻄﺌﺎ ﺬﻩ ﺍﻟﻈﺎﻫﺮﺓﺩﻋﻴﺖ ﻫﻭ ﻟﻘﺪ   ، ﺣﺔﻣﺘﺎﻣﺴﺄﻟﺔ  ﺘﺨﺪﻳﺮﺍﻟﻁﺒﻴﺐ 
 ﻣﻦ ﻧﻘﺺ ﺍﻟﻮﺯﻥ . ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻓﻲ ﺃﻛﺜﺮﺎ ﺣﺘﻰ ﻭ ﺭﺑﻤ ﺃﻳﻀﺎ ﻣﻮﺟﻮﺩ ﺘﻨﺎﻗﺾﺍﻟ ﺍﻟﺮﻏﻢ ﻣﻦ ﺃﻥ
 
ﻁﺒﻴﺐ ﺍﻟﺘﺨﺪﻳﺮ  ﻳﺪﻓﻲ  ﺑﺎﻋﺘﺒﺎﺭﻫﺎ ﺃﺩﺍﺓ ﻗﻮﻳﺔ ﺻﺪﻯ ﺍﻟﻘﻠﺐ ﺗﺨﻄﻴﻂ ﺇﺟﺮﺍء ﻗﻴﻤﺔ ﻟﻠﺘﺪﻟﻴﻞ ﻋﻠﻰ ﺩﺭﺍﺳﺘﺎﻥ ﺃﺟﺮﻳﺖ،  ﺍﻟﺠﺰء ﺍﻟﺜﺎﻧﻲﻓﻲ 
 ﺍﺽ ﺍﻟﻘﻠﺐﺃﻣﺮﻭ ﺘﺨﻄﻴﻂ ﺻﺪﻯ ﺍﻟﻘﻠﺐﺑ ﺍﻟﻤﻌﻨﻴﺔ ﺍﻟﻤﺠﺘﻤﻌﺎﺕ ﺗﻮﺻﻴﺎﺕ ﻭﺗﻔﺴﻴﺮ، ﻭﺗﻄﺒﻴﻖ  ﺍﻟﻤﺤﻴﻄﺔ ﺑﺎﻟﺠﺮﺍﺣﺔﺍﻟﻌﺎﻣﻞ ﻓﻲ ﺍﻟﻘﺘﺮﺓ 
ﺘﺨﻄﻴﻂ ﺻﺪﻯ ﺍﻟﺠﻤﻌﻴﺔ ﺍﻷﻣﺮﻳﻜﻴﺔ ﻟﻭ ،  ﻷﻣﺮﺍﺽ ﺍﻟﻘﻠﺐ ﺍﻟﺠﻤﻌﻴﺔ ﺍﻷﻭﺭﻭﺑﻴﺔ ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺫﺍﺕ ﺍﻟﻌﻼﻗﺔ ﺑﻔﺘﺮﺓ ﻣﺎ ﺣﻮﻝ ﺍﻟﺠﺮﺍﺣﺔ
ﺍﻷﺩﻟﺔ  ﻋﻠﻰ ﺍﻟﺘﻮﺻﻴﺎﺕ ﺍﻟﻤﺒﻨﻴﺔ ﺍﻻﻟﺘﺰﺍﻡ ﺑﻬﺬﻩﻣﻼﺣﻈﺔ  ﻣﻦ ﺍﻟﻤﺘﻮﻗﻊﻛﺎﻥ  ﻭ ﻴﻦ ، ﻴﺎﺋﺍﻟﻘﻠﺐ ﻭﻋ ﺃﻁﺒﺎء ﺍﻟﺘﺨﺪﻳﺮ ﻭﺟﻤﻌﻴﺔﺍﻟﻘﻠﺐ ، 
ﺍﻟﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﻧﻮﻋﻴﺔ ﺍﻟﺤﻴﺎﺓ ﻭﻣﻦ ﻧﻮﺍﺣﻲ ، ﺃﻱ  ﻣﺎ ﺑﻌﺪ ﺍﻟﺠﺮﺍﺣﺔﻓﻲ ﻓﺘﺮﺓ  ﻨﺘﺎﺋﺞﺍﻟ ﻭﺗﺤﺴﻴﻦ ﺕﺍﻟﻤﻀﺎﻋﻔﺎ ﻣﻌﺪﻝ ﻟﺨﻔﺾ ﺍﻟﺴﺮﻳﺮﻳﺔ
 ﺃﺑﻌﺪ ﻣﻦ ﻣﺠﺮﺩﻓﻲ ﻣﺪﻯ  ﺍﻟﻤﺤﻴﻄﺔ ﺑﺎﻟﺠﺮﺍﺣﺔ ﺮﻳﺨﺪﺍﻟﺘ ﻓﻲ ﺍﻟﻤﻘﺎﻡ ﺍﻷﻭﻝ ﺇﺩﺍﺭﺓ ﺗﺴﺘﻬﺪﻑ ﻫﺬﻩ ﺍﻟﻤﺒﺎﺩﺉ ﺍﻟﺘﻮﺟﻴﻬﻴﺔ ، ﺣﻴﺚ ﺃﻥ ﺍﻟﺤﻴﺎﺓ
 . ﻋﻠﻰ ﻧﺤﻮ ﺳﻠﺲﺟﺮﺍء ﺍﻟﻌﻤﻠﻴﺎﺕ ﺍﻟﺠﺮﺍﺣﻴﺔ ﺍﻟﺴﻤﺎﺡ ﻹ
 
 ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﻣﺆﺷﺮ ﻣﻔﺎﺭﻗﺔ  :ﺍﻟﺠﺰء ﺍﻷﻭﻝ
 ﺍﻟﺘﺎﺟﻲ ﺽ ﺍﻟﺸﺮﻳﺎﻥﺍﻣﺮﺃ ﻳﻌﺎﻧﻮﻥ ﻣﻦ  ﻳﻀﺎﻣﺮ ٠٥٩٥ ﻳﺒﻠﻎ ﻋﺪﺩﻫﺎﻣﺠﻤﻮﻋﺔ ﻣﻦ ﺍﻟﻤﺮﺿﻰ  ﺩﺭﺳﻨﺎﻣﺠﻤﻮﻋﺔ ﺩﺭﺍﺳﺎﺗﻨﺎ ، ﻓﻲ ﺑﺪﺍﻳﺔ 
 ﺘﺤﺪﻳﺪﺍﻟ ﺗﻤﻜﻨﺎ ﻣﻦﻭ ﻟﻘﺪ  ( . ﺍﻷﻭﻝ ﺍﻟﻔﺼﻞ) ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻫﺎ ﻣﻦ ﺣﻴﺚ ﻭﻗﻮﻉ ﻣﻔﺎﺭﻗﺔ ﻓﻲ ﻭﺟﻮﺩ ﺍﻟﻤﺸﺘﺒﻪ ﺃﻭﻗﻄﻌﺎ ﻓﺔ ﺍﻟﻤﻌﺮﻭ
 ﺏ ﻭ ﻣﻦ ﺍﻟﻮﻓﺎﺓ ﺍﻟﻘﻠﺒﻴﺔ ، ﺟﻤﻴﻊ ﺍﻷﺳﺒﺎ ﻣﻦ ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞﻣﻌﺪﻝ ﺍﻟﻮﻓﻴﺎﺕ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﻭﻌﻜﺴﻴﺔ ﺑﻴﻦ ﺍﻟﻌﻼﻗﺔ ﺍﻹﻳﺠﺎﺑﻲ ﻟﻠ
ﺃﻭ  ﺍﻹﺟﻤﺎﻟﻲ ﻟﻠﻮﻓﻴﺎﺕ ﻮﻗﻮﻉﺍﻟﻣﻦ ﺣﻴﺚ  ﺃﻋﻠﻰ ﻣﺨﺎﻁﺮ ﺤﻤﻞﺗ ﻤﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻟ ﺍﻟﻔﺌﺎﺕ ﺫﻭﺍﺕ ﺍﻟﻤﻌﺪﻻﺕ ﺍﻟﻤﻨﺨﻔﻀﺔﺃﻥ  ﺑﺤﻴﺚ
 . ﻋﻠﻰﺍﻷ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﺫﻭﺍﺕ ﻣﻦ ﺍﻟﻔﺌﺎﺕﺃﻛﺜﺮ  ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞﻣﻦ ﺍﻟﻮﻓﻴﺎﺕ ﺍﻟﻘﻠﺒﻴﺔ 
 
 ﻓﻲ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﻣﻊ ﺯﻳﺎﺩﺓ ﺑﺸﻜﻞ ﻣﻠﺤﻮﻅ ﺍﻧﺨﻔﺾ ﺍﻟﻮﻓﻴﺎﺕ ﺃﻥ ﻣﻌﺪﻝ ﻧﺘﺎﺋﺠﻨﺎ ﺃﻅﻬﺮﺕ ، ﺍﻟﺜﺎﻧﻲﺍﻟﻔﺼﻞ ﻓﻲ 
 ﺎﺕﺍﻟﺠﺮﺍﺣﺇﺟﺮﺍء ﻗﺒﻞ ﺍﻟﺮﺋﺘﻴﻦ  ﻭﻅﺎﺋﻒ, ﺍﺕﺧﺘﺒﺎﺭﺍﻟﺬﻳﻦ ﺧﻀﻌﻮﺍ ﻻ ﻴﺔﻤﺤﻴﻄﺍﻟﺸﺮﺍﻳﻴﻦ ﺍﻟ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﺃﻣﺮﺍﺽ
 ﺃﻥ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻣﺮﺽ ﺍﻹﻧﺴﺪﺍﺩ ﺍﻟﺮﺋﻮﻱ ﺍﻟﻤﺰﻣﻦﺸﺪﺓ ﻟ ﻭﻓﻘﺎ ﺎﻧﺎﻟﻤﺮﺿ ﺍﻟﺘﺤﺘﻲ ﺍﻹﺿﺎﻓﻲ ﺘﺼﻨﻴﻒﺍﻟ ﺃﻅﻬﺮ، ﻭ ﻟﻘﺪ  ﺍﻟﺨﺎﺻﺔ ﺑﻬﻢ
ﺘﺼﺤﻴﺢ .ﻭ ﻟﻠﻤﻔﺎﺭﻗﺔ ﻓﻘﺪ ﺃﺩﻯ ﺍﻟ ﻣﺮﺽ ﺍﻻﻧﺴﺪﺍﺩ ﺍﻟﺮﺋﻮﻱ ﺍﻟﻤﺰﻣﻦ ﻣﻦ ﺃﺷﺪ ﺻﻮﺭﺓ ﻣﻊ ﻴﻦﺮﺗﺒﻄﻣ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﻧﻘﺺ ﺍﻟﻮﺯﻥ
 ﺭﺗﺒﺎﻁ ﺑﻴﻦ ﺍﻟﻤﺮﺿﻰﺍﻹ ﺎء ﻋﻠﻰﺍﻟﻘﻀﺇﻟﻰ  ﻣﺘﻌﺪﺩ ﺍﻟﻤﺘﻐﻴﺮﺍﺕ ﺍﻟﺘﺤﻠﻴﻞ ﻓﻲﻣﺮﺽ ﺍﻹﻧﺴﺪﺍﺩ ﺍﻟﺮﺋﻮﻱ ﺍﻟﻤﺰﻣﻦ ﺸﺪﺓ ﻟﺍﻹﺣﺼﺎﺋﻲ 
ﺍﻟﻤﺮﺗﺒﻄﺔ  ﺍﻟﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓﻣﻦ ﻫﺬﺍ ﺍﻹﺟﺮﺍء ﻓﻲ ﺗﻌﺪﻳﻞ ﻣﻴﺰﺓ  ﻓﺎﺋﺪﺓﺗﺒﺪ ﺛﻤﺔ  ﻢﻟ ﻪ، ﻭﻟﻜﻨ ﺍﻟﻮﻓﻴﺎﺕﺯﻳﺎﺩﺓ  ﻭ ﻧﺎﻗﺼﻲ ﺍﻟﻮﺯﻥ
 . ﻋﻠﻰﺍﻷ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﺍﻟﻤﺮﺿﻰ ﺫﻭﻱ  ﺑﺠﻤﺎﻋﺎﺕ
 
ﻌﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﺔ، ﻓﻠﻤﺘﺎﺑﻌﻟ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞ ﻦﻣ ﺍﻟﻘﺼﻴﺮ ﺍﻟﻤﺪﻯ ﻓﻲ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻣﻔﺎﺭﻗﺔ  ﻅﺎﻫﺮﺓﺍﺧﺘﻠﻔﺖ  ، ﺍﻟﺜﺎﻟﺚ ﺍﻟﻔﺼﻞﻓﻲ 
،  ﺍﻟﻘﺼﻴﺮ ﺍﻟﻤﺪﻯ ﻓﻲ ﺍﻟﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓ ﺎ ﻓﻲ ﻣﻌﺪﻻﺕﺗﺤﺴﻨ ﻭﺍﺃﻅﻬﺮﺍﻟﺰﺍﺋﺪ ﺩﻭﻥ ﺍﻟﺴﻤﻨﺔ  ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺍﻟﻮﺯﻥﺍﻟﺬﻳﻦ  ﺍﻟﻤﺮﺿﻰ ﺃﻥ
ﻴﻦ ﺑ ﻋﻼﻗﺔ ﻋﻜﺴﻴﺔ ﻭﺟﻮﺩ ﻭﻗﺪ ﺗﺒﻴﻦ  .ﺍﻹﻗﺎﻣﺔ ﻓﻲ ﺍﻟﻤﺴﺘﺸﻔﻰ ﻣﻊ ﻁﻮﻝ ﺑﺸﻜﻞ ﻣﺘﻨﺎﻗﺾ ﻣﺮﺗﺒﻄﺎ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻛﺎﻥ ،  ﻣﻊ ﺫﻟﻚ
ﻣﺰﻳﺪ  ﻭﻛﺸﻒ  .ﻤﺮﺿﻰﻫﺬﻩ ﺍﻟﻔﺌﺔ ﻣﻦ ﺍﻟ ﺑﺸﻜﻞ ﻭﺍﺿﺢ ﻓﻲ ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞ ﺍﻹﺟﻤﺎﻟﻲ ﻟﻠﻮﻓﻴﺎﺕ ﻭ ﺍﻟﻤﻌﺪﻝ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ
، ﻓﻲ  ﻭﻓﺎﺓ ﺑﺎﻟﺴﺮﻁﺎﻥ ﻣﻊ ﻛﺎﻥ ﻣﺮﺗﺒﻄﺎ ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ ﺍﻧﺨﻔﺎﺽ ﺃﻥ ﺍﻟﻤﺘﻮﻓﻴﻦ ﺍﻟﻤﺮﺿﻰ ﻓﻲ ﺍﻟﻮﻓﻴﺎﺕ ﺃﺳﺒﺎﺏ ﺣﻮﻝ ﻣﻦ ﺍﻟﺪﺭﺍﺳﺔ
ﻣﺮﺍﺽ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻸﺳﺒﺎﺏ ﺍﻟﻌﺎﺋﺪﺓ ﻷ ﻓﻘﻂ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺯﻳﺎﺩﺓ ﺍﻟﻮﺯﻥ ﺍﻟﺬﻳﻦ ﻠﻤﺮﺿﻰﻟ ﺍﻟﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓﻓﺮﺹ  ﺗﺤﺴﻨﺖﺣﻴﻦ 
 . ﺍﻟﻘﻠﺐ
 
 ﻣﻔﺎﺭﻗﺔ ﻋﻠﻰﻟﺬﻟﻚ ﺍﻟﻤﺤﺘﻤﻞ  ﻭﺍﻟﺘﺄﺛﻴﺮ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ ﺍﻟﻤﺤﻴﻄﻴﺔ ﺍﻟﻤﺘﻌﺪﺩﺓﻤﺮﺽ ﺑﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ  ﻋﻠﻰ  ﺍﻟﺮﺍﺑﻊ ﺍﻟﻔﺼﻞ ﻭﺭﻛﺰ
 ﻓﻲ ﺟﻤﻴﻊ ﺍﻟﻔﺌﺎﺕ ﺍﻟﻄﺒﻲ ﺍﻟﻌﻼﺝ ﻋﻠﻰ ﻗﺪﻡ ﺍﻟﻤﺴﺎﻭﺍﺓ ﻣﻊ ﺍﺳﺘﻬﺪﻓﺖﻗﺪ  ﻮﺭﺓﻋﻮﺍﻣﻞ ﺍﻟﺨﻄ ﻭﺭﻏﻢ ﺃﻥ ﺟﻤﻴﻊ  . ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢ
ﺃﻭﻟﺌﻚ ﺍﻟﻤﺮﺿﻰ ، ﻭﺃﻅﻬﺮ  ﺍﻟﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓﻓﺮﺹ ﻧﺨﻔﺎﺽ ﻻ ﻣﺴﺘﻘﻼ ﺍﺧﻄﺮ ﻛﺎﻥ ﺍﻟﻮﺯﻥ ﺎﻥﻧﻘﺼﻓﺈﻥ ،  ﻤﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻟ
ﻣﺮﺽ ﻧﺘﺸﺎﺭ ﻻﺃﻋﻠﻰ ﻧﺴﺒﺔ  ﺃﻅﻬﺮﺕ ﻣﻦ ﺍﻟﻤﺮﺿﻰ ﻓﺌﺔ ﺯﺍﺋﺪﻱ ﺍﻟﻮﺯﻥ ، ﻓﺈﻥ ﻭﻣﻊ ﺫﻟﻚ  .ﻠﻘﻠﺐﻠﻌﻘﺎﻗﻴﺮ ﺍﻟﻮﺍﻗﻴﺔ ﻟﻟ ﺍﺳﺘﺨﺪﺍﻡ ﺃﺩﻧﻰ
ﺍﻟﺒﻘﺎء ﻓﺮﺹ  ﺘﺤﺴﻦﺑ ﺖ ﻣﺮﺗﺒﻄﺔﻛﺎﻧﻭ،  ﻠﻘﻠﺐﺍﻟﻌﻘﺎﻗﻴﺮ ﺍﻟﻮﺍﻗﻴﺔ ﻟ ﺳﺘﺨﺪﺍﻡﻛﺬﻟﻚ ﻻ ﻭ ﺍﻟﻤﺘﻌﺪﺩﺓ  ﺍﻟﻤﺤﻴﻄﻴﺔﻟﺪﻣﻮﻳﺔ ﺃﻣﺮﺍﺽ ﺍﻷﻭﻋﻴﺔ ﺍ
ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺗﻘﺴﻴﻢ  ﺑﻴﻦ، ﻭ ﻟﻘﺪ ﻭﺟﺪ ﺃﻥ ﺍﻟﺘﻔﺎﻋﻞ ﺍﻹﺣﺼﺎﺋﻲ  ﻮﻓﻴﺎﺕﺍﻟ ﺃﺳﺒﺎﺏﺟﻤﻴﻊ  ﺿﺪ ﻋﻠﻰ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞ ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓ
ﻏﻴﺮ ﺫﻱ ﻗﻴﻤﺔ ﺍﻟﻤﺪﻯ ﺍﻟﻄﻮﻳﻞ ﺍﻟﺒﻘﺎء ﻋﻠﻰ  ﻓﺮﺹ ﻋﻠﻰ ﻧﺘﺎﺋﺠﻬﺎ ﻭ ﻟﻤﺘﻌﺪﺩﺓ ﺍﻟﻤﺤﻴﻄﻴﺔ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ ﺍ ﻣﺮﺽ، ﻭﻭﺟﻮﺩ  ﺍﻟﺠﺴﻢ
 .ﻤﺮﺿﻰ ﻫﺬﻩ ﺍﻟﻔﺌﺔ ﻣﻦ ﺍﻟ ﻓﻲ
 
 ﺃﻥﻟﻘﺪ ﺑﺪﺍ ﻟﻨﺎ   .ﺍﻟﻌﺎﻣﺔ ﺎﺕﺍﻟﺠﺮﺍﺣ ﻣﺮﺿﻰ ﻓﻲ "ﺍﻟﺒﺪﺍﻧﺔ ﻣﻔﺎﺭﻗﺔ"ﻠﻰ ﻴﺔ ﻋﻠﻤﻴﺔ ﻋﺃﺩﺑ ﻣﺮﺍﺟﻌﺔ، ﺃﺟﺮﻳﻨﺎ  ﺍﻟﺨﺎﻣﺲ ﺍﻟﻔﺼﻞﻓﻲ 
ﺃﻋﻠﻰ  ﻢﺪﻳﻬﻟ ﻔﺮﻁﺔﺍﻟﻤﺍﻟﺴﻤﻨﺔ ﺫﻭﻱ  ﻭ ﻧﻘﺺ ﺍﻟﻮﺯﻥﺫﻭﻱ ﻛﻼ ﻣﻦ  ﺍﻟﻤﺘﻀﻤﻨﻴﻦ،  ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺍﻟﺠﺴﻢﻣﻌﺪﻻﺕ  ﺍﻗﺼﻰ ﺍﻟﻤﺮﺿﻰ ﻓﻲ
ﺒﻌﻴﺪ، ﺃﻣﺎ ﺍﻟﺴﺒﺐ ﻭﺭﺍء ﺍﻟﻤﺪﻯ ﺍﻟ ﺣﺘﻰ ﻓﻲ ﻻ ﻳﺰﺍﻝ ﻗﺎﺋﻤﺎ ﺍﻟﺬﻱﺍﻷﻣﺮ ، ﺓ ﺍﻟﺨﻄﺮ ﺎﺕﺑﻌﺪ ﺍﻟﺠﺮﺍﺣ ﻣﻌﺪﻻﺕ ﺍﻻﻋﺘﻼﻝ ﻭﺍﻟﻮﻓﻴﺎﺕ
ﺑﺎﻟﻨﺴﺒﺔ ﺍﻟﺒﻘﺎء  ﻧﺘﺎﺋﺞﺗﺤﺴﻴﻦ  ﻣﻦ ﺃﺟﻞ ﻟﻠﺒﺤﺚ ﻓﻲ ﺍﻟﻤﺴﺘﻘﺒﻞ ﺇﻣﻜﺎﻧﻴﺔ ﻭﻫﺬﺍ ﻳﻮﻓﺮ ﺍﻟﻌﻮﺍﻣﻞ، ﻣﺘﻌﺪﺩ  ﺮﺑﻤﺎ ﻳﻜﻮﻥﻓ "ﺍﻟﺒﺪﺍﻧﺔ ﻣﻔﺎﺭﻗﺔ"




  ﺍﻟﻤﺤﻴﻄﺔ ﺑﺎﻟﺠﺮﺍﺣﺔﺃﺛﻨﺎء ﻭ ﻓﻲ ﺍﻟﻔﺘﺮﺓ  ﻣﺴﺎﻋﺪﺓﺗﺨﻄﻴﻂ ﺻﺪﻯ ﺍﻟﻘﻠﺐ ﻛﺄﺩﺍﺓ ﺍﺳﺘﺨﺪﺍﻡ ﺗﻮﺳﻴﻊ   :ﺍﻟﺠﺰء ﺍﻟﺜﺎﻧﻲ
ﻣﻦ  ﺃﻋﻠﻰ ﻣﻌﺪﻝ ﺍﻟﺴﺎﺩﺱ ﺍﻟﻔﺼﻞﻓﻲ  ﺍﻟﺪﺭﺍﺳﺔ ﺍﻟﺘﻲ ﻗﺪﻣﺖ ﺃﻅﻬﺮﺕﻗﺪ  ﻭ ﺗﺮﺻﺪﻳﺘﻴﻦ .  ﺩﺭﺍﺳﺘﻴﻦ ﺇﺟﺮﺍء ﻫﺬﺍ ﺍﻟﺠﺰءﻣﻨﺎ  ﻄﻠﺐﺗ
، ﺃﻛﺜﺮ ﻣﻦ ﺗﻠﻚ  ﻮﺗﺎﻣﻴﻦﻴﺍﻟﺪﻭﺑﺇﺟﺮﺍء ﺍﻹﺧﺘﺒﺎﺭ ﺍﻹﺟﻬﺎﺩﻱ ﻟﻠﻘﻠﺐ ﺑﺎﺗﺨﺪﺍﻡ ﻋﻘﺎﺭ  ﺧﻼﻝﻣﻦ  ﻤﺤﺮﺽﺍﻟﻘﻠﺒﻴﺔ ﺍﻟ ﻧﻘﺺ ﺍﻟﺘﺮﻭﻳﺔﻣﻈﺎﻫﺮ 
 ﺍﻟﻤﻮﻗﻊ ﺳﻲء ﻣﻦ ﺣﻴﺚ ﻣﻊ ﺍﺗﻔﺎﻕ،  ﺍﻟﺠﺮﺍﺣﺔ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺗﺨﻄﻴﻂ ﺻﺪﻯ ﺍﻟﻘﻠﺐ ﻣﻦ ﺧﻼﻝ ﺗﻨﻈﻴﺮ ﺍﻟﻤﺮﻱءﺍﺛﻨﺎء ﻋﻨﻬﺎ  ﺍﻟﻜﺸﻒﺍﻟﺘﻲ ﺗﻢ 
 ﺍﻟﻤﺤﻴﻄﻴﺔ ﻋﺎﻟﻴﺔ ﺍﻟﺨﻄﻮﺭﺓ .  ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ ﺎﺕﺟﺮﺍﺣ ﻮﺍ ﻹﺟﺮﺍءﺧﻀﻌ ﺍﺍﻟﺬﻳﻦ ﻤﺮﺿﻰﻟﻠ ﻧﻘﺺ ﺗﺮﻭﻳﺔ ﻋﻀﻠﺔ ﺍﻟﻘﻠﺐﺑﻴﻦ ﺃﻣﺎﻛﻦ 
 ﻋﻦ ﻁﺮﻳﻖﺍﻟﻜﺸﻒ ﻋﻨﻬﺎ  ﻭ ﺍﻟﺘﻲ ﺗﻢ ﻤﺮﺿﻰﻣﻦ ﺍﻟﺍﻟﻤﺤﺪﻭﺩﺓ ﻫﺬﻩ ﺍﻟﻔﺌﺔ  ﻓﻲ ﺗﺤﺖ ﺍﻹﻛﻠﻴﻨﻴﻜﻲﺍﻟﻘﻠﺒﻲ  ﻧﻘﺺ ﺍﻟﺘﺮﻭﻳﺔ ﻣﻌﺪﻝ ﺍﻗﺘﺮﺏ
ﺍﺣﺘﺸﺎء  ﺑﻠﻎ ﻣﻌﺪﻝ، ﻓﻲ ﺣﻴﻦ  %٥١ﻧﻘﺺ ﺍﻟﺘﺮﻭﻳﺔ ﺍﻷﺧﺮﻯ ﻣﻦ  ﻣﻈﺎﻫﺮ ﺩﻭﻥ ﻣﺰﻳﺪ ﻣﻦ ﻲﺍﻟﻘﻠﺒ ﺍﻟﺘﺮﻭﺑﻮﻧﻴﻦ ﻣﺴﺘﻮﻳﺎﺕ ﺍﺭﺗﻔﺎﻉ
 ﻧﻘﺼﺎﻥ ﺍﻟﺘﺮﻭﻳﺔ ﺍﻟﻘﻠﺒﻴﺔ ﺤﺪﻭﺙﺑ ﺍﻟﺘﻨﺒﺆ. ﻭ ﻗﺪ ﺃﻣﻜﻦ  ﻣﻦ ﺍﻟﻤﺮﺿﻰ %٦ ﻓﻲﻮﻓﺎﺓ ﻗﻠﺒﻴﺔ ﺍﻟﻤﺼﺪﺭ ﺍﻟ ﺣﺪﺙ . ﻭ  %١١ ﻋﻀﻠﺔ ﺍﻟﻘﻠﺐ
ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﻹﺧﺘﺒﺎﺭ ﺍﻹﺟﻬﺎﺩﻱ ﻟﻠﻘﻠﺐ ﺑﺎﺗﺨﺪﺍﻡ ﻋﻘﺎﺭ ﺍﻟﺮﺍﺣﺔ ﺣﺎﻝ  ﺍﻟﻘﻠﺐ ﺗﺸﻮﻫﺎﺕ ﺣﺮﻛﻴﺔ ﺟﺪﺍﺭﻭ ﺑﻌﺪ ﺍﻟﺠﺮﺍﺣﺔ ﺃﺛﻨﺎء ﻭ
ﺍﻟﺘﻨﺒﺆ ﺑﻤﻮﺍﻗﻊ  ﺖ ﻧﺴﺒﺔﻳﺔ ﺍﻟﺠﺪﻳﺪﺓ . ﻭ ﻗﺪ ﻛﺎﻧﺍﻟﺠﺪﺍﺭ ﺔﻴﺍﻟﺤﺮﻛ ﺗﺸﻮﻫﺎﺕﻟﻠﺘﻨﺒﺆ ﺑﻤﻮﺍﻗﻊ  ﻟﻚ ﻟﻢ ﻳﻜﻦ ﻣﻤﻜﻨﺎ ﺫﻭﻟﻜﻦ ﺍﻟﺪﻭﺑﻴﻮﺗﺎﻣﻴﻦ ، 
ﺑﺎﺳﺘﺨﺪﺍﻡ ﺗﺨﻄﻴﻂ ﺻﺪﻯ ﺍﻟﻘﻠﺐ ﻣﻦ  ، ﺑﻌﺪ ﺍﻟﺠﺮﺍﺣﺔﺍﻟﺘﻲ ﺣﺪﺙ ﺑﻬﺎ ﺍﺣﺘﺸﺎء ﻗﻠﺒﻲ  ﻓﻲ ﺟﻤﻴﻊ ﺍﻟﺤﺎﻻﺕ  %٠٠١ ﺍﻹﺣﺘﺸﺎء ﺍﻟﻘﻠﺒﻲ
 ﺇﻻ ﻓﻲ ﺑﺸﻜﻞ ﺻﺤﻴﺢ ﺍﻟﻤﻮﻗﻊ ﺘﻮﻗﻊﻳ ﻟﻢ ﻗﺒﻞ ﺍﻟﺠﺮﺍﺣﺔﺍﻟﻘﻠﺒﻲ  ﺩﺍﻹﺟﻬﺎ ﺍﺧﺘﺒﺎﺭ، ﻓﻲ ﺣﻴﻦ ﺃﻥ ﺠﺮﺍﺣﺔ ﺃﺛﻨﺎء ﺍﻟ ﺧﻼﻝ ﺗﻨﻈﻴﺮ ﺍﻟﻤﺮﻱء
 ﺎﻥﻧﻘﺼ ﻣﺮﺿﻰ ﻣﺮﺟﺤﺎ ﺇﻟﻰ ﺍﻟﻤﺼﻠﺤﺔ ﺍﻟﻤﻔﺘﺮﺿﺔ ﻟﻠﻌﻼﺝ ﺍﻟﻌﺎﻡ ﺑﺎﻟﻌﻘﺎﻗﻴﺮ ﻓﻲ ﺩﻟﻴﻼ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﺃﺿﺎﻓﺖﻟﻘﺪ   .ﺍﻟﺤﺎﻻﺕ ﻓﻘﻆ  ﺛﻠﺚ
 ﻶﻓﺎﺕﻟ ﻣﺤﺪﺩﺓ  ﺎﺟﻤﺔﻣﻬﻭ  ﺍﻟﺘﺎﺟﻴﺔ ﺍﻹﺧﺘﺮﺍﻗﻲ ﺍﻟﺘﺪﺧﻠﻲ ﺍﻟﺬﻱ ﻳﺮﻛﺰ ﻋﻠﻰ ﺑﻌﺾ ﺍﻟﻔﺮﻭﻉ ﺍﻟﻌﻼﺝ ﻋﻠﻰ، ﻣﺮﺟﺤﺎ ﺇﻳﺎﻩ  ﺍﻟﻘﻠﺐ ﺗﺮﻭﻳﺔ
 . ﺟﺮﺍﺣﺔ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ ﻗﺒﻞ ﺍﻟﺘﺎﺟﻲ ﺍﻟﺸﺮﻳﺎﻥ ﻔﺮﻭﻉﻟ ﺔﺍﻟﺠﺎﻧﻴﺍﻟﺸﺮﻳﺎﻧﻴﺔ 
 
ﺟﺮﺍءﺍﺕ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﺨﻀﻌﻮﻥ ﻹ ﻧﺼﻒ ﻣﻮﺟﻮﺩ ﻓﻲ ﺍﻷﻳﺴﺮ ﻫﻮ ﺍﻟﺒﻄﻴﻦﻭﻅﻴﻔﺔ ﺍﺧﺘﻼﻝ  ﺃﻥ ﺍﻟﺴﺎﺑﻊﺍﻟﻔﺼﻞ  ﺃﻅﻬﺮ ﻭﺃﺧﻴﺮﺍ،
ﺍﻧﻘﺴﻢ  ﻭﺑﻼ ﺃﻋﺮﺍﺽ  ﻛﺎﻧﻮﺍﻦ ﺍﻟﺒﺎﻗﻴﻧﻮﻥ ﺑﺎﻟﻤﺎﺋﺔ ﺍﻟﺜﻤﺎ ﻭ،  ﺃﻋﺮﺍﺽﻫﻨﺎﻙ  ﻛﺎﻧﺖﻓﻘﻂ ﻣﻨﻬﻢ  %٠٢ﻓﻲ ﺍﻟﻤﺤﻴﻄﻴﺔ ،  ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ
. ﻭ ﻗﺪ ﻭﺟﺪ ﺃﻥ ﺍﻹﻟﺘﺰﺍﻡ ﺑﺘﻮﺻﻴﺎﺕ ﺟﻤﻌﻴﺔ ﺍﻟﻘﻠﺐ   ﺍﻻﻧﻘﺒﺎﺿﻲ ﻭﺍﻻﻧﺒﺴﺎﻁﻲ ﺍﻟﺨﻠﻞ ﺑﺎﻟﺘﺴﺎﻭﻱ ﺑﻴﻦﺍﻋﺘﻼﻝ ﻭﻅﻴﻔﺔ ﺍﻟﺒﻄﻴﻦ ﺍﻹﻳﺴﺮ 
ﺍﺕ ﻭ ﺣﺎﺻﺮﺃ  ﺍﻟﻤﺤﻮﻝ ﻟﻸﻧﺠﻴﻮﺗﻨﺴﻴﻦ ﻧﺰﻳﻢﻹﺍ ﻣﺜﺒﻄﺎﺕ ﺎﺳﺘﺨﺪﺍﻡﺑ ﺝﺍﻷﻭﺭﻭﺑﻴﺔ ﻛﺎﻥ ﻓﻘﻂ ﻓﻲ ﺛﻠﺚ ﺍﻟﻤﺮﺿﻰ ﻣﺘﻤﺜﻼ ﻓﻲ ﺍﻟﻌﻼ
ﺍﻟﻤﺒﺎﺩﺉ  ﻣﻘﺎﺭﻧﺔ ﻣﻊ ﻣﻦ ﺍﻟﻤﺮﺿﻰ ﻫﺬﻩ ﺍﻟﻤﺠﻤﻮﻋﺔﻋﻼﺝ ﻋﺪﻡ ﻛﻔﺎﻳﺔ ﺇﻟﻰ  ﻫﺬﻩ ﺍﻟﻨﺘﺎﺋﺞ ﻭﺃﺷﺎﺭﺕ  . ﻣﺪﺭﺍﺕ ﺍﻟﺒﻮﻝ ﻭﺃ ﻣﺴﺘﻘﺒﻼﺗﻪ
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(Belonging to the thesis) 
 




By; Wael Galal Mohamed Mostafa 
Rotterdam, The Netherlands; 2016 
 
1. The phenomenon of inverse relationship between body mass index and mortality is currently 
observed in patients with peripheral arterial disease and coronary artery disease undergoing 
vascular surgery as well as in other general surgical population. (own thesis) 
 
2. In the overweight and obese groups, patients appear relatively better targeted in modern 
societies with therapeutic measures correcting cardiovascular risk factors and the association 
with mortality from cardiovascular causes is modified. (own thesis) 
 
3. A higher prevalence of more severe forms of life-threatening chronic diseases is present 
among underweight patients which requires more vigilant attention. (own thesis) 
 
4. In cardiac patients undergoing non-cardiac surgery, preoperative pharmacologic stress testing 
can predict which patients are at risk for the occurrence of intraoperative and postoperative 
myocardial ischemia and infarction but not the location of such predicted ischemia. This is better 
correlated with intraoperative transesophageal echocardiography. (own thesis) 
 
5. Underestimation of the prevalence of left ventricular dysfunction in peripheral arterial disease 
patients might require routine implementation of preoperative echocardiography prior to vascular 
surgery. (own thesis) 
 
6. The combination of modern medicine and social life have undoubtedly caused the extension in 
both human expectation and bodily mass.  
 
7. If current trends continue, obesity will soon overtake cigarette smoking as the leading cause of 
preventable death in the United States. (Carl J. Lavie, Hector O. Ventura and Richard V. Milani, 
Chest 2008 Nov;134(5):896-8) 
 
8. The high rate of perioperative cardiac deaths, myocardial ischemia and infarction, and sub-
clinical ischemia in cardiac patients who underwent non-cardiac surgeries raise the question to 
escalate the utility of intraoperative TEE in the ESC recommendations. 
 
9. The disconnection between the severity of anatomic obstruction and the MI risk is one of the 
main pieces of evidence that plaque rupture depends on its composition rather than on its size. 
(Balachundhar Subramaniam; Anesthesiology 2010 Mar;112(3):524-6) 
 
10. Intensive medical anti-ischemic therapy is superior to focused therapeutic coronary 
interventions aiming at improving coronary perfusion in patients with ischemic heart disease 
prior to major non-cardiac surgery. (Reflections from McFalls EO et al. NEJM 2004; 351 2795-
804; and Garcia S et al. JACC 2008; 102: 809-813) 
 
11. Modern communities now clearly understand the risks associated with excessive weight loss 
and weight gain. It is not strange that more European countries ban excessively underweight “cat-
walk” fashion models. (The Guardian, BBC and Time; April the 3rd 2015) 
 
 
 
